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Abstract  
 
Unsaturated carbazole frameworks are found in several important naturally occurring and 
synthetic biologically active compounds (Figure 1)1,2 
Figure 1 – Biologically active compounds based on carbazoles. 
 
We envisaged synthesising compounds of this type using an intermolecular Diels-Alder 
reaction between 3-vinyl-1H-indole and a dienophile, followed by an intermolecular ene 
reaction between the resultant Diels-Alder adduct (6) and an enophile. This route was 
tested using tosyl protected 3-vinyl-1H-indole (4) and N-methylmaleimide (5) in a Diels-
Alder reaction, followed by ene reactions with a range of enophiles to give unsaturated 
carbazoles (7) in yields of 50-60% over the two steps (Scheme 1).  
 
Scheme 1 – Two-step Diels-Alder/ ene reaction sequence. 
 
Through utilisation of Soos’s organo-catalyst3, we have been able to control the Diels-Alder 
reaction between 3-vinyl-1H-indole (8) and N-methylmaleimide (5), to form the Diels-Alder 
adduct (9) with high enantiomeric excess (Scheme 2).4  
 
Scheme 2 – Enantioselective Diels-Alder, protection, enantiospecific ene reaction sequence. 
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The subsequent stereospecific ene reaction then gives unsaturated carbazoles (10) in >96% 
ee.  
 
We then developed a sequential “one-pot” Diels-Alder / ene methodology with an N-
protected 3-vinyl-1H-indole (11), a dienophile and an enophile to make unsaturated 
carbazoles and pyridazino[3,4-b]indoles (13) (Scheme 3).3 This methodological approach 
gave increased overall yields and reduced purification steps.  
 
Scheme 3 – One-pot Diels-Alder / ene reaction. 
 
When Cbz N-protected 3-vinyl-1H-indoles were used the Diels-Alder / ene products (14) 
could then be deprotected through a PtO2 catalysed hydrogenation reaction to give 
molecules (15) (Scheme 4). Several of the synthesised compounds (15) showed moderate 
biological activity against Escherichia coli, Staphylococcus aureus and Schizosaccharomyces 
pombe. Compounds (15) are also moderate (µM) inhibitors of several important kinases, 
including Chk2, Aurora B, Src and JAK2, which are potential targets for cancer treatment.  
 
Scheme 4 – Removal of Cbz group by hydrogenation. 
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Abbreviations 
 
Å Angstrom 
Aq  Aqueous 
Ar Aromatic 
Bn Benzyl 
br Broad 
calcd Calculated 
Cbz Carboxybenzyl 
d Days 
DMAP 4-(Dimethylamino)pyridine 
DMAS N,N-dimethylaminosulfonyl 
DMSO Dimethyl sulfoxide 
eq Equivalent 
Et Ethyl 
g Grams 
h Hours 
HRMS High resolution mass spectroscopy 
Hz Hertz 
IR Infrared 
M Molar 
MP Melting point 
Me Methyl  
mg Milligram 
min Minutes 
mL Millilitre  
NBS N-bromosuccinimide 
NMM N-methylmaleimide 
NMR  Nuclear magnetic resonance 
NPM  N-phenylmaleimide 
Ph Phenyl 
ppm  Parts per million 
PTAD 4-phenyl-1,2,4-triazoline-3,5-dione 
rt  Room temperature 
Rf Retention factor 
SOMO Singly occupied molecular orbital   
TLC Thin layer chromatography 
THF  Tetrahydrofuran 
Ts Tosyl  
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Chapter 1 – Introduction- 
The main focus of this thesis is to look at the synthesis of complex indole containing 
compounds with potential biological activity. We believe this can be achieved through the 
use of multiple pericyclic reactions in a single reaction process which will allow the rapid 
synthesis of a diverse range of compounds, whilst also allowing close control of the 
stereochemistry.  
This introduction chapter will be split into four sections covering the key background areas 
of the thesis: 
1.0 – Pericyclic reactions  
2.0 – Pericyclic reactions in multi-component reactions  
3.0 – Indoles in biologically active compounds 
4.0 – Diels-Alder / ene reactions with vinyl-heteroaromatics 
1.1.0 Pericyclic reactions- 
As we propose to use Diels-Alder and ene reactions in our synthesis, we will review general 
Diels-Alder and ene reactions from the literature, to fully understand the pericyclic reactions 
and the products formed from these reactions. 
1.1.1 The Diels-Alder reaction-  
Since its discovery in 19281, the Diels-Alder reaction has been widely used in organic 
synthesis and is one of the most well understood reactions.2,3 The Diels-Alder reaction is a 
[4+2] cycloaddition which allows the simultaneous, stereocontrolled formation of two C-C or 
C-X bonds and the creation of up to four new stereocentres (Scheme 1.1).  These qualities 
are highly desirable for organic chemists and led to its pioneers, Otto Diels and Kurt Alder, 
winning the Nobel Prize for Chemistry in 1950.   
 
Scheme 1.1 – General [4+2] Diels-Alder reaction. 
As the Diels-Alder reaction forms two new bonds and leads to the generation of multiple 
new stereocentres, complex molecules can be rapidly synthesised from relatively simple 
starting materials (Scheme 1.2).4 
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Scheme 1.2 - Diels-Alder reaction in the synthesis of the drug panduratin (6). 
Conventional Diels-Alder reactions use an electron deficient dienophile and an electron rich 
cis-diene. Simple dienes like 1,3-butadiene can adopt two conformers, s-cis (7) and s-trans 
(8), though only the s-cis stereoisomer is in the correct orientation to allow a Diels-Alder 
reaction to occur (Figure 1.1). This problem can be overcome through the use of cyclic 
dienes, such as cyclopentadiene (10), where the two double bonds are fixed in an s-cis 
orientation.  
 
Figure 1.1 – Cis-(7) and trans-(8) 1,3-butadiene and cyclopentadiene (10). 
1.1.2 The ene reaction-  
The ene reaction is an electrocyclic reaction involving an allylic system (ene component) and 
a molecule that contains a π-bond (enophile) (Scheme 1.3). 
 
Scheme 1.3 - Example of a generic ene reaction.5 
1.1.3 Lewis acid catalysed carbonyl ene reactions-  
There are a wide range of different ene components that can be used in ene reactions, 
although the exact reaction mechanism is dependent upon the nature of the enophile. Ene 
reactions generally require higher temperatures than Diels-Alder reactions, therefore Lewis 
acids have been used extensively to catalyse the reaction (Scheme 1.4).5 
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Scheme 1.4 - Ene reaction employing a Lewis acid catalyst. 
The use of Lewis acid catalysts can lead to changes in product distribution when compared 
to thermal reactions that do not use Lewis acid catalysts (Scheme 1.5).6 
 
Scheme 1.5 - Ene reaction under thermal conditions or Lewis acid catalysis. 
In the case of carbonyl ene reactions, Lewis acids are used to coordinate to the carbonyl 
oxygen of the ester, making the C=O double bond more electron deficient thus increasing 
the regiospecificity of the reaction. The use of Lewis acid catalysts also allows the ene 
reaction to proceed under relatively mild reaction conditions.  
1.1.4 Aza ene chemistry- 
Previous work in the group has demonstrated that aza ene reactions can be performed with 
4-phenyl-1,2,4-triazole-3,5-dione (PTAD)  acting as the enophile (Scheme 1.6).7 The N=N 
bond is relatively weak and therefore the reaction rapidly goes to completion at a low 
temperature and short reaction time of one hour.  
 
Scheme 1.6 - Example of an aza-ene reaction on imidazole compound (20). 
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1.1.5 Nitroso ene chemistry- 
Niroso containing molecules can also undergo ene reactions. There is some debate as to the 
precise mechanism of the nitroso ene reaction i.e. whether it is a radical, ionic, pericyclic or 
stepwise process. Scheme 1.7 shows the different proposed mechanisms for an ene reaction 
involving a simple ene component (22) and a nitroso enophile (21).  
 
Scheme 1.7 - The four possible reaction mechanisms proposed for the ene reaction I = via a three 
membered ring intermediate. II = via a zwitterion intermediate. III = via a radical pathway. IV = via 
a concerted, pericyclic pathway.8 
It has previously been shown that the reaction between nitroso-methane (28) and o-
isotoluene (29) occurs via a concerted pericyclic mechanism (Scheme 1.8).8 Density 
functional calculations have demonstrated that transition state (30) does not contain either 
a diradical or a zwitterionic species suggesting that the reaction proceeds via a fully 
concerted, pericyclic pathway. 
 
Scheme 1.8 - Concerted nitroso-ene reaction mechanism. 
Although there is evidence from computational studies to support the theory that the ene 
reaction proceeds via a fully concerted mechanism as in the instance above, there is 
evidence to suggest a different mechanistic pathway is prominent in other ene reactions.  
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It has been reported that a biradical / zwitterionic mechanism may be favoured by 
molecules that are too hindered for the concerted mechanism to occur, and that have the 
ability to stabilise a radical / charged intermediate.5,9 This is supported by the fact that ene 
reactions using cyclopentene and cyclohexene can be initiated with a free radical initiator.5 
The proposed mechanism for the radical reaction involves a three membered ring 
intermediate (Scheme 1.9).  
 
Scheme 1.9 – Proposed radical  nitroso-ene pathway.10 
1.1.6 Ene regioselectivity-  
The final step in the ene reaction, which is common to all of the mechanisms proposed, is 
abstraction of a hydrogen. In an unsymmetrical alkene there can be several possible 
hydrogens that may be abstracted during the ene reaction. The hydrogen which is 
abstracted depends upon the sterics of the surrounding groups (Scheme 1.10).10 
 
Scheme 1.10 - Transition state (38) will be more favoured than the bottom reaction pathway (40) 
due to the steric effects between the aromatic ring and the methyl groups. 
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In the TSTWIN structure (38) the aromatic group (Ar) is pointing towards the more sterically 
hindered side of the alkene, which makes this transition state high in energy and therefore 
unfavourable. In the TSTWIX orientation (40), the aromatic group is pointing towards the 
unsubstituted region of the alkene where there are less steric interactions. This makes the 
TSTWIX orientation lower in energy and therefore kinetically favourable than the TSTWIN 
orientation. 
In the favoured TSTWIX orientation (40) there are two CH3 groups from which a proton can be 
abstracted, the top red CH3 group or the bottom blue CH3 group. However, the aromatic 
group on the nitroso compound experiences a steric interaction with the single CH3 group 
on the opposite side of the molecule. This steric interaction causes the nitroso compound to 
rotate, moving the oxygen towards the bottom blue CH3 group. Therefore the proton 
abstraction will occur from the blue CH3 group leading to the formation of (41) as the major 
product. 
1.2.0 Multi-component reactions- 
Our plan is to utilise two pericyclic reactions in a multi-component process to allow the 
rapid synthesis of complex compounds with high control of the stereochemistry. Therefore 
we will review literature work which has used multi-component reactions in organic 
synthesis.  
Multi-component reaction processes involve a single chemical operation in which the 
majority of the atoms from three or more components are combined to form a new target 
molecule. Multi-component reactions are not a new idea in organic chemistry and have 
been utilised in many famous synthetic reactions. One of the first, the Strecker synthesis of 
amino acids, was reported in 185011 and still remains a popular reaction for organic 
chemists today.12 The great appeal of multi-component reactions is the ability to start from 
very simple starting materials and rapidly generate highly complex molecules in an efficient, 
atom economical manner. For example, the Hantzsch synthesis involves the creation of 
complex substituted pyridine systems simply starting from ammonia, an aldehyde and a β-
keto-ester (Scheme 1.11).  
 
Scheme 1.11 - Hantzsch pyridine synthesis. 
Pericyclic reactions, such as Diels-Alder and ene reactions, can form multiple C-C / C-X bonds 
and new stereocentres. However, despite the advantage of forming highly complex 
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compounds in a relatively simple reaction sequence, there are few examples of tandem 
pericyclic reaction processes being used in the literature.  
1.2.1 Diels-Alder / Diels-Alder reactions-  
There are a large number of tandem, pericyclic reaction sequences that involve the use of 
multiple Diels-Alder reaction steps. In Diels and Alder’s original paper from 19281, they 
identified the products formed from a single Diels-Alder reaction (49) and a tandem Diels-
Alder / Diels-Alder reaction (50) process (Scheme 1.12). 
 
Scheme 1.12 - Products from single Diels-Alder (49) and tandem Diels-Alder reactions (50).  
Denmark et. al.13-16 have carried out extensive work in developing tandem intermolecular 
Diels-Alder / intramolecular cycloaddition reaction sequences involving nitroalkenes. A 
nitroalkene is used as a dienophile which undergoes a [4+2] Diels-Alder reaction, followed 
immediately by a further [3+2] cycloaddition reaction. This has allowed the researchers to 
utilise this tandem Diels-Alder reaction sequence to great effect in the synthesis of many 
natural products including (+)-crotanecine (55), a base component in a range of pyrrolizidine 
alkaloids (Scheme 1.13).13 
 
Scheme 1.13 - Tandem Diels-Alder reactions used in the synthesis of (+)-crotanecine (55). 
Many people have built upon the work by Denmark’s group including Avalos et al.17, who 
have adapted the tandem [4+2] Diels-Alder / [3+2] cycloaddition reactions in their synthesis 
of carbohydrates (Scheme 1.14). However, whilst Denmark’s work involved an 
intermolecular Diels-Alder / intramolecular Diels-Alder reaction sequence, Avalos et al. have 
developed an intermolecular Diels-Alder / intermolecular Diels-Alder reaction sequence 
using nitroalkene (56) as the diene and ethyl vinyl ether (57) as the dienophile.   
                                                                                                                                          Chapter 1 - Introduction   
 
8 | P a g e  
 
 
Scheme 1.14 - [4+2] Diels-Alder / [3+2] cycloaddition reaction sequence 
Through consideration of frontier molecular orbital theory, it is possible to predict the 
stereo- and regio-selectivity of the Diels-Alder reaction and therefore the stereochemistry of 
the resultant Diels-Alder adduct.  
Roush et al.18 have exploited these properties in their total synthesis of (-)-chlorothricolide 
(64), through a domino intermolecular [4+2] Diels-Alder / intramolecular [4+2] Diels-Alder 
reaction sequence to form (64) in a yield of 55%. Product (64) is the major product formed 
in preference to 96 other compounds that could be formed from two sequential Diels-Alder 
reactions when the endo, exo, stereo-, and regio- selectivity possibilities are considered 
(Scheme 1.15).  
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Scheme 1.15 - Intermolecular Diels-Alder / intramolecular Diels-Alder reaction sequence in the 
synthesis of (-)-chlorothricolide (64). 
1.2.2 Diels-Alder / ene reactions-  
All Diels-Alder reactions generate a new double bond, therefore it could be envisaged that 
this double bond could be reacted further in an ene reaction, leading to the formation of 
new C-C or C-X bonds. There are however, surprisingly few examples of this reaction 
sequence in the literature.  
Heathcock et al.19 demonstrated in their synthesis of Daphniphyllum alkaloid (±)-methyl 
homosecodaphniphyllate (70), how a one-pot intra-Diels-Alder / intra-ene reaction could be 
used to rapidly generate complex compounds (Scheme 1.16). 
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Scheme 1.16 - One-pot Diels-Alder / ene reaction in the synthesis of (±)-methyl 
homosecodaphniphyllate (70). 
Diol (65) is subjected to a Swern reaction followed by cyclisation to form diene (67). Diene 
(67) is then able to undergo an intramolecular hetero-Diels-Alder reaction and subsequent 
intramolecular ene reaction, to give compound (69) in an overall yield of 77%. This elegant 
synthesis exemplifies the great utility in combining one-pot Diels-Alder / ene reactions to 
generate high molecular complexity.   
Despite Heathcock demonstrating the power of one-pot Diels-Alder / ene reactions, the 
next example of an intermolecular-Diels-Alder / intramolecular ene reaction was not 
reported until 2004 by Kraus and Kim.20 Whilst trying to synthesise bromo-aldehyde (73) via 
a Diels-Alder reaction, they discovered that the major product (74) isolated resulted from a 
Diels-Alder / ene reaction sequence (Scheme 1.17) 
 
Scheme 1.17 - Unexpected ene adduct (74) formed from a Diels-Alder / ene reaction. 
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The initial Diels-Alder reaction between aldehyde (71) and diene (72) leads to the formation 
of Diels-Alder adduct (73) which then undergoes a carbonyl ene reaction with the aldehyde 
group to form (74). This one-pot Diels-Alder / ene reaction leads to the formation of four 
new stereocentres. 
In the same year as Kraus and Kim’s one-pot Diels-Alder / ene reaction, Inomata et al. 
published a  paper21 on the total synthesis of plant extract (+)-methyl jasmonate (78). The 
formation of (+)-methyl jasmonate (78) was achieved with the use of a one-pot retro-Diels-
Alder / intramolecular ene reaction sequence (Scheme 1.18).  
 
Scheme 1.18 - retro-Diels-Alder / ene reaction used in the synthesis of (+)-methyl jasmonate (78).  
Inomata’s group discovered that, as the ene reaction was the rate determining step for the 
retro-Diels-Alder / ene reaction, the rate of the ene reaction could be greatly improved with 
a trimethylsilyl group adjacent to the enophile. The trimethylsilyl group donates electron 
density into the alkene which raises the energy of the HOMO making it more reactive 
towards enophiles. The same reaction, with a less reactive H group instead of a TMS group, 
ran for the same amount of time, gave a 2: 1 mixture of unsaturated lactone (76) and ene 
adduct (77).  
1.3.0 Indole in biologically active compounds-  
Our target is to synthesise bioactive indole containing compounds using multi-component 
pericyclic reactions. Therefore we need to consider why compounds based upon indole are 
of interest. We will look at a range of biologically active indole compounds from the 
literature. This will allow us to tailor our reactions towards specific molecular frameworks 
and biological properties.  
1.3.1 Common indole-containing compounds- 
The heteroaromatic indole is found in a large number of naturally occurring compounds. It is 
most abundant in nature as tryptophan (79), one of the naturally occurring amino acids and 
it is also found in many important alkaloids such as tryptamine (80) and serotonin (81) 
(Figure 1.2).  
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Figure 1.2 - Tryptophan (79), tryptamine (80) and serotonin (81). 
Many indoles are also used clinically in drugs. The migraine drug sumatriptan (84), 
hallucinogenic lysergic acid diethylamide (LSD) (83) and the anti-emetic ondansetron (82), 
all contain an indole ring and often contain tryptophan-like structures (Figure 1.3). These 
drugs all have similar structural motifs and are all known to bind to serotonin receptors in 
the brain.22-24  
 
Figure 1.3 - Ondansetron (82), LSD (83) and sumatriptan (84). 
In addition to these tryptophan-based bioactive compounds (Figure 1.3), many alkaloids 
including rebeccamycin (85) and staurosporine (86), have a bis-indole ring structure (Figure 
1.4). Compounds in this class are produced by bacteria, such as Staphomycetes, and have a 
range of biological effects.25  
 
Figure 1.4 - Rebeccamycin (85) and staurosporine (86). 
Although rebeccamycin (85) and staurosporine (86) have very similar structures, their 
biological activity is due to inhibition of two different biological targets. Rebeccamycin (85) 
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works by inhibiting topoisomerase I which is an important enzyme involved in the 
replication and transcription of DNA.26 Structure activity relationship studies of synthetic 
analogues of rebeccamycin, such as (87) and (88) (Figure 1.5), have shown that a sugar 
moiety on the indolic nitrogen must be present for the compound to be an effective 
topoisomerase I inhibitor.27,28  
 
Figure 1.5 - Semi-synthetic analogues of rebeccamycin.  
Staurosporine (86), on the other hand, is a kinase inhibitor (IC50 value of 2.7 nM against 
protein kinase C)29 and works by binding to the ATP site on the kinase.30 However, due to 
the lack of selectivity of staurosporine (86), it is unsuitable as a clinical kinase inhibitor. This 
has led to the development of a number of semi-synthetic analogues which show more 
selectivity, such as midostaurin (89) and lestaurtinib (90) (Figure 1.6).28  
 
Figure 1.6 - Midostaurin (89) and lestaurtinib (90). 
1.3.2 Granulatimide (91) and isogranulatimide (92) compounds- 
Another set of compounds which have shown a lot of promise as anti-cancer drugs, is 
granulatimide (91) and isogranulatimide (92). Originally isolated from the sea squirt 
Didemnum granulatum, granulatimide (91) and isogranulatimide (92) have shown to be 
potent inhibitors of Chk1 kinase (Figure 1.7).31 Many current cancer treatments, such as 
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radiation or chemotherapy, are designed to damage the DNA of cancer cells leading to cell 
death. The Chk1 kinase plays a vital role in the G2 cell cycle checkpoint, which delays the cell 
cycle to allow for DNA repair to occur. Therefore Chk1 kinase inhibitors prevent the repair of 
damaged DNA in cells, which leads to death of the cell.32  
 
Figure 1.7 - Structure of granulatimide (91) and isogranulatimide (92) 
Both granulatimide (91) and isogranulatimide (92) contain a pyrrolo[3,4-a]carbazole-1,3-
dione framework (93) shown below (Figure 1.8).  
 
Figure 1.8 - The pyrrolo[3,4-a]carbazole-1,3-dione framework 
1.3.3 Pyrrolo[3,4-a]carbazole-1,3-dione compounds- 
The promising bioactivity shown by granulatimide (91) and isogranulatimide (92) has led to 
much work being carried out in the synthesis of compounds containing a pyrrolo[3,4-
a]carbazole-1,3-dione framework, such as compound (94) (Figure 1.8).33 Structure activity 
relationship (SAR) studies have been conducted on compounds containing this framework, 
to try and identify the pharmacaphore (Scheme 1.19).33 
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Scheme 1.19 - Synthesis of granulatimide analogues (98) and (100). 
The synthesis of (98) and (100) is achieved in three steps with an overall yield of 9 and 10% 
respectively and both compounds were shown not to inhibit Chk1 kinase. This suggested 
that the succinimide group in the top region of granulatimide (91) is important for biological 
activity.  
Building upon this work by Prudhomme et al. led to Caballero et al.34 synthesising 
compounds such as (101) and (102) (Figure 1.9) and testing them for activity against a range 
of cancer cell lines.  
 
Figure 1.9 - Synthetic biologically active indole compounds. 
Caballero et al. observed that tetrahydrocarbazole compounds which are not fully aromatic 
such as (101), showed better bioactivity than carbazole compounds like (102).  
                                                                                                                                          Chapter 1 - Introduction   
 
16 | P a g e  
 
This has led to the development of similar compounds such as (103) and (104), which have 
been shown to  have good biological activity against B16 melanoma cells 35 (Figure 1.10).  
 
Figure 1.10 - Synthetic bioactive indoles. 
1.4.0 Diels-Alder reactions with vinyl-heteroaromatics-  
We intend to use vinyl-indole compounds as the start point in our multi-component 
reactions and therefore we should review general and related work that use vinyl-indole 
compounds in pericyclic reactions.  
1.4.1 Vinyl-heteroaromatic Diels-Alder reactions in synthesis- 
There have been a considerable number of studies into Diels-Alder reactions that use vinyl-
heteroaromatics as the diene, including vinyl-indoles36-40, vinyl-imidazoles41-46, vinyl-
pyrazole47,48 and vinyl-imidazolone.49,50 Although vinyl-heteroaromatics are not traditional 
dienes in Diels-Alder reactions due to the involvement of aromatic π-bonds, they are 
electron rich and therefore can be excellent dienes. 
Diels-Alder reactions of vinyl-heteroaromatics have been used in the synthesis of useful 
biological targets.38 In the total synthesis of the alkaloid eburnamonine (106), an 
intramolecular aza-Diels-Alder reaction is used to simultaneously form two rings of the 
penta-cyclic ring system (Scheme 1.20). 
 
Scheme 1.20 - An intramolecular aza-Diels-Alder reaction in the synthesis of eburnamonine (106).  
Intermolecular Diels-Alder reactions with vinyl-indoles have also been reported.51-53 For 
example, the reaction shown in Scheme 1.21 shows the Diels-Alder reaction between a 
substituted vinyl-indole (107) and substituted acetylene (108).  
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Scheme 1.21 - Intermolecular Diels-Alder reaction of vinyl-indole (107) with substituted acetylene 
(108). 
Much of the Diels-Alder chemistry of vinyl-imidazoles has centred on the synthesis of 
oroidin alkaloids.41,42 Scheme 1.22 below shows the Diels-Alder step used in the synthesis of 
Palau’amine (112). 
 
Scheme 1.22 - Vinyl-imidazole Diels-Alder reaction in the formation of Palau’amine (112).42 
In addition, vinyl-imidazolones have been used in the total synthesis of many naturally 
occurring compounds50, including the complex ring structures found in oroidin alkaloids 
(Scheme 1.23) and the related bisguanidine marine alkaloids.49  
 
Scheme 1.23 – Diels-Alder reaction in the synthesis of complex ring structures found in oroidin 
alkaloids. 
1.4.2 Diels-Alder / ene reactions with vinyl-heteroaromatics- 
In a few cases, Diels-Alder reactions with vinyl-heteroaromatics have led to an interesting 
side reaction occurring between the Diels-Alder product and excess dienophile in the 
reaction mixture. The Diels-Alder product of 3-vinyl-imidazole (116) and N-phenylmaleimide 
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(NPM) (117) as shown below (Scheme 1.24) can undergo an ene reaction with excess NPM 
(117) in the reaction mixture to give product (119).  
 
Scheme 1.24 – Diels-Alder/ene reaction of 1-benzyl-4-vinyl-1H-imidazole (116) and NPM (117).42 
A similar reaction has also been observed in the Diels-Alder reactions of vinyl-pyrazole, 
whereby initial Diels-Alder product (121) reacts with excess dienophile in an ene reaction to 
give (122) and (123) (Scheme 1.25). 
 
Scheme 1.25 - Diels-Alder / ene reaction of 1-phenyl-4-vinyl-1H-pyrazole (120) and prop-1-yne.48 
Sequential Diels-Alder / ene reactions have also been noted with 2-vinyl-indoles. Here the 
ene reaction is in competition with the rearomatisation of Diels-Alder adduct (125) (Scheme 
1.26).36 
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Scheme 1.26 – Diels-Alder / ene versus Diels-Alder / rearomatisation reactions of 2-(prop-1-en-2-
yl)-1H-indole (124). 
1.5.0 Conclusions-  
This introduction chapter has served to be an overall guide through the important chemistry 
that will be discussed in this thesis. We have shown the great synthetic utility of pericyclic 
Diels-Alder and ene reactions that allow the formation of multiple new bonds and 
stereocentres. We have also seen how combining two or more Diels-Alder / ene reactions 
into one multi-component reaction process, allows the synthesis of highly complex 
compounds from relatively simple starting materials.  
The literature on biologically active indole molecules offers insight into the structural 
features necessary for a compound to show biological activity. With this information from 
the literature, we can develop a synthetic plan that will allow us to use this chemistry in a 
novel synthesis of biologically active indole-containing compounds. 
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Chapter 2- Synthesis and Diels-Alder Chemistry of Vinyl-Indoles 
2.1.0 Synthetic route to pyrrolo[3,4-a]carbazole-1,3-dione framework- 
We envisaged synthesising compounds with a pyrrolo[3,4-a]carbazole-1,3-dione framework, 
such as (103), using an intermolecular Diels-Alder reaction between 3-vinyl-1H-indole and a 
dienophile, followed by an intermolecular ene reaction with the resultant Diels-Alder adduct 
(129) formed (Figure 2.1). 
 
Figure 2.1 - Retrosynthetic approach to biologically active compounds.  
Given the wide range of dienophiles and enophiles available, we reasoned that this 
synthetic route could rapidly lead to a diverse series of potentially biologically active 
compounds.  
2.1.1 Synthetic plan- 
The initial aim of the project is to synthesise N-protected 3-vinyl-1H-indoles (133) from 
commercially available 3-carboxaldehyde-1H-indole (131). The nitrogen protecting group 
has a large effect upon the electronics of the indole ring system and consequently a large 
effect upon the Diels-Alder/ ene reactions. As normal electron demand Diels-Alder reactions 
require an electron rich dienophile, a variety of N-protecting groups will be screened to 
determine the most suitable system for the planned Diels-Alder/ ene reaction.  
Following this, the N-protected indoles (132) will be subjected to a Wittig reaction to give N-
protected 3-vinyl-1H-indole compounds (133). Once a range of N-protected 3-vinyl-1H-
indoles (133) are obtained, the Diels-Alder chemistry with a range of dienophiles will be 
investigated.  
We intend to predominantly use maleimide based dienophiles (134). Maleimides are 
excellent examples of electron poor dienophiles, which are required in normal electron 
demand Diels-Alder chemistry. In addition, maleimides (134) are a common feature in a 
range of biologically active unsaturated carbazole compounds (Chapter 1.3).  
Once Diels-Alder cycloadducts (135) are obtained, they will be reacted with a range of 
enophiles, forming compounds (136) with a pyrrolo[3,4-a]carbazole-1,3-dione framework 
(Scheme 2.1). 
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Scheme 2.1 - Planned synthetic route to carbazole compounds.  
2.2.0 Synthesis of N-protected 3-vinyl-indoles and investigation of their Diels-Alder / ene 
chemistry-  
The initial step in the synthetic route (Scheme 2.1) was to synthesise N-protected 3-vinyl-
1H-indoles. Previous work by Porter et al. has shown that protection of the indolic nitrogen 
plays a vital role in controlling the rate of Diels-Alder reactions and the stability of Diels-
Alder adducts (135) formed.54 Porter et al. showed that electron rich dienes, such as 1-
benzyl-3-vinyl-1H-indole (137), readily react with N-phenylmaleimide (NPM) (117) to 
generate Diels-Alder adduct (138). Diels-Alder adduct (138) can be isolated by 
recrystallisation, however rapidly undergoes rearomatisation to form compound (139) in 
polar solvents (Scheme 2.2).  The reactivity of Diels-Alder adduct (138) makes isolation and 
further chemistry difficult.  
Scheme 2.2 - Formation of rearomatised Diels-Alder adduct (139).  
2.2.1 Preliminary Diels-Alder reactions- 
To examine the effect of having no protecting group on the indolic nitrogen, a Diels-Alder 
reaction was carried out between 3-vinyl-1H-indole (140) and N-methylmaleimide (NMM) 
(141). The reaction was carried out in a sealed tube at 70 oC for two hours in DCM with 
clean conversion of 3-vinyl-1H-indole (140) to Diels-Alder adduct (142) being observed 
(Scheme 2.3).  
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Scheme 2.3 - Diels-Alder reaction with 3-vinyl-1H-indole (140) and NMM (141). 
However, attempts at purifying the crude reaction mixture using column chromatography or 
recrystallisation led to rearomatisation of the indole ring to form rearomatised Diels-Alder 
adduct (143) (Figure 2.2).   
 
Figure 2.2 - Rearomatised Diels-Alder adduct (143).  
Although the Diels-Alder reaction between 3-vinyl-1H-indole (140) and NMM (141) offered 
good conversion to Diels-Alder adduct (142), the rapid rearomatisation of the indole ring 
made further chemistry difficult.   
2.2.2 N-Protection of 3-carboxaldehyde-1H-indole- 
As Porter’s research54 and preliminary reactions had shown that no protecting group and  
electron donating N-protecting groups led to rapid rearomatisation, we rationalised that 
electron withdrawing groups might stabilise Diels-Alder adduct (135) and allow further 
chemistry to be performed. Therefore we proposed using tosyl and Boc as N-protecting 
groups for our initial investigations. The use of two protecting groups with different electron 
withdrawing capabilities allows a comparison to be made between the relative rate of Diels-
Alder reactions with maleimides and the stability of resultant Diels-Alder adducts formed.  
Boc and tosyl protection of the indolic nitrogen of 1H-indole-3-carbaldehyde (131) was 
attempted using mild, basic conditions based on literature procedure.55 The reactions 
worked well and the desired compounds were isolated in excellent yields.  
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Conditions Yield Product  
i) NEt3, 0 
oC, 1h 
ii) TsCl, rt, 18 h 
90% 
 
i) NEt3, 0 
oC, 1h 
ii) (Boc)2O, rt, 18 h 
87% 
 
Table 2.1 - N-Protection of 3-carboxaldehyde-1H-indole (131). 
Generally, the deprotonation of an indolic NH requires the use of a strong base.56 However, 
in the case of 3-carboxaldehyde-1H-indole (131), the nitrogen lone pair is conjugated with 
the electron withdrawing carbonyl group which makes the NH more acidic. As a result of 
this, weak bases such as triethylamine, are sufficient to carry out the protection (Scheme 
2.4).  
 
Scheme 2.4 - N-protection of 3-carboxaldehyde-1H-indole. 
2.2.3 Wittig reactions of N-protected-3-carboxaldehyde-indoles-  
With 1-tosyl-1H-indole-3-carbaldehyde (144) and tert-butyl 3-formyl-1H-indole-1-
carboxylate (145) in hand, the next step was to convert them into the corresponding N-
protected 3-vinyl-indole compounds (146) and (147). We did this through a Wittig reaction 
between N-protected 3-carboxaldehyde-1H-indoles (144) and (145), and 
methylenetriphenyl-λ5-phosphane.  
The desired 1-tosyl-3-vinyl-1H-indole (146) was obtained in good yield. However, after 
several attempts, tert-butyl 3-vinyl-1H-indole-1-carboxylate (147) could only be obtained in 
a poor yield of 13% in addition to 10% of 3-vinyl-1H-indole (140) (Scheme 2.5).  
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Scheme 2.5 - Synthesis of N-protected 3-vinyl-indoles (146) and (147). 
The formation of 3-vinyl-1H-indole (140) suggested that the Wittig reaction on tert-butyl 3-
formyl-1H-indole-1-carboxylate (145) was proceeding, but tert-butyl 3-vinyl-1H-indole-1-
carboxylate (147) formed was not stable to Wittig reaction conditions. It was therefore 
decided to proceed to the Diels-Alder chemistry using 1-tosyl-3-vinyl-1H-indole (146). 
2.2.4 Diels-Alder chemistry of 1-tosyl-3-vinyl-1H-indole (146)-  
With the Wittig reaction giving 1-tosyl-3-vinyl-1H-indole (146) in a good yield, the ability of 
(146) to undergo Diels-Alder chemistry was investigated.  
A 1: 1 mixture of 1-tosyl-3-vinyl-1H-indole (146) and NMM (141) was dissolved in DCM and 
the solution was stirred at room temperature (Scheme 2.6).  
 
Scheme 2.6 - Initial Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and NMM (141).  
The initial reaction gave the desired Diels-Alder adduct (148) in a good yield of 76%, after 
stirring for 96 hours at room temperature. 
Optimisation of the reaction was performed in different solvents and at different 
temperatures to try and reduce the Diels-Alder reaction time. We used 1H NMR to monitor 
the reaction. A typical example is shown below (Figure 2.3).  
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Figure 2.3 - 1H NMR of Diels-Alder reaction performed at 70 oC in DCM-d2 at 0, 16, 24 and 48 hours. 
The best conditions in terms of reaction time were obtained when the Diels-Alder reaction 
was performed in a sealed tube, in DCM at 70 oC. This lead to a substantial reduction in the 
reaction time, from 96 hours at room temperature, to 48 hours using the new conditions.  
2.2.5 N-phenylmaleimide Diels-Alder chemistry- 
After optimising the Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and NMM 
(141), the next step was to investigate the scope of the Diels-Alder reaction with further 
dienophiles. The Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and NPM 
(117) was performed using identical conditions to the previous Diels-Alder reaction with 
NMM (141) (Scheme 2.7).  
Ha Hd Hb H
c 
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Scheme 2.7 - Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and NPM (117). 
The Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and NPM (117) gave Diels-
Alder adduct (149) in a good yield of 81%. 
2.2.6 PTAD Diels-Alder chemistry- 
4-Phenyl-1,2,4-triazole-3,5-dione (PTAD) (150) is a potent dienophile and is known to readily 
undergo Diels-Alder reactions with indole based compounds.57-59 Due to the reactivity of 
PTAD (150), the Diels-Alder reaction with 1-tosyl-3-vinyl-1H-indole (146) was carried out at -
78 oC to give desired Diels-Alder adduct (151) in an excellent yield of 88% (Scheme 2.8).   
 
Scheme 2.8 - Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and PTAD (150). 
2.3.0 Relative stereochemistry of Diels-Alder adducts (148), (149) and (151)- 
Diels-Alder adducts (148) and (149), generated from the reaction between 1-tosyl-3-vinyl-
1H-indole (146) and NMM (141) or NPM (117), can form two possible diastereomers (Figure 
2.4). The Diels-Alder adduct formed is dependent upon the geometry of the transition state. 
The substituents can arrange themselves in either an endo or exo transition state which 
leads to the endo-Diels-Alder adduct (153) or exo-Diels-Alder adduct (152) being formed. In 
our Diels-Alder reactions, only one diastereomer is observed in the 1H NMR. 
 
Figure 2.4 - The two possible Diels-Alder products, exo (152) and endo (153).  
In order to confirm whether the endo- or exo- Diels-Alder adduct was formed, crystals were 
grown of Diels-Alder adduct (148) for X-ray crystallography, by slow evaporation from DCM. 
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The X-ray crystal structure showed the formation of Diels-Alder adduct (148) proceeded 
through an endo transition state (Figure 2.5).  
 
 
Figure 2.5 - X-ray structure of tosyl protected Diels-Alder adduct.  
This suggests that the reaction is under kinetic control as the highest energy Diels-Alder 
adduct (148) is formed preferentially and it also demonstrates that the reaction is not 
reversible.  A reversible Diels-Alder reaction would have led to the formation of the more 
thermodynamically stable exo-Diels-Alder adduct. 
The crystal structure also confirms that Diels-Alder adduct (148) is formed in the reaction. 
The bond length between C(15) and C(7) is 1.510 Å, which is characteristic for a C-C single 
bond. The bond length between C(7) and C(8) on the other hand is 1.334 Å, which is typical 
for a C-C double bond. This suggests that the double bond is between the C(7) and C(8) 
bond and Diels-Alder adduct (148) has not rearomatised.  
This is supported by the hybridisation of C(15) compared to C(8). The bond angle at C(7)-
C(15)-C(14) is 109.10o which suggests that C(15) is an sp3 hybridised carbon atom. In 
comparison, the bond angle at C(7)-C(8)-C(9) is 116.98o which suggests C(8) is an sp2 
hybridised carbon.  
The formation of endo-Diels-Alder adduct (148) is further supported by the 1H NMR 
spectrum of (148). The coupling constant between H(14) and H(15) is 7.2 Hz, which is typical 
for coupling between an axial and equatorial proton. If the exo-Diels-Alder adduct had been 
formed then the dihedral angle would be approximately 180o, which would give a coupling 
constant of around 10 Hz due to axial-axial coupling. 
The same relative stereochemistry is observed in the X-ray crystal structure of Diels-Alder 
adduct (149) (Figure 2.6).  
                                                                    Chapter 2 – Synthesis and Diels-Alder chemistry of vinyl-indoles  
 
28 | P a g e  
 
 
 
Figure 2.6 - X-ray structure of Diels-Alder adduct (149). 
The bond lengths between C(5)-C(12) is 1.507 Å and C(4)-C(5) is 1.335 Å which are 
comparable to the equivalent bond lengths seen in Diels-Alder adduct (148).  
Diels-Alder adduct (151) generated from the reaction between 1-tosyl-3-vinyl-1H-indole 
(146) and PTAD (150) was crystallised from DCM by slow evaporation. The X-ray structure 
confirmed that the expected Diels-Alder adduct (151) had indeed been formed (Figure 2.7). 
 
 
Figure 2.7 - X-ray structure of PTAD Diels-Alder adduct (151). 
Although the Diels-Alder reaction proceeds through either an endo or exo transition state, 
the nature of the dienophile makes it impossible to assign whether Diels-Alder adduct (151) 
is formed from an endo or exo transition state.  
2.4.0 Carbonyl ene reactions with Diels-Alder adduct (148)-  
With an efficient method for the synthesis and purification of Diels-Alder adduct (148), the 
next step was to investigate the ene chemistry of adduct (148). Carbonyl compounds have 
long been used as enophiles in ene reactions and there are many examples in the 
literature60-62 demonstrating their readiness to undergo ene reactions. We therefore 
proposed reacting a range of carbonyl enophiles with Diels-Alder adduct (148). 
Lewis acids have previously been shown to catalyse carbonyl ene reactions by coordinating 
to the oxygen of the carbonyl bond (Figure 2.8).63 The Lewis acid draws electron density 
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away from the carbonyl bond thus making it more reactive towards nucleophilic attack and 
therefore ene chemistry.  
 
Figure 2.8 - Lewis acid DMAC binding to carbonyl compound.  
We proposed reacting Diels-Alder adduct (148) with a range of carbonyl enophiles, using 
dimethylaluminium chloride (DMAC) as the Lewis acid. 
Due to the reactive nature of the DMAC, Diels-Alder adduct (148) and carbonyl enophiles 
(155) – (164) were first dissolved in DCM before the solution was cooled to -78 oC for the 
addition of DMAC. The reaction was then allowed to warm to room temperature overnight. 
The results are summarised in Table 2.2.   
Carbonyl Ene Reactions 
 
Entry R-CHO Conditions Product Yield 
1 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
2 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
3 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
4 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
5 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
6 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
7 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
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8 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
9 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 5 days 
No Reaction N/A 
10 
 
i) Me2AlCl, 
-78 oC, 15 min 
ii) rt, 18 h 
 
82% 
Table 2.2 - Results of the reaction between Diels-Alder adduct (148) and a range of carbonyl 
enophiles (155) – (164). 
The carbonyl ene reactions with the aldehydes and ketones (Table 2.2, entries 1-9) saw no 
reaction occur after 5 days of stirring, and Diels-Alder adduct (148) was recovered from the 
reactions. 
The reaction between 2,3,4,5,6-pentafluorobenzaldehyde (164) and Diels-Alder adduct 
(148) (Table 2.2, entry 10) afforded ene adduct (165) as a 6:1 mixture of diastereomers. The 
crude product was purified by column chromatography to give an excellent yield of 82%, 
although the mixture of diastereomers could not be separated. 
2.5.0 Aza-ene reactions with Diels-Alder adduct 148- 
Our investigations had shown that the carbonyl ene reaction required a very electron 
deficient enophile before the reaction could occur. Therefore we decided to move away 
from carbonyl compounds and instead look at more reactive enophiles. Previous work in the 
literature7,64 has shown that 4-phenyl-1,2,4-triazole-3,5-dione (PTAD) (150) is an excellent 
enophile as a result of the N=N bond being adjacent to two electron withdrawing carbonyl 
groups. We therefore examined the Diels-Alder reaction between Diels-Alder adduct (148) 
and PTAD (150). 
Due to the reactivity of PTAD (150), the ene reaction between Diels-Alder adduct (148) and 
PTAD (150) was carried out at 0 oC and led to the formation of desired ene adduct (167) as a 
single diastereomer in a good yield (Table 2.3). 
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Aza Ene Reactions 
 
Entry X R’ R-N=N-R Conditions Product Yield 
1 CH Me 
 
0 oC, 2.5 h 
 
73% 
Table 2.3 - Ene reaction between Diels-Alder (148) and PTAD (150). 
2.6.0 Nitroso-ene reactions with Diels-Alder adduct (148)-   
Nitroso compounds are well known in the literature10 for their ability to undergo ene 
reactions. Previous work7 in the MJH group has shown that nitrosobenzene readily 
undergoes ene reactions with appropriate imidazole compounds. We therefore proposed to 
examine the nitroso-ene chemistry of Diels-Alder adduct (148).  
Our initial investigations were carried out by dissolving Diels-Alder adduct (148) in DCM at 
room temperature and adding nitrosobenzene to the solution. This led to the formation of 
the desired ene adduct (171) in a good yield (Table 2.4, Entry 1). The 1H NMR of ene adduct 
(171) was carried out at 30 oC as the spectra obtained at room temperature (21 oC) showed 
a series of broad peaks instead of well-defined peaks. However upon running the 1H NMR at 
30 oC, the broad peaks were resolved into sharp peaks. 
With a working method for the ene reaction between Diels-Alder adduct (148) and 
nitrosobenzene (170) in hand, the next step was to test the scope of this reaction with other 
enophiles.  
We did this by examining the ene reaction between a range of commercially available 
nitroso compounds and Diels-Alder adduct (148). The results are summarised in Table 2.4, 
entries 1-5. 
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Nitroso-ene Reactions 
 
Entry X R’ R-NO Conditions Product Yield 
1 CH Me 
 
rt, 18 h 
 
68% 
2 CH Me 
 
rt, 18 h 
 
72% 
3 CH Me 
 
rt, 7 days No Reaction N/A 
4 CH Me 
 
rt, 7 days No Reaction N/A 
5 CH Me 
 
rt, 7 days No Reaction N/A 
6 N 
Ph 
 
 
rt, 18 h 
 
74% 
7 N Ph 
 
rt, 18 h 
 
72% 
Table 2.4 – Nitroso-ene reactions with Diels-Alder adduct (148). 
The two successful ene reactions between nitrosobenzene (170) / 1-methyl-2-
nitrosobenzene (172) and Diels-Alder adduct (148) (Table 2.4, entries 1 and 2) gave the 
desired ene adducts (171) and (173) in good yields of 68 and 72%.  
There was no reaction between the nitroso compounds with adjacent electron donating 
groups (Table 2.4, entries 3-5) and Diels-Alder adduct (148). The 1H NMR spectra showed no 
reaction had occurred after seven days at room temperature and Diels-Alder adduct (148) 
starting material could be recovered from the reaction.  
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The electron donating groups adjacent to the nitroso group can donate electron density into 
the nitroso group. This raises the energy of the LUMO of the enophile and thus raises the 
activation energy of the ene reaction (Figure 2.9).  
 
Figure 2.9 - Resonance form of N,N-dimethyl-4-nitrosoaniline (174). 
The successful ene reactions were repeated using PTAD Diels-Alder adduct (151) and the 
same reaction conditions (Table 2.4, entries 6-7). The desired ene adducts (177) and (178) 
were obtained in excellent yields, comparable to the previous nitroso-ene reactions with 
Diels-Alder adduct (148) (Table 2.4, entries 1-2). 
2.7.0 Halogenation reactions- 
Having examined a range of different conditions and a variety of enophiles, we next 
investigated what other chemistry could be performed on the double bond of Diels-Alder 
adduct (148). Previous work by Lovely et al.65 has shown that the double bond formed from 
a Diels-Alder reaction between vinyl-imidazole (116) and NPM (117), can react with both 
dimethyldioxirane (DMDO) and N-bromosuccinimide (NBS) (Scheme 2.9).  
 
Scheme 2.9 - Lovely’s reaction using DMDO or NBS to create alcohols (179) and (180). 
We proposed using N-bromosuccinimide (NBS) to brominate Diels-Alder adduct (148), and 
then displace the bromine with a nucleophile through a nucleophilic substitution reaction 
(Scheme 2.10). 
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Scheme 2.10 - General scheme for bromination / substitution reactions.  
The first step in investigating this route was the bromination of Diels-Alder adduct (148) to 
form compound (181). The bromination reaction was initially performed at room 
temperature using one equivalent of NBS, for one hour. Three major products were isolated 
from the crude mixture using column chromatography (Scheme 2.11). 
  
Scheme 2.11 - Products formed from the reaction with NBS. 
Although the bromination reaction (Scheme 2.11) did not give desired product (181), 
carbazole compounds (183) and (184) suggested that brominated product (181) was being 
formed as an intermediate. We propose that carbazole (183) is generated from the E1 
elimination reaction of brominated compound (181) (Scheme 2.12).   
 
Scheme 2.12 - Proposed reaction to form carbazole (183) via brominated intermediate (181).  
In an attempt to isolate brominated product (181), the reaction was repeated but the time 
was reduced from one hour to thirty minutes and the reaction temperature was dropped 
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from room temperature to 0 oC (Scheme 2.13). It was hoped that this would allow isolation 
of brominated product (181) before the elimination to carbazole (183) could occur.  
 
Scheme 2.13 - Bromination reaction performed at 0 oC for 0.5 hours. 
The major product isolated from the reaction was eliminated carbazole product (183), in a 
higher yield than was achieved in the previous reaction. The other major products isolated 
from the reaction were a mixture of desired brominated compound (181) and another 
unidentified compound with an identical Rf value. The mixture of two compounds could not 
be separated by column chromatography so instead a recrystallisation by slow evaporation 
was attempted to determine if one product crystallised preferentially to the other. One 
product did crystallise preferentially and therefore it was possible to get an X-ray crystal 
structure (Figure 2.10).   
 
 
 
Figure 2.10 - X-ray structure of brominated Diels-Alder product (186).  
The X-ray structure obtained was of a new compound (186) which we had not previously 
identified. The X-ray crystal structure indicated that the double bond was between C(7) and 
C(8) which is backed up by examination of the bond lengths and bond angles. The C(7)-C(8) 
bond length is 1.328 Å, typical of a C-C double bond, while the C(14)-C(7) bond length is 
1.516, typical for a C-C single bond. This is confirmed by examining the hybridisation of C(7) 
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and C(14). The bond angle between C(7)-C(14)-C(13) is 111.6 o which suggests C(14) is an sp3 
hybridised carbon. The bond angle between C(7)-C(8)-C(9) is 120.0 o which would be 
expected if C(8) is an sp2 hybridised carbon.  
We propose that product (186) arises from the final elimination step, after the initial 
bromination step has occurred (Scheme 2.14). There are two possible hydrogens that can be 
eliminated (Ha or Hb) and hence a mixture of products is formed. Elimination of Ha leads to 
the thermodynamically favourable rearomatised indole ring (181), while elimination of Hb 
leads to the formation of minor product (186), which crystallises preferentially. 
 
Scheme 2.14 - Products formed in the bromination reaction. 
Although brominated compound (186) crystallised preferentially to compound (181), it was 
still not possible to get a pure sample of either brominated products (181) or (186). This was 
due to the brominated products (181) and (186) rapidly decomposing in solution to 
elimination product (183) (Scheme 2.12).   
2.7.1 One-pot bromination / substitution-  
Although brominated product (181) could not be isolated, it could be formed in situ. 
Therefore another approach had to be developed for the bromination / substitution 
reaction. A one-pot bromination / substitution reaction was attempted as this negated the 
need to isolate brominated product (181) (Scheme 2.15).  
It was reasoned that substituted product (188) would be more stable towards isolation. 
Diethylamine was chosen as a simple nucleophile to be used in the reaction.  
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Scheme 2.15 - One-pot bromination / substitution.  
The one-pot bromination / substitution reaction led to the isolation of diethylamine 
substituted product (188) in a moderate yield of 52%, along with 16% of unreacted Diels-
Alder adduct (148). The isolation of 16% of Diels-Alder adduct (148) suggested that the 
initial bromination reaction was not going to completion before addition of diethylamine. It 
was therefore reasoned that the reaction time should be increased to allow the Diels-Alder 
adduct (148) to react fully.  
2.7.2 One-pot Diels-Alder / bromination / substitution- 
As the Diels-Alder reaction to form Diels-Alder adduct (148) had already been optimised, it 
allowed a total one-pot Diels-Alder / bromination / substitution reaction to be attempted.  
Starting from 1-tosyl-3-vinyl-1H-indole (146), the Diels-Alder reaction with NMM (141) was 
carried out as before to give Diels-Alder adduct (148). The reaction mixture was then cooled 
to 0 oC for the bromination reaction, before diethylamine was added to form compound 
(188) (Scheme 2.16).  
 
Scheme 2.16 - One-pot Diels-Alder / bromination / substitution. 
Column chromatography led to the isolation of compound (188) in an excellent yield of 78% 
(Scheme 2.16).  
We propose the relative stereochemistry of the final substituted product (188) is different 
to that of the ene products formed previously (Chapter 2.6.0) (Scheme 2.17).  
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Scheme 2.17 – Comparison of the relative stereochemistry of ene product (173) and substituted 
product (188). 
The ene reaction proceeds through a concerted mechanism whereby H1, adjacent to the 
indolic nitrogen, is abstracted in concurrence with formation of the new C-N bond.  This 
ensures that the nitroso group is added to the same face as H1. The Diels-Alder reaction 
proceeds via an endo-transition state, which results in the succinimide group of Diels-Alder 
adduct (148) being on the opposite face to H1. Therefore the nitroso group and the 
succinimide group are on opposite faces in ene adduct (173).  
We propose that the bromination / substitution reaction results in the diethylamine group 
occupying the same face of compound (188) as the succinimide group (Scheme 2.18).  
  
Scheme 2.18 - Proposed stereochemistry of diethylamine substituted product (188). 
The succinimide group sterically blocks one face of Diels-Alder product (148), forcing 
bromine to add to the opposite face, which is less sterically hindered. This leads to the 
formation of compound (181). Substitution of bromine by diethylamine occurs via an SN2 
mechanism, leading to an inversion of stereochemistry and product (188) being formed.  
This theory is supported by comparison of the J-coupling between axial (Ha) and equatorial 
(He) protons, in the 1H NMR spectrum of substituted compound (188) and ene compound 
(173).  
Firstly the conformation of the six-membered cyclohexene ring on which the hydroxylamine 
group sits must be considered. The cyclohexene adopts a half chair conformation, which is 
the lowest possible energy conformation for the compound. This leads to the six-membered 
ring shown in Figure 2.11, with H1 sitting equal distance between Ha and He.  
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Figure 2.11 – Conformatio adopted by the six-membered cyclohexene ring in (173). 
In the 1H NMR of ene adduct (173), the signal corresponding to proton H1 is split into an 
apparent triplet (Figure 2.12). This can only occur if proton H1 is coupled to the adjacent 
axial proton Ha and equatorial proton He, with the same or very similar coupling constants.  
 
Figure 2.12 - 1H NMR of ene adduct (173).  
In the 1H NMR spectrum of substituted product (188), the coupling constant between 
protons H1 and He is 4.5 Hz, which indicates an equatorial-axial coupling, whereas the 
coupling constant between protons H1 and Ha is 9.2 Hz. The size of this coupling is typical for 
an axial-axial coupling. This suggests the dihedral angle between protons H1 and Ha is 
approximately 180 o and the dihedral angle between protons H1 and He is around 60 o. This 
indicates that compound (188) has the structure shown below (Figure 2.13). 
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Figure 2.13 - 1H NMR of substituted product (188). 
2.8.0 Conclusions-  
The main aim of this chapter was to synthesise N-protected 3-vinyl-1H-indole compounds 
and examine their subsequent reaction in Diels-Alder / ene reactions with a range of 
dienophiles and enophiles. We have shown that 1-tosyl-3-vinyl-1H-indole (146) can be 
synthesised in a quick and high yielding reaction sequence.    
The same reaction sequence to form tert-butyl 3-vinyl-1H-indole-1-carboxylate (147) led to 
a mixture of 3-vinyl-1H-indole (140) and tert-butyl 3-vinyl-1H-indole-1-carboxylate (147) in a 
poor yield of 13%. We propose the mixture of products formed from the Wittig reaction is a 
result of the instability of tert-butyl 3-vinyl-1H-indole-1-carboxylate (147) to Wittig reaction 
conditions.  
The synthesised 1-tosyl-3-vinyl-1H-indole (146) readily undergoes Diels-Alder reactions with 
a range of dienophiles including NMM (141), NPM (117) and PTAD (150). The single 
diastereomer Diels-Alder adducts formed from these reactions readily crystallise and allow 
the relative stereochemistry of the Diels-Alder adducts to be determined. The Diels-Alder 
reactions proceed through an endo-transition state which indicates that the Diels-Alder 
reactions are under kinetic control and are not reversible.  
Screening Diels-Alder adducts (148) and (151) has shown they readily undergo ene reactions 
with reactive nitroso compounds, such as nitrosobenzene (170) and 1-methyl-2-
nitrosobenzene (172). However the ene reaction is very dependent upon the structure of 
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the nitroso compound; electron donating groups adjacent to the nitroso group prevent the 
ene reaction from occurring. We believe this is due to the electron donating groups raising 
the energy of the LUMO of the enophile, which raises the activation energy of the ene 
reaction, preventing any reaction from occurring.  
Further ene reactions with carbonyl compounds demonstrated that an ene reaction would 
only occur with the addition of a Lewis acid to catalyse the reaction. However even with the 
Lewis acid, only the very electron deficient 2,3,4,5,6-pentafluorobenzaldehdye (164) would 
react with Diels-Alder adduct (148).   
Attempts to isolate the product formed from the reaction between NBS and Diels-Alder 
adduct (148) led to the isolation of E1 elimination products (183) and (184). Although the 
bromination reaction led to the formation of (181), (181) rapidly underwent elimination 
reactions before isolation of brominated compound (181) could be achieved. This was in 
part due to the ability of the lone pair of electrons on the indolic nitrogen to eliminate the 
bromine via an E1 reaction mechanism. 
Diels-Alder adduct (148) could be subjected to a one-pot bromination / substitution reaction 
with NBS and diethylamine to give substituted indole compound (188), in a moderate yield 
of 52%. However the yield could be greatly improved through a one-pot Diels-Alder / 
bromination / substitution reaction to give the same substituted Diels-Alder adduct in an 
overall yield of 78%.  
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Chapter 3 – One-pot Diels-Alder / Ene Chemistry of Vinyl-indoles 
3.1.0 One-pot multi-component reactions-  
One-pot multi-component reactions (MCR) are a popular tool in organic chemistry as a 
means of improving the efficiency of a chemical process, by having several sequential 
reactions occur in one reaction vessel without the need for isolation of intermediates. This 
allows a reduction of waste as it negates the need for any isolation / purification steps. 
Examples of one-pot multi-component reactions which have been widely utilised in organic 
synthesis include the Strecker66, Hantzsch67, Mannich68 and Ugi69 reactions (Scheme 3.1). 
 
Scheme 3.1 – Example of Ugi, Strecker, Hantzsch and Mannich MCR.  
The reactions shown above (Scheme 3.1) are described under the all-encompassing term as 
one-pot reactions, whereby multiple chemical processes occur in one lab process. In order 
to more specifically describe a one-pot reaction process, the terms domino, tandem, 
cascade and sequential are all widely used. Several groups have tried to define the range of 
terminology used in one-pot MCR chemistry: 
One-pot – Any reaction where multiple chemical processes are occurring in the same 
reaction vessel.  
Multi-component reaction – A reaction where three or more reagents react to form a single 
product and most of the atoms from the starting material contribute to the product.  
MCRs can then be further referred to as domino, tandem, cascade or sequential:  
Domino – Tietze has defined a domino reaction as “a process involving two or more bond-
forming transformations (usually C-C bonds) which take place under the same reaction 
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conditions without adding additional reagents and catalysts, and in which the subsequent 
reactions result as a consequence of the functionality formed in the previous step”.70  
Tandem – Denmark and Thorarensen define a tandem reaction as any reactions which occur 
one after the other and then qualifies this term with either cascade or sequential to 
describe how the reactions occur.71  
Cascade – A cascade reaction is one in which the next reaction can only occur due to the 
structural change brought on by the previous step.71  
Sequential – The sequential reaction is defined as one which requires the addition of a 
reagent in the second stage of the reaction.71  
One-pot MCRs offer several advantages over traditional linear synthetic routes including 
maximising atom economy, reducing purification steps (and therefore waste), and the 
opportunity for rapid complexity generation.72,73 In the previous chapter we demonstrated 
the synthesis of tetrahydracarbazoles in a Diels-Alder / ene reaction sequence. We believed 
that this reaction sequence could be improved through the use of a one-pot MCR sequence.  
3.1.1 Aims-  
The Diels-Alder / ene reactions with N-protected vinyl-indole compounds in the previous 
chapter gave the desired tetrahydrocarbazole products in reasonable overall yields (50-60% 
over two steps). We wanted to develop this Diels-Alder / ene chemistry into a one-pot 
reaction process, whereby Diels-Alder adduct (190) would not be isolated (Scheme 3.2). We 
believed this would lead to better yields of ene adduct (191), reducing waste and making 
the process operationally simple.  
 
Scheme 3.2 - Proposed one-pot Diels-Alder / ene reaction sequence. 
3.2.0 Domino One-pot Diels-Alder / ene reaction-  
First we looked at domino Diels-Alder / ene conditions, as this would be practically the most 
simple one-pot MCR. 1-Tosyl-3-vinyl-1H-indole (146), NMM (141) and 1-methyl-2-
nitrosobenzene (172) were all added to the reaction vessel at the beginning of the reaction 
and stirred for five days (Scheme 3.3).  
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Scheme 3.3 - “Domino” Diels-Alder / ene reaction.  
After five days, no 1-tosyl-3-vinyl-1H-indole (146) could be observed by TLC. The crude 1H 
NMR showed that several products had been formed. The two products isolated were 
rearomatised Diels-Alder adduct (143) and desired ene product (173). Although the desired 
ene adduct (173) was obtained from the reaction, it was only isolated in a moderate yield of 
40% and there were several unidentified side products from the reaction.   
Therefore to try and improve the yield of the reaction, a sequential one-pot process was 
attempted to avoid the formation of unwanted side products.  
3.3.0 Sequential One-pot NMM Diels-Alder / ene-  
The Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and NMM (141) was 
repeated, followed by addition of 1-methyl-2-nitrosobenzene (172) to the reaction mixture 
with no purification, isolation or solvent swaps (Scheme 3.4).  
 
Scheme 3.4 - One-pot Diels-Alder / ene reaction. 
Diels-Alder/ ene adduct (173) was isolated in a 71% yield as a single diastereomer. 
Due to the success of the sequential one-pot reaction to form ene adduct (173), we 
expanded the range of enophiles used to test the scope of the reaction (Table 3.1). Two 
aryl-nitroso compounds (170) and (172), PTAD (150) and a carbonyl compound (164) were 
utilised as enophiles in the reaction as they had proven to be good enophiles previously 
(Chapter 2). This allowed a direct comparison to be made between the yields of the two-
step Diels-Alder / ene and the sequential one-pot MCR Diels-Alder / ene reactions.  
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Starting 
Material 
Diels-Alder 
Conditions 
Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
NMM (141), 
40 oC, 
48 h 
PhNO (170), 
rt, 18 h 
 
71% 
 
NMM (141), 
40 oC, 
48 h 
o-TolNO 
(172), 
rt, 18 h 
 
71% 
 
NMM (141), 
40 oC, 
48 h 
PTAD (150), 
0 oC, 4 h 
 
76% 
 
NMM (141), 
40 oC, 
48 h 
C6F5CHO 
(164), 
DMAC, 
-78 oC to rt, 
18 h  
72% 
Table 3.1 - Sequential one-pot Diels-Alder / ene reaction conditions and yields. 
Nitroso and aza ene products (171), (173) and (167) were isolated as single diastereomers in 
excellent yields ranging from 71-76%. Diels-Alder/ ene adduct (165) was isolated as a 6: 1 
mixture of diastereomers. The MCR process led to a reduction in waste and an increase in 
the overall % yield of the ene adducts when compared to the two-step approach seen in 
Chapter 2.  
3.3.1 One-pot Diels-Alder / ene (PTAD / nitroso-ene)-  
In Chapter 2.2.6 we demonstrated that the Diels-Alder reaction between 1-tosyl-3-vinyl-1H-
indole (146) and PTAD (150) led to Diels-Alder adduct (151) in a good yield. Diels-Alder 
adduct (151) could then be reacted in an ene reaction with nitrosobenze (170) and 1-
methyl-2-nitrosobenzene (172), leading to the formation of ene adducts (177) and (178). 
We wanted to see if these reactions could be improved through a one-pot MCR process. 
Therefore the Diels-Alder / ene reactions from 1-tosyl-3-vinyl-1H-indole (146) using PTAD 
(150) as the dienophile and nitroso compounds (170) and (172) as the enophile, were 
repeated using our one-pot MCR conditions (Table 3.2).  
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Starting 
Material 
Diels-Alder 
Conditions 
Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
PTAD (150), 
-78 oC, 4 h 
PhNO (170), 
rt, 18 h 
 
66% 
 
PTAD (150), 
-78 oC, 4 h 
o-TolNO 
(172), 
rt, 18 h 
 
66% 
 
PTAD (150), 
-78 oC, 4 h 
PTAD (150), 
0 oC, 4 h 
 
65% 
Table 3.2 - Sequential one-pot Diels-Alder / ene reaction conditions and yields.  
The one-pot MCR led to the formation of desired nitroso ene adducts (177) and (178) in 
good yields of 66%. As the reaction using PTAD as both the dienophile and enophile 
progressed, a precipitate formed, suggesting ene adduct (193) was only partially soluble. 
This allowed ene adduct (193) to be purified by trituration leading to a reduction in waste as 
no column chromatography had to be performed.  
Confirming the structure of ene adduct (193) was difficult to do with 1H NMR analysis, as 
PTAD does not contain any protons in the five-membered ring. Therefore an X-ray crystal of 
ene adduct (193) was grown by slow evaporation from DCM, as a way of confirming the 
structure (Figure 3.1).  
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Figure 3.1 - X-ray structure of ene adduct (193). 
The X-ray crystal structure showed that Diels-Alder / ene adduct (193), crystallised in the 
monoclinic space group P21/c, with four molecules in the unit cell. Due to Diels-Alder 
product (151) being racemic, the ene reaction leads to a racemic mixture of (R)-(193) and 
(S)-(193) being formed. The unit cell contains two molecules of (R)-(193) and two molecules 
of (S)-(193). The X-ray crystal structure shows that there is a H-bonding interaction between 
N7H on one molecule and O1 on the adjacent molecule.   
3.4.0 Maleimide Diels-Alder chemistry- 
With our sequential one-pot MCR operating successfully, we turned our attention to 
applying this technique to synthesising biologically active targets. The Diels-Alder / ene 
sequence we have developed leads to the formation of tetrahydrocarbazole compounds 
(191) as single diastereomers (Scheme 3.5).  
 
Scheme 3.5 - One-pot MCR Diels-Alder / ene reaction sequence with N-protected vinyl-indoles. 
The tetrahydrocarbazole compounds (191) synthesised from the Diels-Alder / ene reaction 
(Scheme 3.5) have many structural similarities to biologically active cabazole and 
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tetrahydrocarbazole compounds (194), (195) and (196) described in the literature (Figure 
3.2).33,35,74  
 
Figure 3.2 - Range of biologically active indole containing compounds from the literature.  
We therefore reasoned that our one-pot MCR Diels-Alder / ene sequence could allow the 
rapid synthesis of a library of potentially biologically active compounds. 
Ty et al.35 have undertaken a structural activity relationship (SAR) study on compounds of 
class (195) (Figure 3.3). The compounds in the SAR study were judged for their cytotoxicity 
against B16 melanoma cells and inhibition of tubulin polymerisation (ITP).  
 
 
 
Figure 3.3 - SAR study of compounds of the class (195). 
Tetrahydrocarbazole compounds from our one-pot Diels-Alder / ene reactions (191) have 
either a methyl or phenyl group on the succinimidyl nitrogen. Therefore to synthesise 
compounds with a free NH on the succinimide moiety, which would more closely match the 
structure Ty et al. proposed in their SAR study, a series of one-pot MCRs were attempted 
with maleimide (196) employed as the dienophile (Scheme 3.6).  
Carbazole compounds with aromatic C 
ring have higher activity than 
tetrahydrocarbazole compounds 
which do not have an aromatic C ring. 
R
3
 = Bn compounds show little or no 
activity against B16 melanoma cells.  
R
3
 = H compounds show activity against 
B16 melanoma cells 
R
1 
≠ H, R
2
 ≠ H compounds showed 
higher activity than compounds 
where R
1 
= R
2
 = H. 
R
1
 = H, R
2
 = OMe compound had 
the best activity.  
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Scheme 3.6 - One-pot maleimide Diels-Alder/ ene reactions between 1-tosyl-3-vinyl-1H-indole 
(146) and maleimide (196). 
The Diels-Alder reaction between 1-tosyl-3-vinyl-1H-indole (146) and maleimide (196) 
proceeded in the same time as the reaction between 1-tosyl-3-vinyl-1H-indole (146) and 
NMM (141). To allow comparison with the previous MCR one-pot Diels-Alder/ ene reactions 
(Chapter 2), nitrosobenzene (170), 1-methyl-2-nitrosobenzene (172), PTAD (150) and 
pentafluorobenzaldehyde (164) were employed as enophiles (Table 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 - Diels-Alder / ene between 1-tosyl-3-vinyl-1H-indole (146) and maleimide (196).  
Starting 
Material 
Diels-Alder 
Conditions 
Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
Maleimide 
(196), 
 40 oC, 48 h 
PhNO (170),  
rt, 4 h 
 
89% 
 
Maleimide 
(196),  
40 oC, 48 h 
o-TolNO 
(172),  
rt, 4 h 
 
82% 
 
Maleimide 
(196),  
40 oC, 48 h 
C6F5CHO 
(164),  
DMAC,  
-78 oC to rt, 
18 h  
71% 
 
Maleimide 
(196), 
40 oC, 48 h 
PTAD (150),  
0 oC, 4 h 
 
75% 
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The one-pot MCR with maleimide (196) as the dienophile gave the desired ene adducts as 
single diastereomers in excellent yields ranging from 71-89%.  
3.4.1 Relative stereochemistry of Diels-Alder/ ene adduct (200)- 
Confirming the relative stereochemistry of ene adduct (200) is difficult to accomplish using 
NMR techniques. Therefore a single crystal was grown of ene adduct (200) for X-ray 
crystallography by slow evaporation from DCM. This allowed the relative stereochemistry of 
the ene reaction to be confirmed and shows that the hydroxylamine group and the 
succinimide group are on opposite faces of the compound to each other (Figure 3.4).  
 
 
Figure 3.4 - X-ray crystal structure of Diels-Alder/ ene adduct (200) with hydrogens removed for 
clarity.  
The X-ray crystal structure showed that, in ene adduct (200), the enophile adds to the si-
face of the alkene which results in the hydroxylamine group being on the opposite face of 
Diels-Alder adduct (197) relative to the dienophile (Figure 3.4).  
This stereochemistry is dictated by the initial endo-Diels-Alder reaction which sets the 
relative stereochemistry at positions C10, C13 and C14. As the ene reaction is a concerted 
process, the nitroso compound is directed on to the si-face by the twix-proton at C13 
(Scheme 3.7).  
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Scheme 3.7 - Proposed reaction mechanism for nitroso-ene reaction 
This results in 1-methyl-2-nitrosobenzene (172) adding to the si-face of the alkene in Diels-
Alder adduct (148), which is the opposite face relative to the succinimide moiety.  
3.5.0 Functionality on the indole ring- 
Many of the examples of biologically active carbazole compounds have functionality around 
the indole ring system (R1 and R2 positions). Ty et al. have demonstrated using SAR studies 
that compounds where R1 ≠ H and R2 ≠ H, show better biological activity against B16 
melanoma cells (Figure 3.5) than compounds where R1 = R2 = H.  
 
 
Figure 3.5 - Biologically active carbazole compounds with functionality around the indole ring. 
We wanted to introduce the same functionality in to our one-pot Diels-Alder / ene reactions 
by synthesising compounds of the type shown below (191) (Scheme 3.8).  
 
Scheme 3.8 - One-pot Diels-Alder / ene reaction with 5-substituted N-protected vinyl-indole.  
R
3
 = Bn compounds show little / 
no activity against B16 
melanoma cells.  
R
3
 = H compounds show activity 
against B16 melanoma cells 
Carbazole compounds with aromatic C 
ring have higher activty than 
tetrahydrocarbazole compounds 
which do not have an aromatic C ring. 
R
1 
≠ H, R
2
 ≠ H compounds showed 
higher activity than compounds 
where R
1 
= R
2
 = H. 
R
1
 = H, R
2
 = OMe compound had 
the best activity.  
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We started with the addition of a simple methoxy group to the 5-position of the indole ring, 
using 5-methoxy-1H-indole (203) which was commercially available. We proposed a 
Vilsmeier / N-protection / Wittig reaction sequence to synthesise desired 5-methoxy-1-
tosyl-3-vinyl-1H-indole (206) (Scheme 3.9).  
 
Scheme 3.9 - Proposed route to synthesise 5-methoxy-1-tosyl-3-vinyl-1H-indole (206). 
We expected the electron donating properties of the methoxy group of 5-methoxy-1-tosyl-
3-vinyl-1H-indole (206) to increase the electron density of the diene, which would lower the 
activation energy for the Diels-Alder reaction with maleimide compounds. 
Starting from 5-methoxy-1H-indole (203), 5-methoxy-1H-indole-3-carbaldehyde (204) was 
synthesised in an excellent yield via a Vilsmeier reaction (Scheme 3.10).  
 
Scheme 3.10 - Vilsmeier reaction to form 5-methoxy-1H-indole-3-carbaldehyde (204). 
Following on from the Vilsmeier reaction, the next step was the tosyl protection of the 
indolic NH group. The NH was protected using tosyl chloride and triethylamine to give 5-
methoxy-1-tosyl-1H-indole-3-carbaldehyde (205) in an excellent yield (Scheme 3.11). 
 
Scheme 3.11 - Tosyl protection of 5-methoxy-1H-indole-3-carbaldehyde (204). 
The final step was to carry out the Wittig reaction to synthesise 5-methoxy-1-tosyl-3-vinyl-
1H-indole (206) (Scheme 3.12). 
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Scheme 3.12 - Wittig reaction to form 5-methoxy-1-tosyl-3-vinyl-1H-indole (206) 
The Wittig reaction formed the desired 5-methoxy-1-tosyl-3-vinyl-1H-indole (206) in a 77% 
yield. With an efficient method to synthesise of 5-methoxy-1-tosyl-3-vinyl-1H-indole (206) in 
hand, several one-pot Diels-Alder / ene reactions were attempted between (206), NMM 
(141) and 2,3,4,5,6-pentafluorobenzaldehyde (164) and between (206), maleimide (196) and 
PTAD (150) (Scheme 3.13).  
 
Scheme 3.13 - One pot Diels-Alder / ene.  
Table 3.4 - One-pot Diels-Alder / ene reaction with 5-methoxy-1-tosyl-3-vinyl-1H-indole (206).  
The one-pot MCRs with 5-methoxy-1-tosyl-3-vinyl-1H-indole (206), resulted in the formation 
of (208) and (209) in good yields with (208) produced as a single diastereomer. Ene adduct 
(209) was isolated as an inseparable mixture of diastereomers in an 8: 1 ratio. We expected 
the electron donating methoxy group to increase the electron density of the indole ring and 
Starting 
Material 
Diels-Alder 
Conditions 
Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
NMM (141),  
40 oC, 48 h 
C6F5CHO 
(164), 
DMAC,  
-78 oC to rt,  
18 h  
70% 
 
Maleimide 
(196),  
40 oC, 48 h 
PTAD (150),  
0 oC, 4 h 
 
75% 
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therefore increase the rate of the Diels-Alder/ ene reactions. However, we discovered that 
the added electron density did not have a significant effect on the overall reaction time of 
the Diels-Alder/ ene reaction (Table 3.4). The success of these reactions suggested that our 
one-pot MCR could tolerate simple electron donating groups on the indole ring.  
3.6.0 Alternative N-protecting groups- 
The previous examples of one-pot Diels-Alder / ene reaction sequences gave an 
operationally simple, highly efficient method to quickly synthesise tetrahydrocarbazoles and 
pyridazino[3,4-b]indoles.  
In Chapter 2, we discovered that an electron donating N-protecting group on the indolic 
nitrogen increased the rate of the Diels-Alder reaction and caused the Diels-Alder adduct 
formed to rapidly rearomatise to (210). Conversely, electron withdrawing N-protecting 
groups were found to slow the Diels-Alder reaction and stabilise the Diels-Alder adduct 
(135) generated (Scheme 3.14).   
 
Scheme 3.14 - Effect of N-protecting group upon the stability of Diels-Alder adduct (135).  
We wanted to examine the scope of the one-pot Diels-Alder / ene reactions with a range of 
different N-protecting groups. It was hoped that changing the N-protecting group would 
expand the range of enophiles that we could use in the one-pot MCR. 
The one-pot Diels-Alder / ene reaction sequences were very successful with a tosyl 
protecting group, so the next protecting group examined was N,N-dimethylaminosulfonyl 
(DMAS), which is another sulfonyl based group similar to tosyl.  
To synthesise DMAS protected indole, sodium hydride was added to 1H-indole-3-
carbaldehyde (131) followed by the addition of N,N-dimethylsulfamoyl chloride, to give 3-
formyl-N,N-dimethyl-1H-indole-1-sulfonamide (211) (Scheme 3.15).   
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Scheme 3.15 - DMAS protection of 1H-indole-3-carboxaldehyde (131). 
N,N-dimethyl-1H-indole-1-sulfonamide (211) was then reacted in a Wittig reaction with 
methylenetriphenyl-λ5-phosphane to form N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide 
(212) in a good yield (Scheme 3.16).  
 
Scheme 3.16 - Wittig reaction to form N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (212). 
3.7.0 DMAS protected Diels-Alder / ene chemistry- 
With N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (212) in hand, the next step was to 
screen it against a range of dienophiles and enophiles in a one-pot Diels-Alder / ene reaction 
sequence (Scheme 3.17).  
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Scheme 3.17 - One-pot DMAS Diels-Alder / ene reaction. 
Table 3.5 – DMAS Diels-Alder / ene reaction conditions. 
The one-pot MCR with N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (212) as starting 
material gave the desired ene adducts as single diastereomers in good overall yields. We 
expected N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (212) to have similar reactivity to 1-
tosyl-3-vinyl-1H-indole (146) as both are sulfonyl based  protecting groups. This was 
confirmed as the Diels-Alder reaction between N,N-dimethyl-3-vinyl-1H-indole-1-
sulfonamide (212) and NMM (141) took the same amount of time to go to completion as 
the Diels-Alder reactions between tosyl-3-vinyl-1H-indole (146) and NMM (141) (Chapter 
2.2.4).  
Starting 
Material 
Diels-Alder 
Conditions 
Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
NMM (141),  
40oC, 48 h 
C6F5CHO (164),  
DMAC,  
-78 oC , 1 h 
 
77% 
 
NMM (141),  
40oC, 48 h 
o-TolNO (172),  
rt, 3 h  
 
74% 
 
Maleimide (196),  
40 oC, 48 h 
o-TolNO (172),  
rt, 3 h 
 
77% 
 
PTAD (150),  
-78 oC, 1 h 
o-TolNO (172),  
rt, 4 h 
 
76% 
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The nitroso-ene reactions with DMAS protected Diels-Alder adduct, went to completion at a 
moderately improved rate relative to the tosyl protected nitroso-ene reactions. The nitroso-
ene reactions with tosyl protected Diels-Alder adduct (148) took 18 hours to go to 
completion however with DMAS protecting group, that time was reduced to 3-4 hours. The 
same trend was observed when 2,3,4,5,6-pentafluorobenzaldehyde (164) was used as the 
enophile, with the reaction taking 1 hour with DMAS protected Diels-Alder adduct (213) to 
go to completion, compared to 18 hours with tosyl protected Diels-Alder adduct (148). 
This change in the reactivity of the ene reaction suggested the electronics of the Diels-Alder 
adducts (148) and (213) are dependent upon the protecting group. It also suggests that the 
DMAS protecting group is less electron withdrawing than the tosyl protecting group. This 
means DMAS protected Diels-Alder adduct (213) is more electron rich compared to (148) 
making it more reactive towards enophiles.  
3.7.1 Stereochemistry of Diels-Alder /  ene adduct (215)- 
The one-pot Diels-Alder / ene adduct from the reaction between N,N-dimethyl-3-vinyl-1H-
indole-1-sulfonamide (212), NMM (141), and 2,3,4,5,6-pentafluorobenzaldehyde (164) has 
the potential to form two diastereomers (Figure 3.6).  
 
Figure 3.6 - Two possible diastereomers that can be formed in the reaction between N,N-dimethyl-
3-vinyl-1H-indole-1-sulfonamide (212), N-methylmaleimide (141), and 2,3,4,5,6-
pentafluorobenzaldehyde (164).  
Only one diastereomer is seen in the 1H NMR of Diels-Alder / ene adduct (215). It was 
difficult to elucidate which diastereomer is formed using NMR studies, therefore (215) was 
crystallised from DCM using slow evaporation to give single crystals suitable for X-ray 
analysis. The X-ray crystal structure showed that Diels-Alder / ene adduct (215) had an (S) 
stereocentre at the C16 position (Figure 3.7).  
                                                                    Chapter 3 – One-pot Diels-Alder / ene chemistry of vinyl-indoles 
 
58 | P a g e  
 
 
 
 
Figure 3.7 - X-ray crystal structure of Diels-Alder / ene adduct (215). 
The possibility of two diastereomers being formed arises from two possible transition states 
in the ene reaction between Diels-Alder adduct (213) and 2,3,4,5,6-
pentafluorobenzaldehyde (164). However, only (S)-diastereomer (215) is generated due to 
one of the two possible transition states being higher energy and therefore unfavourable 
(Scheme 3.18). 
 
Scheme 3.18 - Ene reaction with unfavourable transition state (219) due to steric clash between 
C6F6 group and H
9. 
In transition state (219) there is an unfavourable steric interaction between the C6F5 group 
of 2,3,4,5,6-pentafluorobenzaldehyde (164) and the two protons at the C9 position. On the 
other hand transition state (220) has the C6F5 ring pointing away from any groups so that 
there are no unfavourable steric interactions. This means that transition state (220) is lower 
in energy, relative to (219), making ene adduct (215), formed as a result of this transition 
state, the major diastereomer (Scheme 3.19).   
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Scheme 3.19 - Ene reaction with favoured transition state (220). 
3.8.0 One-pot Diels-Alder / ene reactions of Bn protected indoles- 
Previous work by Porter et al.54 has shown that the Diels-Alder reaction between 1-benzyl-3-
vinyl-1H-indole (137) and NPM (117) rapidly goes to completion. However, Diels-Alder 
adduct (138) is difficult to handle and readily rearomatises to form (139) due to the electron 
donating properties of the benzyl protecting group (Scheme 3.20).  
Scheme 3.20 - Diels-Alder / rearomatisation reaction leading to formation of (139).
54 
It was because of this difficulty in purifying and handling Diels-Alder adduct (221) that we 
had focused on more electron withdrawing groups, such as tosyl and DMAS. However, our 
new one-pot Diels-Alder / ene reaction sequence means that benzyl Diels-Alder adduct 
(221) only has to be formed in situ and therefore the problems with handling and isolating it 
could be negated (Scheme 3.21).   
 
Scheme 3.21 - One-pot Diels-Alder / ene reactions of Bn protected indoles. 
We anticipated that as the ene reaction of Diels-Alder adduct (221) leads to concurrent 
rearomatisation of the indole ring system, this would make ene adduct (222) more stable to 
purification. We proposed exploiting the electron donating benzyl protecting group by 
employing a wider range of less reactive enophiles.  
To test this theory, 1-benzyl-3-vinyl-1H-indole (137) first had to be synthesised. Starting 
from 1-benzyl-1H-indole-3-carbaldehyde (223), a Wittig reaction was performed with 
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methylenetriphenyl-λ5-phosphane to give 1-benzyl-3-vinyl-1H-indole (137) in an excellent 
yield (Scheme 3.22).  
 
Scheme 3.22 - Wittig reaction to form 1-benzyl-3-vinyl-1H-indole (137). 
1-Benzyl-3-vinyl-1H-indole (137) was then subjected to a one-pot Diels-Alder / ene reaction 
with NMM (141) and 1-methyl-2-nitrosobenzene (172). As the benzyl protecting group 
increased the reactivity of the indole towards dienophiles, the Diels-Alder reaction was 
carried out at 0 oC. After two and a half hours, 1-methyl-2-nitrosobenzene (172) was added 
and the reaction was maintained at 0 oC (Scheme 3.23). The ene reaction went to 
completion after two hours and afforded ene adduct (224), which could be readily purified 
in an excellent overall yield of 73%. 
 
Scheme 3.23 - One-pot benzyl Diels-Alder / ene to form (224).  
The previous one-pot Diels-Alder / ene reaction had shown that 1-benzyl-3-vinyl-1H-indole 
(137) was more reactive towards dienophiles and enophiles than the corresponding 1-tosyl-
3-vinyl-1H-indole (146) or N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (212). It was 
thought that a less reactive enophile could be used in the ene reaction. Therefore the Diels-
Alder reaction between 1-benzyl-3-vinyl-1H-indole (137) and NMM (141) was repeated 
before pivaldehyde (225) was added to the reaction as the enophile (Scheme 3.24). 
Pivaldehyde was chosen as an example of a very simple aldehyde that could be easily 
observed in the 1H NMR spectrum. 
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Scheme 3.24 - One-pot MCR with 1-benzyl-3-vinyl-1H-indole (137), NMM (141) and pivaldehyde 
(225). 
The ene reaction between Diels-Alder adduct (138) and pivaldehyde (225) was allowed to 
stir at 0 oC for three hours, however in this time no ene reaction occurred and rearomatised 
Diels-Alder adduct (226) was the only product isolated from the reaction. This suggested 
that the relative rate of the rearomatisation reaction was much greater than the rate of the 
ene reaction with pivaldehyde (225) under these conditions.  
DMAC had previously been used to catalyse the ene reaction between 2,3,4,5,6-
pentafluorobenzaldehyde (164) and tosyl protected Diels-Alder adduct (148) (Chapter 
2.4.0). Therefore DMAC was used to catalyse the ene reaction between Diels-Alder adduct 
(138) and pivaldehyde (225). The one-pot Diels-Alder ene reaction was repeated with the 
Lewis acid DMAC used to catalyse the ene reaction (Scheme 3.25). The crude 1H NMR of the 
reaction showed that no starting material remained, however the reaction had formed two 
major compounds as well as other minor products.  
The two products could be separated using column chromatography. The major product 
isolated was the expected pivaldehyde ene product (227), in a modest yield of 29% (Scheme 
3.25). 
 
Scheme 3.25 - DMAC catalysed Diels-Alder / ene reaction with pivaldehyde.  
The minor product from the reaction was the result of two NMM (228) molecules 
undergoing a Diels-Alder and ene reaction with 1-benzyl-3-vinyl-1H-indole (137) (Scheme 
3.25).  
The formation of compound (228) suggested that, as only one equivalent of NMM (141) was 
added initially, the Diels-Alder reaction was not going to completion in the initial 2.5 hours. 
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That meant that when the reaction was cooled to -78 oC and DMAC added, the DMAC was 
catalysing the ene reaction between Diels-Alder adduct (221) and another NMM (141) 
molecule as well as the ene reaction with pivaldehyde (225) (Scheme 3.26). The yields 
obtained for (227) and (228) only account for 59% of the total NMM (141) added to the 
reaction. This suggested that NMM (141) was reacting to form other products which were 
unidentified besides the two major products we isolated. 
 
Scheme 3.26 - Diels-Alder / ene reaction leading to the formation of (227) and (228). 
The formation of (228) indicated that the Diels-Alder reaction of 1-benzyl-3-vinyl-1H-indole 
(137) and NMM (141) was not going to completion before the addition of DMAC and 
pivaldehyde (225). The same reaction was attempted again with the Diels-Alder step 
reaction time being increased to four hours. It was hoped that this would allow the Diels-
Alder reaction to go to completion so no NMM (141) remained when DMAC was added. 
However, this led to decomposition of Diels-Alder adduct (221) to the rearomatised Diels-
Alder adduct (222) before the ene reaction could occur and therefore no ene adduct could 
be isolated. Diels-Alder adduct (221) was found to be unstable in solution and readily 
rearomatised unless it was reacted further to form the more stable ene adduct (227).  
The Diels-Alder / ene reaction led to the formation of two new stereocentres in products 
(227) and (228) (Figure 3.8).   
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Figure 3.8 - Products (227) and (228) formed in the one-pot Diels-Alder / ene reaction. 
The stereocentres on the six membered ring can be assigned either (R) or (S) using the 
concerted ene mechanism which we postulated in Chapter 3.4.1, which predicts that the 
enophiles attack from the si face of the Diels-Alder adduct. This leads to an (S) stereocentre 
in (227) and an (R) stereocentre in (228). Attempts were made to grow single crystals of 
both (227) and (228) in order to confirm the stereochemistry of both stereocentres adjacent 
to the alcohol group, however this was not successful.  
Due to the capricious nature of the benzyl protected indoles in the Diels-Alder / ene 
reaction sequence, they were not studied any further.  
3.9.0 Bioassay of Ts, DMAS and Bn protected Diels-Alder / ene adducts- 
Using our one-pot MCR process, a range of tosyl, DMAS and benzyl protected ene adducts 
were synthesised, analogous to a range of known biologically active compounds (Figure 3.9). 
Compounds of the class (195) have been shown in the literature to have good activity 
against B16 melanoma cells with an IC50 of 2.6 µM +/- 1.5 µM (R1 = OMe, R2 =H, R3 = H).
35 
 
Figure 3.9 - Compound class (195) active against B16 melanoma cells and general structure of 
synthesised compounds from Diels-Alder / ene reactions (191).  
The synthesised tosyl, DMAS and benzyl Diels-Alder / ene compounds were run in a Kirby-
Bauer disk diffusion assay, as a test for biological activity.  
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We chose to screen the compounds against two bacteria and a yeast - Staphylococcus 
aureus (S. auereus), Escherichia coli (E. coli) and Schizosaccharomyces pombe (S. pombe). S. 
pombe is used as a toxicity model for eukaryotic organisms. S. pombe is a yeast and 
therefore has cell walls so will have a different uptake mechanism of compounds compared 
to human cells. However, it is still relevant as a fast and simple method to gain insight into 
toxicity towards eukaryotic organisms.  
S. aureus is used as a representation of Gram-positive bacteria. This species of bacteria 
include several pathogenic strains including methicillin resistant S. aureus (MRSA). MRSA is 
immune to many common antibiotics and the increasing number of MRSA cases, especially 
in hospitals, is of great concern. Therefore many efforts are being made to find novel 
antibiotics that kill the bacteria.75  
E. coli is used as an example of Gram-negative bacteria and also contains many pathogenic 
strains including New Delhi metallo-β-lactamase (NDM1). NDM1 is a relatively newly 
discovered antibiotic resistant bacteria and therefore, as with MRSA, new compounds which 
can kill the bacteria are of great importance.76  
Each Diels-Alder / ene compound was dissolved in DCM at a concentration of 10 mg/ mL 
and was tested for activity against S. aureus, S. pombe and E. coli. The plates were left to 
incubate at 30 oC overnight after which time no zone of inhibition could be observed on the 
plates.    
A comparison between the compounds that are known to be active against B16 melanoma 
cells (195) and the general structure of Diels-Alder / ene compounds (191) we had 
synthesised, suggested that a free NH on the indole moiety of the compound was important 
for biological activity (Figure 3.10).  
 
Figure 3.10 - Biologically active compound (195) and general structure of synthesised compounds 
from Diels-Alder / ene reaction (191).   
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We hypothesised that a lack of a free NH on the Diels-Alder / ene compounds that we 
synthesised prevented them from being biologically active. Therefore to increase the 
likelihood that our compounds would be biologically active, attempts were made to remove 
the protecting groups.  
3.9.1 Ts and DMAS protecting group removal- 
The benzyl compounds (224), (227) and (228) were very reactive and could only be isolated 
in low yields. We thought that they would not be stable to deprotection under 
hydrogenation conditions and therefore no attempt was made to remove the benzyl group. 
Previous work in the group had found difficulties in removing the DMAS and tosyl protected 
Diels-Alder / ene compounds.77 The tosyl and DMAS protected compounds were subjected 
to either basic deprotection conditions using potassium or sodium hydroxide, or single 
electron transfer conditions using sodium or magnesium in mercury amalgams.78-80 It was 
found that neither the tosyl or DMAS protecting groups could be removed using these 
conditions without leading to decomposition of the molecule. Therefore an alternate 
protecting group had to be found that was compatible with our one-pot Diels-Alder / ene 
conditions and that would readily undergo deprotection.  
3.10.0 Cbz protected indole-  
Previous work (Chapter 2) had shown that an electron withdrawing protecting group was 
required for the Diels-Alder / ene chemistry to occur. We required a protecting group that 
would allow the one-pot MCR to occur and could be easily removed from the resulting Diels-
Alder / ene adducts. The ideal protecting group would have to be sufficiently electron 
withdrawing to stabilise the Diels-Alder adduct formed from the Diels-Alder reaction with a 
range of dienophiles. However, if the protecting group were too electron withdrawing, it 
would prohibit further chemistry from being carried on the Diels-Alder adduct. The 
protecting group would also need to be easily removed under mild conditions so as not to 
cause other functional groups on the molecule to decompose.   
Our choice of protecting group was the carboxybenzyl (Cbz) protecting group as it was 
electron withdrawing and we believed it could be readily removed under hydrogenation 
conditions.  The first step in the synthesis of benzyl 3-vinyl-1H-indole-1-carboxylate (230) 
was the synthesis of benzyl 3-formyl-1H-indole-1-carboxylate (229) using triethylamine, 
benzyl chloroformate and 1H-indole-3-carboxylate (131) (Scheme 3.27).  
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Scheme 3.27 - Cbz protection of 1H-indole-3-carboxylate (131). 
The N-protection reaction gave the desired benzyl 3-formyl-1H-indole-1-carboxylate (229) in 
an excellent yield of 92%.  
Benzyl 3-formyl-1H-indole-1-carboxylate (229) was then subjected to a Wittig reaction with 
methylenetriphenyl-λ5-phosphane to form benzyl 3-vinyl-1H-indole-1-carboxylate (230) 
(Scheme 3.28).   
 
Scheme 3.28 - Synthesis of benzyl 3-vinyl-1H-indole-1-carboxylate (230). 
The Wittig reaction gave benzyl 3-vinyl-1H-indole-1-carboxylate (230) in a good yield of 76%. 
Once a reliable method to synthesise benzyl 3-vinyl-1H-indole-1-carboxylate (230) was 
established, we planned to first test the one-pot Diels-Alder / ene chemistry with NMM 
(141) as the dienophile and 1-methyl-2-nitrosobenzene (172) as the enophile. This allowed 
us to determine if the Cbz protected Diels-Alder / ene adducts could be readily synthesised 
as single diastereomers in good yields. 
The Diels-Alder reaction between benzyl 3-vinyl-1H-indole-1-carboxylate (230) and NMM 
(141) was closely monitored by TLC and showed clean conversion to Diels-Alder adduct 
(231) after stirring at 40 oC for 24 hours. The enophile 1-methyl-2-nitrosobenzene (172) was 
then added to the solution and the ene reaction went to completion after 18 hours (Scheme 
3.29).   
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Scheme 3.29 - One-pot Cbz protected Diels-Alder / ene reaction.  
Ene adduct (232) could be isolated using column chromatography in a good yield of 78%. 
This initial test reaction suggested that benzyl 3-vinyl-1H-indole-1-carboxylate (230) readily 
underwent Diels-Alder / ene reactions and the ene product formed was stable to isolation 
and purification. We then moved on to investigate if the Cbz protecting group could be 
readily removed.   
We attempted to remove the Cbz group in a series of hydrogenation reactions using 5% or 
10% palladium on carbon as the catalyst, and either atmospheric pressure or 5 atmospheres 
of hydrogen gas. The hydrogenation deprotection reactions were unsuccessful and Diels-
Alder / ene adduct (232) was recovered from the reaction in each case (Table 3.6, entries 1-
3).  
Entry 
Ene 
Adduct 
Deprotection 
Conditions 
Product Yield 
1 
 
5% Pd/C, 1 atm H2, 
rt, 8 h 
No 
Reaction 
NA 
2 
 
10% Pd/C, 1 atm H2, 
rt, 8 h 
No 
Reaction 
NA 
3 
 
10% Pd/C, 5 atm H2, 
rt, 18 h 
No 
Reaction 
NA 
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Table 3.6 - Reaction conditions attempted for Cbz deprotection. 
As the hydrogenation deprotection reactions with palladium on carbon were having no 
success, the hydrogenation catalyst was changed to platinum (IV) oxide (Adam’s catalyst). 
The hydrogenation was attempted with platinum (IV) oxide and an atmospheric pressure of 
hydrogen for 18 hours. The crude 1H NMR showed loss of the distinctive benzylic Cbz peaks, 
indicating that the deprotection had been successful. However, upon purification of the 
crude reaction mixture by column chromatography, the isolated product was not the 
expected deprotected ene adduct (Table 3.6, Entry 4). Instead, methoxy substituted product 
(233) was isolated in a 60% yield (Scheme 3.30). 
 
Scheme 3.30 - Unexpected methoxy product (233) isolated from the hydrogenation reaction.  
We believed that the methoxy group originated from the reaction solvent and hoped that 
changing the solvent to a more sterically bulky, less polar solvent would circumvent the 
substitution. Therefore the reaction was repeated with platinum (IV) oxide and an 
atmospheric pressure of hydrogen, with ethanol as the solvent (Scheme 3.31).  
 
Scheme 3.31 - Deprotection reaction with ethanol solvent.  
The crude 1H NMR showed the reaction had formed two major products; the expected 
ethoxy substituted compound (234) and a small amount of deprotected ene adduct (235). 
4 
 
PtO2, 
rt, 18 h 
 
60% 
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As 20% of deprotected product (235) was isolated from the reaction, the change in solvent 
from methanol to ethanol clearly has an effect upon the reaction.  
We proposed that changing the solvent to a non-nucleophilic solvent would allow the 
formation of the desired deprotected Diels-Alder / ene product (235).  
The reaction was therefore repeated with THF as the solvent (Scheme 3.32).  
 
Scheme 3.32 - Cbz deprotection hydrogenation reaction.  
The change to a non-nucelophilic solvent meant no substitution reaction could occur and 
the desired deprotected ene adduct (235) was isolated as a single diastereomer in an 
excellent yield of 87%.  
3.10.1 Mechanism for the formation of (233) and (234)-  
We believed the methoxy and ethoxy substituted products (233) and (234) could be formed 
via two possible reaction pathways; SN1 or SN2. The SN1 mechanism could arise from the 
hydrogenation reaction firstly removing the Cbz group from the indolic nitrogen to form 
(235). This increases the electron density throughout the indole ring system allowing the 
indolic nitrogen to eliminate the hydroxylamine group leading to the formation of (236). 
After the hydroxylamine group has been eliminated, methanol can attack the unsaturated 
iminium group via a Michael addition, forming (233) (Scheme 3.33).   
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Scheme 3.33 - Proposed SN1 mechanism by which compound (233) is formed.  
The change in solvent from MeOH to EtOH shows a decrease in the amount of substituted 
product (234) being formed. This can be rationalised in the SN1 reaction as the formation of 
the charged unsaturated iminum compound (236) would be favoured by a more polar 
solvent which can delocalise the charge. Therefore the more polar MeOH solvent stabilises 
the formation of (236). The EtOH on the other hand, does not favour the elimination of the 
hydroxylamine group and therefore there is a reduction in the amount of unsaturated 
iminium (236) and consequently ethoxy substituted product (234) formed in the reaction.  
All of the one-pot Diels-Alder / ene adducts synthesised were subjected to high resolution 
mass spectroscopy (HRMS) to confirm the expected compounds had indeed been 
synthesised. The HRMS data showed that one of the major peaks for all of the ene adducts 
formed, regardless of protecting group, was the hydroxylamine eliminated product (237) 
(Figure 3.11).  
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Figure 3.11 - HRMS of tosyl protected ene adduct (171).  
This provides evidence for the possibility of (236) being generated from the elimination of 
the hydroxylamine group from (235), as it is readily formed under ionising conditions.  
There is, however, also the possibility that (233) is formed through an SN2 reaction 
mechanism. The SN2 mechanism could arise from the removal of the Cbz group from the 
indolic nitrogen to generate (235). This is followed by the methanol attacking (235) in an SN2 
mechanism, with hydroxylamine acting as the leaving group, leading to the formation of 
(233) (Scheme 3.34). 
 
Scheme 3.34 - Proposed SN2 reaction pathway for the formation of (233). 
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The difference in the amount of substituted product formed, depending on which solvent is 
used, can also be explained in the SN2 mechanism. The SN2 reaction is dependent upon the 
rate the solvent attacks the tertiary carbon centre on (235). The smaller methanol molecule 
can more easily do this compared to the more sterically hindered ethanol. Therefore more 
methoxy substituted product (233) is formed compared the ethoxy product (234) under the 
same reaction conditions.  
As both of mechanisms can be used to explain the change in products generated depending 
on the solvent used, another method had to be found to deduce the reaction mechanism. 
We thought we could do this by studying the relative stereochemistry of products (233) and 
(234).  
We propose that the relative stereochemistry of methoxy product (233), formed from the 
SN1 reaction pathway, is determined by which face (re- or si-) of compound (236) the 
methanol attacks from. We believe the succinimide moiety of compound (236) will block 
one face of the compound leading to the methanol attacking from the least hindered, si-
face of compound (236) (Scheme 3.35).  
 
 
Scheme 3.35 - Methanol attack leading to the relative stereochemistry seen in compound (233). 
This leads to the methoxy group being on the opposite face of compound (233) relative to 
the succinimide moiety. Overall the substitution is an SN1 reaction with retention of 
stereochemistry. 
In the SN2 reaction mechanism, the final step is nucleophilic attack 180
o to the 
hydroxylamine leaving group. This would result in an inversion of stereochemistry at the 
reaction centre leading to the formation of (233) (Figure 3.12).  
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Figure 3.12 - SN1 reaction would lead to the formation of (S)-(233) while SN2 reaction would lead to 
the formation of (R)-(233).  
By considering the coupling constants for proton (Ha) (Figure 3.13) attached to the same 
carbon as the methoxy group, we are able to deduce which mechanism occurs. In the 
product generated via an SN1 mechanism, the equatorial proton (H
e) is coupled to both the 
equatorial proton (He) and axial proton (Ha) on the adjacent carbon. The bond angles are 
similar for He-He and He-Ha and therefore you would expect the coupling constants to be 
similar for both (Figure 3.13).  
Axial proton (Ha) on product (R)-(233) from the SN2 reaction, would couple to the equatorial 
proton He and axial proton Ha on the adjacent carbon. As there is a large difference between 
the bond angles of the axial-axial proton and axial-equatorial protons you would expect to 
see one large coupling constant for the axial-axial (Ha-Ha) interaction and one much smaller 
coupling constant for the axial-equatorial (Ha-He) interaction.  
 
Figure 3.13 - The two diastereomers possible as a result of an SN1 or SN2 reaction.  
The 1H NMR shows that proton Ha, in both (233) and (234), is an apparent triplet with a 
coupling constant of 2.7 Hz for methoxy product (233) and 2.8 Hz for ethoxy product (234). 
This suggests that the substitution reactions proceed via an SN1 reaction mechanism to give 
the stereochemistry shown in (S)-(233) (Figure 3.12). If the products were formed through 
an SN2 reaction mechanism, the coupling between H
a-He and Ha-Ha would be sufficiently 
different to observe a clear doublet of doublets peak.  
3.10.2 X-ray structure of (235)-  
To confirm the structure and stereochemistry of deprotected Diels-Alder / ene adduct (235), 
a single crystal was grown by slow evaporation from DCM and was then subjected to X-ray 
diffraction (Figure 3.14).  
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Figure 3.14 - X-ray crystal structure of deprotected ene product (235).  
The structure generated from the X-ray diffraction confirmed that the Cbz group had been 
lost from the indolic nitrogen. It also allowed us to prove the relative stereochemistry of 
deprotected product (235) had not changed from Cbz protected Diels-Alder/ ene adduct 
(232), with the succinimide moiety remaining on the opposite face of the molecule relative 
to the hydroxylamine group.  
3.10.3 Cbz one-pot Diels-Alder / ene chemistry- 
With an efficient method for the removal of the Cbz protecting group, the scope of the Cbz 
Diels-Alder / ene reaction and subsequent Cbz deprotection could be investigated. To allow 
for comparison with the previous tosyl protected Diels-Alder / ene adducts (208) and (209), 
functionality was added to the indole ring with the introduction of a methoxy group in the 
five position. 
Therefore, benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (239) needed to be 
synthesised. Starting from 5-methoxy-1H-indole-3-carbaldehyde (237), the Cbz protection 
could be carried out using benzyl chloroformate and triethylamine (Scheme 3.36). 
 
Scheme 3.36 - Cbz protection of 5-methoxy-1H-indole-3-carbaldehyde (238). 
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The reaction gave the desired product (238) in an excellent yield of 98%. 
The next step was the Wittig reaction with methylenetriphenyl-λ5-phosphane to form benzyl 
5-methoxy-3-vinyl-1H-indole-1-carboxylate (239) (Scheme 3.37). 
 
Scheme 3.37 - Cbz protected Wittig reaction. 
The crude 1H NMR showed a mixture of two compounds was generated in a 1: 1 ratio. 
Separation by silica gel chromatography gave the desired benzyl 5-methoxy-3-vinyl-1H-
indole-1-carboxylate (239) and 5-methoxy-3-vinyl-1H-indole (240). This suggested that, 
although the Wittig reaction was giving desired product (239), the conditions used in the 
Wittig reaction were leading to decomposition of benzyl 5-methoxy-3-vinyl-1H-indole-1-
carboxylate (239) to form 5-methoxy-3-vinyl-1H-indole (240).    
The isolation of both (239) and (240) from the Wittig reaction did not occur when the 
methoxy group was not on the indole ring. The previous Wittig reaction to form benzyl 3-
vinyl-1H-indole-1-carboxylate (230) gave a good yield of 76% with no deprotected product 
being observed in the reaction. The fact that the Cbz group is only removed when there is a 
methoxy group at the 5 position on the indole ring suggests that the electron donating 
properties of the methoxy group is stabilising a positive charge build up in the 
decomposition mechanism. 
As the Wittig reaction conditions were leading to loss of the Cbz group and therefore only 
modest yields of benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (239), a more reliable 
synthesis had to be developed. We proposed doing the Wittig reaction first to form (240), 
before carrying out the protection step to form (239). That required deprotonating the 
indolic NH as a means of temporarily protecting the indolic nitrogen. This would stop the 
ylide formed in the Wittig reaction from deprotonating the acidic NH instead of attacking 
the carbonyl group. If the NH is already deprotonated, it forces the ylide to react with the 
aldehyde and undergo a Wittig reaction.  
The first step in the new reaction sequence was the Wittig reaction of 5-methoxy-1H-indole-
3-carbaldehyde (237) to give 5-methoxy-3-vinyl-1H-indole (240). This was achieved by first 
deprotonating 5-methoxy-1H-indole-3-carbaldehyde (237) with sodium 
bis(trimethylsilyl)amide (NaHMDS), before performing the Wittig reaction using Ph3PMeI 
and nbutyllithium (Scheme 3.38).   
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Scheme 3.38 - Wittig reaction to form 5-methoxy-3-vinyl-1H-indole (240). 
The Wittig reaction gave 5-methoxy-3-vinyl-1H-indole (240) in an excellent yield of 94%.  
The final step in the synthesis of benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (239) 
was the Cbz protection of the indolic nitrogen using NaHMDS and benzyl chloroformate 
(Scheme 3.39). 
 
Scheme 3.39 - Cbz protection of 5-methoxy-3-vinyl-1H-indole (240).  
The Cbz protection led to benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (239) being 
isolated in a good yield of 71%. The deprotonation step requires the use of the strong base 
NaHMDS compared to the protection step with benzyl 5-methoxy-3-vinyl-1H-indole-1-
carboxylate (237), which used triethylamine. The NH in benzyl 5-methoxy-3-vinyl-1H-indole-
1-carboxylate (237) is conjugated into the aldehyde double bond making the NH more acidic 
compared to benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (240). The lack of aldehyde 
for the NH to conjugate into makes the NH a lot less acidic and therefore a stronger base is 
required.  
With an efficient method for the synthesis of benzyl 5-methoxy-3-vinyl-1H-indole-1-
carboxylate (239) and benzyl 3-vinyl-1H-indole-1-carboxylate (230), the one-pot Diels-Alder 
/ ene reactions could be attempted with NMM (141), maleimide (196), PTAD (150) as 
dienophiles and nitrosobenzene (170), 1-methyl-2-nitrosobenzene (172), and PTAD (150) as 
enophiles (Scheme 3.40). The one-pot chemistry developed in the synthesis of ene adduct 
(232) could be used to quickly synthesise a range of Cbz protected ene adducts (Table 3.7).  
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Scheme 3.40 - General scheme for Cbz protected one-pot Diels-Alder / ene reaction. 
Starting 
Material 
D-A / Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
Starting 
Material 
D-A / Ene 
Conditions 
Ene 
Adduct 
MCR 
Yield 
 
i) NMM (141), 
40 oC, 24 h 
ii) PhNO (170), 
rt, 18 h 
 
74%  
 
i) NMM (141), 
40 oC, 18 h 
ii) o-TolNO (172), 
rt, 3 h 
 
74% 
 
i) NMM (141), 
40 oC, 24 h 
ii) o-TolNO (172), 
rt, 18 h 
 
78%  
 
i) Maleimide 
(196),  
40 oC, 18 h 
ii) PhNO (170), 
rt, 2.5 h  
79% 
 
i) NMM (141), 
40 oC, 24 h 
ii) PTAD (150),  
0 oC 1 h, rt 18 h 
 
54%  
 
i) Maleimide 
(196),  
40 oC, 18 h 
ii) o-TolNO (172), 
rt, 3.5 h  
76% 
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i) Maleimide 
(196),  
40 oC, 24 h 
ii) PhNO (170), 
rt, 18 h  
70%  
 
i), PTAD (150), 
-78 oC, 5 h 
ii) PhNO (170), 
rt, 3 h 
 
72% 
 
i) Maleimide 
(196),  
40 oC, 24 h 
ii) o-TolNO (172), 
rt, 4 h  
83%  
 
i) PTAD (150), 
-78 oC, 5 h 
ii) o-TolNO (172), 
rt, 18 h 
 
68% 
 
i) Maleimide 
(196),  
40 oC, 24 h 
ii) PTAD (150), 
0 oC, 1 h 
 
58%  
 
i) PTAD (150), 
-78 oC, 1.5 h 
ii) PhNO (170), 
rt, 20 h 
 
78% 
 
i) PTAD (150), 
-78 oC, 1.5 h 
ii) PhNO (170),  
rt,3 h 
 
73%  
 
i) PTAD (150), 
-78 oC, 1.5 h 
ii) o-TolNO (172), 
rt, 24 h 
 
82% 
Table 3.7 - One-pot Cbz protected Diels-Alder / ene reaction conditions.  
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The one-pot MCRs allowed us to synthesise fourteen novel Cbz protected Diels-Alder / ene 
adducts as single diastereomers. The nitroso-ene reactions gave yields ranging from 68-83% 
whilst the aza-ene reactions, which used PTAD as an enophile, gave slightly lower yields of 
54-58%. This slightly lower yield was due to several unidentified side products that were 
also formed in the reaction. 
The Diels-Alder reactions between benzyl 3-vinyl-1H-indole-1-carboxylate (230) and NMM 
(141) or maleimide (196), all went to completion in the same time of 24 hours, with no 
significant difference between the NMM Diels-Alder reactions and the maleimide Diels-
Alder reactions. The tosyl and DMAS protected Diels-Alder reactions took 48 hours to go to 
completion.  
The NMM (141) or maleimide (196) Diels-Alder reactions with benzyl 5-methoxy-3-vinyl-1H-
indole-1-carboxylate (239) went to completion after just 18 hours, which we propose is due 
to the electron donating methoxy group making the diene more electron rich. The same 
trend is observed with the PTAD Diels-Alder reactions. The PTAD Diels-Alder reaction with 
benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (239) goes to completion after 1.5 hours 
compared to 5 hours with benzyl 3-vinyl-1H-indole-1-carboxylate (230). 
3.10.4 Cbz protecting group removal-  
With a range of Cbz protected ene adducts, the next step in the synthesis of biologically 
active analogues was the removal of the Cbz protecting group in a hydrogenation reaction. 
As seen previously (Chapter 3.10.0), this could be done using Adam’s catalyst and an 
atmospheric pressure of hydrogen gas (Scheme 3.41). 
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Scheme 3.41 - Cbz protecting group removal.  
Starting 
Material 
Hydrogenation 
Conditions 
Product Yield  
Starting 
Material 
Hydrogenation 
Conditions 
Product Yield 
 
PtO2, 
H2 (1 atm), 
5 h 
 
75%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
44% 
 
PtO2, 
H2 (1 atm), 
7 h 
 
87%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
70% 
 
PtO2, 
H2 (1 atm), 
5 h 
 
91%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
70% 
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PtO2, 
H2 (1 atm), 
10 h 
 
41%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
60% 
 
PtO2, 
H2 (1 atm), 
6 h 
 
70%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
85% 
 
PtO2, 
H2 (1 atm), 
5 h 
 
64%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
38%81 
 
PtO2, 
H2 (1 atm), 
5 h 
 
65%  
 
PtO2, 
H2 (1 atm), 
5 h 
 
64% 
 
Table 3.8 - Hydrogenation reaction conditions. 
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The hydrogenation reactions all gave the desired deprotected ene adducts as single 
diastereomers.  
3.11.0 Biological Activity-  
With fourteen deprotected ene adducts, plus methoxy (233) and ethoxy (234) side products 
in hand, we tested the compounds for biological activity. The compounds were subjected to 
a Kirby-Bauer disk diffusion assay against Staphylococcus aureus (S. aureus), 
Schizosaccharomyces pombe (S. pombe) and Escherichia coli (E. coli) at a concentration of 10 
mg/ mL.  
The deprotected compounds, along with Cbz protected compound (232), were dissolved in 
DMSO, spotted on filter paper disks and placed on Agar plates inoculated with S. aureus, S. 
pombe or E.Coli Each plate was also spotted with an appropriate positive control for 
comparison (nystatin for S. pombe, Kanamycin for S. aureus and Ampicillin for E. coli) and 
incubated overnight at 30 oC. The zones of inhibition could then be measured for each 
compound giving an indication of their relative biological activity.  
As expected, compound (232) which was Cbz protected, showed no activity against any of 
the bacteria and yeast. This backed up the data from the previous bio-assay of the tosyl, 
benzyl and DMAS protected compounds, which suggested the indolic NH must be 
deprotected for the compound to show biological activity (Chapter 3.9.0).   
The deprotected samples showed moderate biological activity against the two bacteria and 
yeast (Table 3.9). 
Compound Zone of inhibition/ cm 
 
S. 
pombe 
S. 
aureus 
E. 
coli 
 
- 1.2 - 
 
- - - 
 
- 1.4 - 
 
- 1.4 - 
Compound Zone of inhibition/ cm 
 
S. 
pombe 
S. 
aureus 
E. 
coli 
 
- - - 
 
- 0.7 0.6 
 
- 0.6 - 
 
- 0.7 - 
 
1.1 - - 
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0.9 1.1 - 
 
0.7 1.2 - 
 
0.8 1.5 - 
 
1.2 2.0 - 
 
- 1.1 - 
 
- 1.2 - 
Positive control zone of inhibition/ cm 
Nystatin 3.5 - - 
Kanamycin - 3.0 - 
Ampicillin - - 2.3 
 
 
- 0.6 - 
 
1.4 1.6 0.6 
Positive control zone of inhibition/ cm 
Nystatin 0.8 - - 
Kanamycin - 2.1 - 
Ampicillin - - 4.0 
Table 3.9 - Results from disk diffusion assay. 
The results from the disk diffusion assay gave a good indication of which compounds were 
the most biologically active. Following on from the disk diffusion assay, the minimum 
inhibitory concentration (MIC) of the tested compounds was determined against 
Staphylococcus aureus and Escherichia coli (Table 3.10).82 
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Compound MIC in µg/ mL MIC in µg/ mL  Compound MIC in µg/ mL MIC in µg/ mL 
 S. aureus E. coli   S. aureus E. coli 
 
>125 >125 
 
 
>125 >125 
 
25 - 
 
 
25 - 
 
100 - 
 
 
100 - 
 
125 >125 
 
 
100 - 
 
62.5 >125 
 
 
100 - 
 
>100 - 
 
 
>100 - 
 
125 >125 
 
 
50 - 
 
15.6 125 
 
 
50 - 
Table 3.10 - MIC of tested compounds against S. aureus and E. Coli. 
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The results from the MIC experiment suggest that the methoxy group in the 5 position of 
the indole ring has a detrimental effect upon the biological activity of the compounds. 
Compounds (258) and (264), deriving from the Diels-Alder reaction with PTAD, have a MIC 
of 25 µg/ mL against S. aureus without the methoxy group. However, when the 5-methoxy 
group is added (compounds (267) and (268)) the MIC rises to 50 µg/ mL against S. aureus. 
The same trend is observed when comparing hydroxylamine compounds (255), (256), (261) 
and (262) with 5-methoxy substituted compounds (259), (260), (265) and (266).   
Another trend that can be observed from the MIC results is that compounds (257) and 
(263), derived from the ene reaction with PTAD, are not as active as the compounds derived 
from the ene reaction with the nitroso compounds. The hydroxylamine compounds have an 
average MIC of 63 µg/ mL, which is significantly better than the >100 µg/ mL that is seen 
from the PTAD derived compounds.   
From these results it is possible to build an initial SAR diagram of the tetrahydrocarbazole 
framework with the various groups we have tested (Figure 3.15).  
 
 
 
 
 
Figure 3.15 - SAR diagram of tetrahydrocarbazole framework.  
3.11.1 Proposed mode of action- 
We suggest the difference in biological activity between the PTAD and hydroxylamine ene 
adducts can be explained through a difference in the mode of action of the compounds. It is 
possible that the mode of action of compounds (255) – (268) that we synthesised is a 
conjugate addition mechanism. There are many compounds in clinical trials that use an 
electrophilic site on the drug molecule to react with nucleophiles at the target binding 
site.83-87 These compounds, such as the kinase inhibitor hypothemycin (269) shown below, 
bind irreversibly to protein kinases through a Michael addition on a 1,4-unsaturated 
carbonyl system, which leads to inhibition of the kinase (Scheme 3.42).84 Hypothemycin 
(269) inhibits a range of human kinases including MEK and ERK.  
R3 = H No activity when R ≠ H 
R1 = H Compounds not as 
active when R1 = OMe 
R2 = N(OH)Ar 
Better actvity when Ar = o-
Tol 
R4 = Me or H No correlation 
between R4 group and 
activity  
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Scheme 3.42 - Mode of action for hypothemycin (269). 
Molecules such as hypothemycin (269) are competitive inhibitors of ATP, binding to the 
protein kinases through a nucleophilic cysteine. This blocks any ATP from binding to the 
kinase, which has an inhibitory effect. 
We propose that our compounds synthesised via a one-pot Diels-Alder / ene reaction are 
active through a similar pathway.  We have shown previously, with the synthesis of methoxy 
and ethoxy substituted products (233) and (234), that the hydroxylamine groups are labile 
(Scheme 3.43).  
 
Scheme 3.43 - SN1 reaction to form compounds (233) and (234). 
We believe that compounds such as (232) can undergo the same substitution reaction in a 
biological system and competitively bind to the ATP binding site on kinases (Scheme 3.44). 
 
Scheme 3.44 - Proposed mode of action for compounds (255) – (268). 
If our proposed mode of action was correct, it would explain why compounds (257) and 
(263), where R3 = PTAD (Scheme 3.44), show less activity than those where R3 = 
hydroxylamine. The activity is dependent upon the elimination of R3 (Scheme 3.44) before 
the resulting compound (272) can covalently bind to the ATP binding site in the biological 
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system through a nucleophilic sulphur from a cysteine amino acid. The hydroxylamine 
groups are better leaving groups than PTAD and this would explain why the PTAD 
compounds (257) and (263) are not as active as the hydroxylamine compounds. 
3.11.2 Human kinase screening- 
As several tetrahydrocarbazoles are known to be kinase inhibitors74,88, four of our 
deprotected Diels-Alder / ene adducts were submitted for screening against 51 human 
kinases at a 10 µM concentration. Many kinases are known to have an important role in the 
growth and survival of tumours  therefore there are many kinase inhibitors currently in 
clinical trials as anti-cancer drugs.89   
Compounds (256) and (262), where the enophile used was 1-methyl-2-nitrosobenzene, 
showed little or no activity against any of the kinases. However compounds (255) and (261), 
where the enophile used was nitrosobenzene, both showed modest activity against MLK3 
and Src kinases. These results indicate that changing the aromatic ring from a phenyl to an 
o-tolyl has a large effect upon the activity of the compounds.  
Additionally, compound (255) showed activity against JAK2 kinase and compound (261) 
showed activity against Aurora B kinase (Table 3.11). 
 % Activity Remaining (10 µM) 
 
    
Aurora B 32±2 56±2 21±1 67±2 
JAK2 28±13 81±8 68±10 98±15 
MLK3 28±6 64±2 17±3 73±7 
Src 15±6 57±5 17±1 76±0 
Table 3.11 - Table showing activity against a range of kinases. 
Although the human kinome contains over 500 kinases, identifying selective kinase 
inhibitors is not trivial and remains a very active area of research.90 Compound (261) 
showed good activity against Aurora B, MLK3 and Src but limited activity against JAK2. This 
selectivity demonstates that compounds (255), (256), (261) and (262) do not intrinsically 
inhibit all kinases. This makes the compoundssuitable as potential drug compounds as 
targeting of specific kinases is required for drug compounds. In addition, by inhibiting 
certain kinases and monitoring the changes in the biological system when compared to a 
control, allows a greater understanding of the function the inhibited kinase has in the 
organism.91,92  
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Although (255), (256), (261) and (262) showed selective inhibition of several kinases, there 
are other properties that need to be addressed before the compounds can be considered as 
potential drug molecules. The Diels-Alder / ene adducts would need to be developed further 
so that they are active at nM concentrations, for them to be considered as viable drug 
compounds.   
3.12.0 Conclusion-  
Using the same Diels-Alder / ene chemistry that was developed in the previous chapter, we 
have built upon the chemistry to make the reaction sequence a one-pot procedure. The 
one-pot procedure led to an increase in the overall yields, from around 50% for the two step 
procedure to 75%, as well as a reduction in waste and operational complexity. Using the 
one-pot procedure, a range of Diels-Alder / ene compounds were rapidly synthesised in 
yields ranging from 29-89% (Scheme 3.45).  
 
Scheme 3.45 - General scheme for one-pot Diels-Alder / ene reaction. 
Of the Diels-Alder / ene compounds synthesised the Ts, DMAS and Bn were tested for 
biological activity against S. Aureus, S. Pombe and E. Coli but were found to show no activity. 
We reasoned this was due to the protecting groups on the indolic nitrogen of the 
compounds. Attempts to remove the Ts and DMAS protecting groups were unsuccessful. 
Therefore a new protecting group had to be found that could be easily removed, whilst still 
allowing the one-pot Diels-Alder / ene reactions to occur. Cbz was used to protect the 
indolic NH during the Diels-Alder / ene reactions and could be easily removed using 
hydrogenation chemistry (Scheme 3.46).   
 
Scheme 3.46 - General scheme for Cbz protecting group removal. 
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The fourteen deprotected compounds formed from the hydrogenation reaction, were then 
tested for biological activity in a disk diffusion assay. The compounds showed promising 
biological activity against S. Pombe and S. Aureus with compound (262) having the best MIC 
of 15.6 µg/ mL. This confirmed our theory that for the Diels-Alder / ene adducts to be 
biologically active, a free indolic NH is essential. Four of the compounds were then 
submitted for screening against 51 human kinases; (255) and (261) showed moderate 
activity against Aurora B, JAK2, MLK3 and Src kinases which are important targets in anti-
cancer research. 
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Chapter 4 - Enantioselective Diels-Alder  / Ene Chemistry 
4.1.0 EnantioselectiveDiels-Alder / ene reaction-  
In Chapters 1 and 2, we developed an efficient one-pot Diels-Alder / ene reaction process 
that led to the formation of a range of tetrahydrocarbazole compounds which showed 
moderate biological activity.  We next want to investigate if we can make this process 
enantioselective, so that only one enantiomer of the tetrahydrocarbazole compound is 
formed in the reaction. We hope this will lead to an improvement in the biological activity of 
the compounds. This can be done by two different methods. The first method is making the 
Diels-Alder reaction an enantioselective process so that only one enantiomer (190) is 
formed. Then, as the ene reaction is stereospecific, ene adduct (191) will be produced as a 
single enantiomer (Scheme 4.1).  
 
Scheme 4.1 - Catalysed Diels-Alder reaction followed by ene reaction to form enantiopure 
tetrahydrocarbazole (191). 
The second method involves carrying out the Diels-Alder reaction with no catalyst to form 
racemic Diels-Alder product (190). Then an enantioselective catalyst can be used in the ene 
step leading to the formation of enantiopure product (191) (Scheme 4.2).  
 
Scheme 4.2 - Racemic Diels-Alder reaction followed by catalysed ene reaction to form enantiopure 
tetrahydrocarbazole (191). 
However, one disadvantage of making the ene reaction the enantioselective step is the fact 
that only half of racemic Diels-Alder adduct (190) will react in the ene reaction. Due to this 
disadvantage in making the ene reaction the enantioselective step, we chose to concentrate 
on making the initial Diels-Alder reaction the enantioselective process.  
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4.2.0 Enantioselective organocatalysts- 
Enantioselective organocatalysts have many advantages over traditional metallic or 
enzymatic catalysts including their lack of toxicity, ease of availability, ease of synthesis and 
their tolerance of many functional groups.93 We proposed using an organocatalyst due to 
these reasons as well as the large amount of literature available on using enantioselective 
organocatalysts in Diels-Alder reactions.94-97 Therefore we needed to identify an 
enantioselective organocatalyst that would allow the enantioselective synthesis of 
tetrahydrocarbazoles.  
There are three main classes of enantioselective organocatalysts that each use different 
methods to make a reaction enantioselective; singly occupied molecular orbital (SOMO) 
catalysts, hydrogen bonding catalysts and covalent catalysts.  
4.2.1 Covalent catalysts-  
Natural products such as proline have become popular tools in organocatalysis as they are 
produced enantiomerically pure in nature. Proline and organocatalysts derived from proline, 
work through the formation of covalent bonds with the substituents. This then forces the 
reaction to occur through a particular geometry leading to enantiopure products being 
formed. The first example of this type of organocatalysed process utilised in Diels-Alder 
chemistry was by MacMillan et al., in what they described as “the first highly 
enantioselective organocatalytic Diels-Alder reaction” (Scheme 4.4).98 
 
Scheme 4.4 - MacMillan et al. first example of highly enantioselective Diels-Alder reaction.   
Organocatalyst (281) works through a reaction with (280), forming iminium ion (283) 
(Scheme 4.5). The formation of iminium (283) activates the dienophile towards the Diels-
Alder reaction by lowering the energy level of the LUMO, as well as dictating the orientation 
of attack by blocking one face of iminum (283). This leads to the generation of (282) as a 
single enantiomer.  
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Scheme 4.5 - The mechanism by which catalyst (281) catalyses the Diels-Alder reaction. 
There have also been examples of enantioselective Diels-Alder reactions with 3-vinyl-indole 
compounds similar to the ones which were used in the Chapters 1 and 2. Enders et al.99 
used a proline derived organocatalyst in the reaction between 3-vinyl-1H-indole (140) and 
cinnamaldehyde (284) (Scheme 4.6).  
 
Scheme 4.6 - Organocatalysed Diels-Alder/aza-Michael/aldol condensation reaction.  
In the reaction developed by Enders et al., organocatalyst (285) does not just catalyse the 
Diels-Alder reaction, but also catalyses the Michael addition and aldol condensation 
reactions through iminium activation and enamine activation. This leads to the formation of 
product (287), which has four new stereocentres, in an excellent ee.   
4.2.2 SOMO-organocatalysis- 
SOMO-catalysis is based upon a one electron oxidation of an enamine system to form a 
highly reactive radical cation. This process activates a singly occupied molecular orbital 
which can rapidly react with a range of weak nucleophiles. There are few examples of 
SOMO-catalysed Diels-Alder reactions in the literature. The few that are available in the 
literature are not traditional concerted Diels-Alder reactions between a dienophile and a 
diene. Instead, an alkene and an aldehyde react through a step-wise manner (Scheme 
4.3).100,101 
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Scheme 4.3 - SOMO-catalysed cycloaddition between aldehyde (277) and alkene (278). 
The enantioselectivity in SOMO catalysis derives from the organocatalyst either hindering 
one face of the substrate or directing a substrate on to one face preferentially. 
4.2.3 Hydrogen bonding catalysts-  
The final major class of organocatalyst is one that uses hydrogen bonding to hold one or 
both of the reactants in a particular geometry. A lot of hydrogen bonding organocatalysts 
are based upon a thiourea framework, such as catalyst (289) developed by Barbas et al.102, 
which has four NH units that can form hydrogen bonds. 
Barbas et al.102 have utilised organocatalyst (289) in the Diels-Alder reaction between 3-
vinyl-1H-indole (140) and methyleneindolinone (288) to form a range of compounds, such as 
(290), containing a carbazolespirooxindole framework  (Scheme 4.7). 
 
Scheme 4.7 - Barbas et al. organocatalysed Diels-Alder reaction to form carbazolespirooxindoles 
(290). 
Catalyst (289) works by forming hydrogen bonds with the reactants which fixes the 
orientation of the Diels-Alder reaction, leading to the formation of (290) as a single 
enantiomer.  
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Work by Ricci et al.103,104 has demonstrated, through use of organocatalyst (291) that was 
developed by Soos et al.105,  a method for the stereocontrolled Diels-Alder reaction between 
3-vinyl-1H-indole (140) and a range of maleimide based dienophiles (Scheme 4.8). Diels-
Alder adduct (142), initially formed in the reaction, is then subjected to an indolic N-
protection with trifluoroacetic anhydride (TFAA) to give product (292).  
 
Scheme 4.8 - Ricci’s reaction to form enantiomerically pure compounds of type (292). 
Ricci et al.103 postulated that catalyst (291) works through hydrogen bonding both the 3-
vinyl-1H-indole (140) and maleimide compound (276) in the transition state, which fixes the 
orientation of the Diels-Alder reaction, resulting in a single enantiomer being formed (Figure 
4.1).  
 
Figure 4.1 - Ricci’s proposed transition state for the Diels-Alder reaction between 3-vinyl-1H-indole 
(140) and maleimide (276).  
4.3.0 Enantioselective organocatalysed Diels-Alder / ene plan- 
Previous work81 in the group has attempted to use the work by Barbas et al. to develop 
enantioselective Diels-Alder / ene chemistry. However this was not successful due to the 
capricious nature of the Diels-Alder reaction, and unwanted rearomatisation of the initial 
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Diels-Alder adduct formed before the ene reaction could occur. Also, the 
carbazolespirooxindoles generated in Barbas’s catalytic procedure do not have many 
structural similarities with the tetrahydrocarbazoles (190) we synthesised in Chapters 1 and 
2 (Figure 4.2).  
The work by Enders et al. was also not compatible with our Diels-Alder / ene approach as 
the proline derived catalyst used requires a free aldehyde group to attack. Our Diels-Alder 
reactions between N-protected 3-vinyl-indoles and maleimide compounds means there is 
no free carbonyl group for the catalyst to attack.  
Ricci’s procedure led to the formation of single enantiomer tetrahydrocarbazole compounds 
(292) which are similar to the compounds (190) we had been synthesising using our one-pot 
Diels-Alder / ene approach (Figure 4.2). We therefore decided to use Ricci’s catalytic 
procedure as a means of synthesising single enantiomer Diels-Alder adducts (292).  
 
Figure 4.2 - Compounds (190) synthesised through our one-pot Diels-Alder ene procedure and 
compound (290) synthesised by Barbas, compound (287) synthesised by Enders and compounds 
(292) synthesised by Ricci. 
We believed we could use Ricci’s organocatalytic procedure to synthesise enantiopure 
compounds such as (190). With single enantiomer Diels-Alder adducts (190) in hand, we 
could then subject them to ene reactions with the same nitroso, aza, and carbonyl enophiles 
used in Chapters 2 and 3, to produce a range of single enantiomer Diels-Alder / ene adducts 
(293) (Scheme 4.9).  
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Scheme 4.9 - Proposed route to single enantiomer Diels-Alder / ene adducts (293). 
4.4.0 Enantioselective organocatalysed Diels-Alder chemistry- 
We needed to synthesise 3-vinyl-1H-indole (140) in a good yield. Ricci et al. has shown that 
deprotonating 1H-indole-3-carbaldehyde (131) and reacting the ion formed with 
methylenetriphenyl-λ5-phosphane, leads to the formation of 3-vinyl-1H-indole (140) in an 
excellent yield (Scheme 4.10).  
 
 
Scheme 4.10 - Wittig reaction to form 3-vinyl-1H-indole (140) from 1H-indole-3-carbaldehyde 
(131).  
The deprotonation is a means of temporarily protecting the NH and stopping it from being 
deprotonated by methylenetriphenyl-λ5-phosphane. After the Wittig reaction has occurred, 
the indolic nitrogen is protonated during the work up.  
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With 3-vinyl-1H-indole (140) in hand, we first decided to test the Diels-Alder / ene chemistry 
as a non-enantioselective process, before using catalyst (291) to make the process 
enantioselective. This would allow us to optimise the Diels-Alder / N-protection / ene 
chemistry before using the catalyst.  
In Chapter 2 we discussed the Diels-Alder reaction between 3-vinyl-1H-indole (140) and 
NMM (141) (Scheme 4.11). Diels-Alder adduct (142) could be observed by 1H NMR however 
attempts to isolate it led to rearomatisation of the indole ring to form (143).   
 
Scheme 4.11 - Diels-Alder reaction between 3-vinyl-1H-indole (140) and NMM (141).  
The Diels-Alder reaction between 3-vinyl-1H-indole (140) and NMM (141) was repeated and 
after two hours the reaction was cooled to room temperature before TFAA was added 
(Scheme 4.12).  
 
Scheme 4.12 – One-pot Diels-Alder / N-protection reaction to form (292). 
The reaction gave the desired N-protected Diels-Alder adduct (292) as a racemic mixture in 
an excellent yield of 91%.  
With Diels-Alder adduct (292) in hand, we then attempted an ene reaction between Diels-
Alder adduct (292) and nitrosobenzene (170) (Scheme 4.13). 
 
Scheme 4.13 - Ene reaction between Diels-Alder adduct (292) and nitrosobenzene (170). 
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The ene reaction was stirred at room temperature for five days, however no reaction 
occurred and Diels-Alder adduct (292) was recovered. We propose this is due to the 
electron withdrawing nature of the trifluoroacetyl protecting group on the indolic nitrogen. 
Previous work (Chapters 1 and 2) has shown the significant effect the electronics of the N-
protecting group have upon the rate of both the Diels-Alder and ene reactions. The electron 
withdrawing nature of the trifluoroacetyl group pulls electron density away from the indole 
ring which prohibits the ene reaction from occurring within a reasonable timeframe.  
As Diels-Alder adduct (292) would not undergo an ene reaction, an alternative, less electron 
withdrawing protecting group had to be found.  
4.4.1 Diels-Alder / Boc protection of 3-vinyl-1H-indole (140)- 
We needed a protecting group that had similar chemistry to the trifluoroacetyl group, 
however it needed to be less electron withdrawing to allow further ene reactions to occur. 
We therefore investigated the Boc protecting group. The Boc group has similar chemistry to 
TFAA in that it is also an anhydride, therefore we hoped that this would make it compatible 
with organocatalyst (291).  
The Diels-Alder reaction between 3-vinyl-1H-indole (140) and NMM (141) was repeated. 
Upon conversion to Diels-Alder adduct (142), di-tert-butyl dicarbonate and triethylamine 
were added (Scheme 4.14). 
Scheme 4.14 - Diels-Alder / N-protection reaction between 3-vinyl-1H-indole (140) and NMM (141) 
to give (294). 
The reaction did form desired Diels-Alder adduct (294) in a poor yield of 40%. Rearomatised 
Diels-Alder adduct (143) was also isolated in a 26% yield which suggested that the final Boc 
protection step was not occurring before Diels-Alder adduct (142) rearomatised to (143). 
Therefore, to try to increase the rate of the protection step, the reaction was attempted 
again and a catalytic amount of DMAP was added to the final protection step (Scheme 4.15).   
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Scheme 4.15 - Diels-Alder / protection reaction with Boc anhydride and catalytic DMAP. 
The addition of DMAP to the reaction led to an increase in the yield of Diels-Alder adduct 
(294) by 17% on the previous attempt. There was a reduction of rearomatised Diels-Alder 
adduct (143) isolated from the reaction to just 8%.  
With a method for the synthesis of Diels-Alder adduct (294) in a moderate yield developed, 
we next investigated the ene reaction between Diels-Alder adduct (294) and a range of 
enophiles (Scheme 4.16). The enophiles chosen were nitrosobenzene (170), 1-methyl-2-
nitrosobenzene (171) and PTAD (150) which we had previously used successfully (Chapters 2 
and 3). 
Scheme 4.16 - Proposed ene reaction with Diels-Alder adduct (294). 
Starting 
Material 
Ene 
Conditions 
Ene 
Adduct 
Ene 
Adduct 
yield 
Yield 
(296) 
Yield 
(297) 
 
PhNO (170), 
rt, 4 h 
 
47% 10% 23% 
 
o-TolNO 
(171), 
rt, 3 h 
 
37% 5% 14% 
 
PTAD (150), 
0 oC, 4 h 
 
46% 9% 11% 
Table 4.1 - Reaction conditions for ene reactions with Diels-Alder adduct (294). 
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The ene reactions gave desired products (298) – (300) in generally poor yields of between 
37 – 47%. The low yields for the ene reactions are partially a result of unwanted side 
products (296) and (297) being formed as well as further unidentified products. The 
formation of these side products suggested that Diels-Alder adduct (294) was not stable in 
solution or when exposed to enophiles.  
Due to the moderate yields of the Diels-Alder reaction to form (294) and the poor yields for 
the ene reactions, work on the Boc protecting group was stopped. We chose instead to 
investigate the acetyl protecting group. 
4.4.2 Diels-Alder / acetyl protection of 3-vinyl-1H-indole (140)-  
To test the suitability of an acetyl protecting group in the Diels-Alder / N-protection and ene 
chemistry, the Diels-Alder reaction between 3-vinyl-1H-indole (140) and NMM (141) was 
repeated as previously, before acetic anhydride, triethylamine and DMAP were added 
(Scheme 4.17).  
 
Scheme 4.17 - Diels-Alder / acetyl protection reaction between 3-vinyl-1H-indole (140) and NMM 
(141). 
The reaction gave the desired Diels-Alder adduct (301) in a moderate yield of 55%. 
Unprotected Diels-Alder adduct (143) was also isolated in a 6% yield, which suggested the 
protection reaction was again not going to completion. The reaction was attempted once 
more, with a longer reaction time for the final protection step of 24 hours, however the 
overall yield remained unchanged.   
We then moved to screening compound (301) in a range of ene reactions. The same 
enophiles as previously used with the Boc protected Diels-Alder adduct (294) were again 
utilised. The results are summarised in Table 4.2. 
 
Scheme 4.18 - Proposed ene reaction with Diels-Alder adduct (302). 
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Starting 
Material 
Ene 
Conditions 
Ene 
Adduct 
Yield 
% 
 
PhNO (170), 
rt, 18 h 
 
64% 
 
o-TolNO 
(172), 
rt, 18 h 
 
75% 
 
PTAD (150), 
0 oC, 5 h 
 
57% 
Table 4.2 - Reaction conditions for ene reactions with Diels-Alder adduct (301). 
The ene reactions formed the desired ene adducts (303) – (305) as single diastereomers in 
yields ranging from 57 – 75%. Many attempts were made to improve the yields of the ene 
adducts formed, however the ene reactions were found to be variable and the yields were 
difficult to replicate.  
To confirm the structure and relative stereochemistry of ene adduct (303), a single crystal 
was grown for analysis by X-ray diffraction, by slow evaporation from chloroform (Figure 
4.3).  
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Figure 4.3 - X-ray crystal structure of ene adduct (303).  
Ene adduct (303) crystallises in the triclinic crystal system with a P1 space group, containing 
two molecules in the asymmetric unit. The X-ray crystal structure showed that ene adduct 
(303) has the hydroxylamine group on the opposite face of the molecule relative to the 
succinimide group. This is consistent with the previous X-ray crystal structures obtained 
from one-pot Diels-Alder / ene chemistry (Chapter 2). Interestingly the X-ray crystal 
structure indicates that there is hydrogen bonding between the N3 on one molecule and the 
O4H of the adjacent molecule. This H-bond interaction has a length of 2.793 Å.  
The N-protection, step after the Diels-Alder reaction, had given a moderate yield of Diels-
Alder adduct (301) of 55%. We wanted a procedure that would lead to a higher yield of 
Diels-Alder compound, therefore a new protecting group had to be found that would allow 
the reliable synthesis of the Diels-Alder and ene adducts. 
4.4.3 Diels-Alder / tosyl protection of 3-vinyl-1H-indole (140)-  
In previous chapters, we had a lot of success with the tosyl protecting group and had 
already optimised the ene reactions with tosyl protected Diels-Alder adduct (148). 
Therefore we attempted to synthesise tosyl protected Diels-Alder adduct (148) from 3-vinyl-
1H-indole (140). The N-protection step had to be optimised as most tosyl protections are 
performed using p-toluenesulfonyl chloride, which is not as reactive as the anhydrides we 
had previously tried. We attempted to perform a Diels-Alder reaction between 3-vinyl-1H-
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indole (140) and NMM (141), followed by tosyl protection with p-toluenesulfonyl chloride 
(Scheme 4.19). 
 
Scheme 4.19 - Diels-Alder / N-protection between 3-vinyl-1H-indole (140) and NMM (141). 
The Diels-Alder reaction was carried out as previous (Chapter 2) and after two hours p-
toluenesulfonyl chloride and triethylamine were added. However, the 1H NMR of the crude 
reaction mix showed that the N-protection reaction had not occurred and instead Diels-
Alder adduct (142) had rearomatised to form (143). This suggested that p-toluenesulfonyl 
chloride was not reactive enough to perform the N-protection step before the Diels-Alder 
adduct (142) rearomatised to (143). 
We therefore used a more reactive source of the tosyl protecting group in the form of p-
toluenesulfonic anhydride. The reaction was repeated as above but in the N-protection step 
p-toluenesulfonic anhydride, triethylamine and DMAP were added (Scheme 4.20).  
 
 
Scheme 4.20 - Diels-Alder / N-protection to form Diels-Alder adduct (148). 
The Diels-Alder / N-protection reaction gave the desired Diels-Alder adduct (148) as a single 
diastereomer in a good yield of 70%.  
With an efficient method for the synthesis of Diels-Alder adduct (148) starting from 3-vinyl-
1H-indole (140) developed, we next wanted to see if this reaction could be performed as an 
enantioselective process using Ricci’s procedure.103   
4.5.0 Synthesis of Soos’s organocatalyst (291)- 
Firstly, we needed to synthesise Soos’s organocatalyst (291). We employed the same 
method as Soos had used in his original paper105 (Scheme 4.21).  Starting from quinine (304), 
a one-pot Mitsunobu / Staudinger reduction lead to compound (306), which was then 
reacted with 3,5-bis(trifluoromethyl)phenyl isothiocyanate to give catalyst (291).  
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Scheme 4.21 - Synthesis of Soos’s organocatalyst (291).  
With catalyst (291) synthesised, we could then investigate the catalysed Diels-Alder / tosyl 
protection reaction.  
4.6.0 Organocatalysed Diels-Alder chemistry-  
We attempted a Diels-Alder / N-protection reaction using the same conditions Ricci et al. 
had optimised. 3-Vinyl-1H-indole (140), catalyst (291) and NMM (141) were stirred at -55 oC 
for 48 h before p-toluenesulfonic anhydride was added to the reaction (Scheme 4.22).  
 
Scheme 4.22 - Organocatalysed Diels-Alder / N-protection reaction to form Diels-Alder adduct 
(148). 
The organocatalysed Diels-Alder reaction led to the formation of desired Diels-Alder adduct 
(148) in a good yield of 74%.  
Having previously synthesised Diels-Alder adduct (148) as a racemic product (Scheme 4.20), 
it allowed us to compare the chiral HPLC traces of the racemic adduct to the single 
enantiomer. The racemic mixture was run through an AD-H chiral column with a hexane and 
isopropanol solvent system. The HPLC trace clearly shows the two enantiomers at 35 and 77 
minutes. We then ran the single enantiomer Diels-Alder adduct using the same column and 
conditions. The peak at 35 minutes remains unchanged however the second peak at 77 
minutes has drastically reduced. This indicates the formation of a single enantiomer from 
the reaction with an ee of >95%.  This is confirmed by the specific rotation, which was 
calculated be [α]D= +180.     
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With an efficient method for the synthesis of Diels-Alder adduct (148) as a single 
enantiomer in a good yield and good ee, we could investigate whether the single 
enantiomer Diels-Alder adduct (148) lead to the formation of single enantiomer ene 
adducts. We planned to react Diels-Alder adduct (148) with nitrosobenzene (170), 1-methyl-
2-nitrosobenze (172), and 2,3,4,5,6-pentafluorobenzaldehyde (164) catalysed by DMAC 
(Scheme 4.23).  
 
Scheme 4.23 - Proposed ene reaction with Diels-Alder adduct (148). 
Starting 
Material 
Ene 
Conditions 
Ene 
Adduct 
Yield ee 
 
PhNO (170), 
rt, 18 h 
 
73% >95% 
 
o-TolNO 
(172), 
rt, 18 h 
 
70% >95% 
 
C6F5CHO 
(164), 
DMAC,  
-78 oC 45 
min, rt 18 h 
 
70% >95% 
Table 4.3 – Ene reactions between enantiomerically pure Diels-Alder adduct (148) and a range of 
enophiles.  
The ene reactions between the enantiomerically pure Diels-Alder adduct (148) and 
enophiles (170), (172) and (164) gave the desired ene adducts as single diastereomers in 
good yields. We had previously synthesised compounds (171), (173) and (165) as racemic 
products and this allowed us to optimise the chiral HPLC conditions. As with Diels-Alder 
adduct (148), the traces for the racemic ene adducts were compared to the traces for the 
organocatalysed ene adducts. This allowed us to calculate the enantiomeric excess for (171), 
(173) and (165). This showed that the enantiomeric excess from the enantioselective 
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organocatalysed Diels-Alder reaction was retained through the ene reaction, leading to the 
formation of ene adducts (171), (173) and (165) with an ee of >95%.  
Conclusions-  
We have demonstrated a simple procedure for the synthesis of complex 
tetrahydrocarbazole compounds such as (171), (173) and (165) with excellent enantiomeric 
excess. The ene reactions with acetyl and Boc protected Diels-Alder adducts (301) and (294) 
were found to be capricious and the ene adducts could not be isolated in good yields. We 
propose this is due to the reactivity of the acetyl and Boc protected Diels-Alder adducts, 
whereby several undesired side reactions, including rearomatisation, were competing with 
the ene reaction. Exchanging the acetyl and Boc protecting groups for a tosyl protecting 
group allowed the reliable synthesis of Diels-Alder adduct (148) in high enantiomeric excess, 
and the subsequent ene reactions formed the desired ene adducts in high yields. Thus far, 
only compounds with a tosyl protecting group have been reliably synthesised, however 
further work would involve expanding the range of protecting groups.  
In Chapter 2 we demonstrated how tetrahydrocarbazole compounds such as (171), (173) 
and (165) without an N-protecting group, show moderate biological activity. A synthetic 
route that allows the synthesis of these compounds as single enantiomers could greatly 
improve the biological activity that these compounds show. Therefore developing the 
organocatalysed Diels-Alder / N-protection to allow for the addition of a Cbz protecting 
group, which we have shown can be easily removed (Chapter 3.10.4), would be of great 
interest.   
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Chapter 5 – Conclusions and Future Work 
5.0 Conclusions-  
The aim of this project was to examine the Diels-Alder / ene chemistry of N-protected 3-
vinyl-1H-indole compounds. The tetrahydrocarbazole compounds formed would be 
analogues of known biologically active compounds in the literature. We hoped this would 
give us a means of synthesising biologically active compounds using a novel Diels-Alder / 
ene route.  
We developed a procedure that allowed the synthesis of Diels-Alder adducts (190) from the 
reaction between N-protected 3-vinyl-indoles (189) and maleimide compounds (Scheme 
5.1).  
 
Scheme 5.1 - Route to the synthesis of Diels-Alder adducts (190).  
We discovered that the more electron donating the protecting group, the quicker the Diels-
Alder reaction went to completion. We propose that electron donating groups increase the 
electron density of the indole diene. This raises the energy level of the diene HOMO and 
therefore increases the rate of the Diels-Alder reaction.  
Using X-ray crystallography we were able to deduce the relative stereochemistry of several 
Diels-Alder adducts (190). The X-ray crystal structures revealed that the Diels-Alder reaction 
goes through an endo transition state leading to the endo-Diels-Alder adduct (190). This 
means the hydrogen adjacent to the indolic nitrogen is on the opposite face of the molecule 
relative to the succinimide moiety.   
After devising a reliable method for the synthesis of Diels-Alder adducts (190), we then 
examined their ability to undergo ene chemistry with a range of nitroso, aza and carbonyl 
enophiles. All of the ene reactions were found to be very dependent upon the structure of 
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the enophile. Enophiles with an electron donating group adjacent to the nitroso or carbonyl 
group did not react. We believe that the electron donating groups raises the energy of the 
enophile LUMO, which prevents the reaction from occurring within a reasonable time 
frame. We discovered that Diels-Alder adducts (190) readily undergo ene reactions with 
nitrosobenzene (170), 1-methyl-2-nitrosobenzene (172), PTAD (150) and 2,3,4,5,6-
pentafluorobenzaldehyde (164) (Scheme 5.2).  
 
Scheme 5.2 - General scheme for the ene reactions with Diels-Alder adduct (190).  
The success of the ene reactions demonstrated that it was possible to perform chemistry on 
the double bond formed in the Diels-Alder reaction. We were able to use X-ray 
crystallography to deduce the relative stereochemistry of several of the ene adducts (191). 
They showed that the enophile adds to the opposite face of the molecule relative to the 
succinimide moiety. This suggests that the ene reaction is undergoing a concerted 
mechanism whereby the new bond between the enophile and Diels-Alder adduct is being 
formed at the same time as the hydrogen adjacent to the indolic nitrogen is being 
abstracted (Scheme 5.3).  
 
Scheme 5.3 - Proposed mechanism for ene reaction with Diels-Alder adduct (190). 
The readiness of Diels-Alder adduct (190) to react with electrophilic enophiles suggested 
that the nucleophilic double bond in Diels-Alder adduct (190) could react with further 
electrophiles. Therefore we developed a one-pot Diels-Alder/ bromination / nucleophilic 
substitution reaction starting from (146) (Scheme 5.4).  
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Scheme 5.4 - One-pot Diels-Alder/ bromination/ nucleophilic substitution reaction.   
Although the one-pot Diels-Alder/ bromination / nucleophilic substitution reaction gave the 
desired product (188), the reaction was far more capricious than the ene reactions and 
bromintated product (181) rapidly decomposed to form eliminated products.  
Optimisation of the Diels-Alder and ene reactions meant we could develop a one-pot Diels-
Alder / ene approach, which allowed us to synthesise ene adducts of the type (191) in one 
step without the need to isolate Diels-Alder adduct (190) (Scheme 5.5).  
 
Scheme 5.5 - General one-pot Diels-Alder / ene reaction sequence.  
Using this method we were able to synthesise over thirty different Diels-Alder / ene adducts 
in excellent yields, in what is the first example of a one-pot intermolecular Diels-Alder / 
intermolecular ene reaction sequence.  
The compounds synthesised from the one-pot Diels-Alder / ene reaction contained the 
same pyrrolo[3,4-a]carbazole-1,3-dione framework seen in a range of biologically active 
compounds from the literature33,34. Therefore the compounds we synthesised were tested 
for biological activity in a disk diffusion assay against S. Aureus, E. coli and S. Pombe. 
However, the disk diffusion assay showed no halo of inhibition for any of the compounds. 
Comparison of our adducts with known biologically active compounds suggested that the 
protecting groups on the indolic nitrogen were prohibiting our molecules from being active. 
Therefore we attempted to remove the protecting groups.  
Previous work within the group had found difficulties in removing the tosyl and DMAS 
protecting groups without decomposition of the Diels-Alder / ene compound (190). 
However, we found the Cbz protecting group could be readily removed using Adam’s 
catalyst and an atmospheric pressure of hydrogen gas. This allowed the synthesis of 
fourteen novel deprotected compounds (275) (Scheme 5.6). 
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Scheme 5.6 - Cbz deprotection using Adam’s catalyst and an atmospheric pressure of hydrogen 
gas. 
A disk diffusion assay on deprotected compounds (275) showed that they had moderate 
activity against S. Aureus, E. coli and S. Pombe with the most active compound having a MIC 
of 16 µg/ mL. Four of these compounds were chosen for screening against fifty one human 
kinases, of which two compounds showed moderate activity.  
The activity of the deprotected adducts (275) suggests that a free indolic NH is essential for 
the compounds to be active. We believe there are several possible reasons that the free NH 
is essential for activity. The free NH could be forming a hydrogen bonding interaction 
between the compound and the active site, which would greatly improve the overall binding 
interaction between the two. This would not be possible with a protecting group on the 
nitrogen.  
It is also possible that removing the large lipophilic protecting group leads to a decrease in 
the partition coefficient (log P) value of the compounds, bringing them more in line with 
Lipinski’s rule of five.106 The rule of five states that a compound with a high log P factor is 
more likely to suffer from poor absorption into biological systems, making it less likely to be 
a successful drug compound.   
The final possibility is that removal of the protecting group has a large effect on the 
electronics of the indole ring system which, in turn, has an effect on the mode of action of 
the compound. With no protecting group on the indolic nitrogen, the lone pair of electrons 
on the nitrogen can eliminate the hydroxylamine group from the Diels-Alder / ene 
compounds. This was observed when the deprotection reactions were carried out in 
methanol or ethanol, with the hydroxylamine group being substituted by a methoxy or 
ethoxy group in an SN1 reaction (Scheme 5.7).  
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Scheme 5.7 - Proposed SN1 mechanism by which compounds (233) and (234) are formed.  
We believe it is possible that unsaturated iminium compound (236) is the compound 
responsible for biological activity. As the double formed in the elimination is highly 
electrophilic, it could readily be attacked by a nucleophilic group at an active site. This 
would lead to formation of a covalent bond between the active site and compound (236), 
and therefore a strong binding interaction. If our proposed mode of action is correct, the 
ability of (256) to eliminate the hydroxylamine group and form unsaturated iminium 
compound (236) would be vital for the compound to be biologically active. A free NH group 
would allow the elimination of the hydroxylamine to occur rapidly, leading to the active 
unsaturated iminium (236).  
Future SAR studies on Diels-Alder / ene adducts of the type (256), could test the theory that 
the unsaturated iminium compound (236) is the active compound. If the elimination step is 
necessary for the molecules to become active, the addition of electron withdrawing groups 
(such as a nitro group) at the 5- and 7- position of the indole ring would severely hinder the 
elimination step (Figure 5.1). 
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Figure 5.1 - Resonance forms of 5- and 7- nitro substituted Diels-Alder / ene compounds. 
The lone pair of electrons on the nitrogen would be conjugated into the electron 
withdrawing nitro group on the indole ring. This would reduce the rate of elimination to 
form unsaturated iminium (236) and, if our proposed mode of action for this class of 
compounds is correct, the biological activity would drop. Conversely, the introduction of 
electron donating groups on to the indole ring should promote the elimination to 
unsaturated iminium (236) and thus increase the biological activity of the compounds. 
5.1 Future Work-  
All of the Diels-Alder / ene adducts we have tested for biological activity have been racemic. 
Synthesising the same compounds as single enantiomers could lead to a substantial increase 
in their activity. The binding sites in biological systems are often chiral and therefore a single 
enantiomer compound will show a significantly better binding affinity than a racemic 
mixture of compounds. 
Forming the single enantiomer compounds could be achieved using the same catalytic Diels-
Alder approach seen in Chapter 3, followed by removal of the protecting group (Scheme 
5.8).  
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Scheme 5.8 – Catalysed Diels-Alder / N-protection / ene / N-deprotection leading to single 
enantiomer compound (275). 
The reaction would have to be modified from the method used in Chapter 3, as previous 
work has shown that it is difficult to remove the tosyl protecting group from 
tetrahydrocarbazoles. That would mean having to use dibenzyl dicarbonate in the 
protection step, leading to the formation of Cbz protected tetrahydrocarbazoles (275).  
Catalyst (291) will generate one enantiomer of Diels-Alder adduct (274), however it is 
unknown which enantiomer is the most active. Therefore it may be necessary to synthesise 
both enantiomers of tetrahydrocarbazole (275) for comparison, and so the opposite 
enantiomer of catalyst (291) would need to be synthesised. This could be achieved using 
quinidine, the opposite enantiomer to quinine, as the starting material. 
Further future work could adapt our Diels-Alder / ene reaction process to try and synthesise 
compounds that more closely resemble (195)35, which is already known in the literature to 
show good biological activity (Figure 5.2).  
 
Figure 5.2 - Product from Diels-Alder / ene reaction (313) and known biologically active compound 
(195). 
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However, to synthesise molecules like (195) would require our compounds (313) to have an 
aromatic group rather than a hydroxylamine, aza or carbonyl group, on the non-aromatic six 
membered ring. We believe this could be achieved by adapting the bromination chemistry 
seen in Chapter 1. We developed a one-pot procedure whereby Diels-Alder adduct (148) 
underwent bromination to generate (181), followed by a substitution reaction with a 
nucleophile such as diethylamine. One of the problems we faced with this reaction was 
bromination product (181) rapidly decomposed via an elimination reaction to form 
compounds (183) and (184) (Scheme 5.9). This elimination occurs via the lone pair of 
electrons on nitrogen eliminating bromine which leads to the formation of an unsaturated 
iminium compound. This unsaturated iminium compound then rapidly decomposes to 
eliminated products (183) and (184). 
 
Scheme 5.9 - Products (183) and (184) formed as a result of an elimination reaction.  
We believe we could reduce the formation of eliminated products (183) and (184) in two 
ways. Firstly, the addition of electron withdrawing groups on the indole ring system would 
prevent the lone pair of electrons on the indolic nitrogen from eliminating bromine, as the 
electron density would be delocalised into the electron withdrawing group (Figure 5.1). A 
more electron withdrawing protecting group could also be used to achieve the same result 
(Figure 5.3).  
Alternatively, the addition of R’ groups to the carbon adjacent to the C-Br bond would 
prevent any elimination from occurring, as there would not be any hydrogens available for 
elimination (Figure 5.3).  
 
Figure 5.3 - Two possible methods for preventing the elimination reactions from occurring. 
These methods would make the brominated product more stable in solution and enable us 
to perform further chemistry on the compound. Starting from brominated product (181), 
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there are several reactions that would allow the synthesis of molecules such as (195) as well 
as further substituted compounds. 
The addition of a metal catalyst would lead to the formation of organometallic compound 
(315) (Scheme 5.10). Depending upon the metal used, a wide range of organometallic 
chemistry would then be available. For example, a zinc catalyst would allow a Barbier 
reaction to be performed; magnesium would lead to the formation of a Grignard reagent 
and a palladium catalyst would allow a Suzuki reaction to occur (Scheme 5.10).  
 
Scheme 5.10 - Reaction pathway for a Suzuki reaction and a Grignard / Barbier reaction. 
There are a large number of electrophiles that are commercially available, which means that 
the Grignard / Barbier reaction pathway could be a quick and simple method for the 
synthesis of a range of compounds such as (317).  
Due to the many commercially available boronic acids and the relative ease by which 
boronic acids can be synthesised, an sp2-sp3 Suzuki coupling could rapidly lead to the 
formation of a wide range of compounds. This would allow the insertion of a variety of 
molecules with the general structure (313) that show a great resemblance to compounds 
such as (195)35, which are known to have very good biological activity against B16 
melanoma cells.  
 
Figure 5.4 - Product from Suzuki reaction (313) and known biologically active compound (195).
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Chapter 6 – Experimental- 
6.1 General experimental information 
1H and 13C NMR spectra were recorded directly with a Jeol Lambda 500 MHz, Jeol ECS-400 
MHz or Bruker Avance 300 MHz. HRMS data were provided by the EPSRC National Mass 
Spectrometry Service (University of Swansea). X-ray diffraction data was obtained on an 
Oxford Diffraction Gemini. IR spectra were obtained as neat samples using a Varian 800 FT-
IR Scimitar Series spectrometer scanning from 4000-600 cm-1. Melting points were obtained 
using a Stuart SMP3 melting point machine. THF was distilled from sodium/benzophenone 
and used directly. DCM was distilled from calcium hydride and used directly.  
 
Kirby-Bauer Disk-Diffusion Assay 
A 10mg/mL solution in DMSO of each test compound was prepared, from which 10µL of 
each was added onto discs of filter paper (6 mm diameter). Agar plates prepared from a 1:1 
mixture of Nutrient Agar and LB, were inoculated with S. aureus or E.Coli., whilst YPD agar 
plates were inoculated with S. pombe. The disks containing test compounds were placed on 
the agar plates along with an appropriate positive control (nystatin, kanamycin or ampicillin) 
and the agar plates were incubated over night at 30 oC. Following this, the plates were 
photographed and zones of inhibition measured in mm. 
 
Minimum Inhibitory Concentration 
For determining the  minimum inhibitory concentrations (MIC), the tested compounds were 
examined via the micro dilution method using Mueller Hinton Broth 2 (Casein hydrolysate 
17.5g/L, Beef extract 3 g/L, Starch 1.5g/L, pH 7.3). Staphylococcus aureus and Escherichia 
coli NCTC 10418. The compounds were dissolved in DMSO. The final DMSO concentration in 
the cultures did not exceed 5%. Growth inhibition was evaluated after incubation for 18h at 
37oC in a FluoroStar optima plate reader, determining the optical density at 600 nm. 
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1-benzyl-3-vinyl-1H-indole – 137  
 
In a Schlenk flask, methyltriphenylphosphonium iodide (9.50 g, 23.4 mmol) was dissolved in 
dry THF (100 mL). The solution was cooled to -78 oC and nBuLi (8.5 mL, 21.2 mmol) was 
added over 15 minutes. The yellow solution was warmed to 0 oC and was left to stir for 1 
hour before being cooled to -78 oC. To the stirred solution, 1-benzyl-1H-indole-3-
carbaldehyde (5.00 g, 21.2 mmol) was added and the solution was stirred at room 
temperature for 3 hours.  The reaction was poured into water (80 mL) and extracted with 
ethyl acetate (3 x 60 mL). The combined organic layers were dried with MgSO4, filtered and 
the solvent removed under pressure to leave the crude product as yellow oil. The product 
was purified using column chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 3 
cm, silica = 15 cm) to give 1-benzyl-3-vinyl-1H-indole (4.36 g, 18.7 mmol, 88 %) as a yellow 
powder.  
MP:  77.1 – 78.9 oC; Rf: 0.94 (Pet:EA 2:1); 
1H NMR (300 MHz, CDCl3): δH 8.01 – 7.89 (1H, m), 
7.38 – 7.29 (4H, m), 7.28 – 7.21 (2H, m), 7.21 – 7.14 (2H, m), 6.93 (1H, dd, J = 17.8, 11.3 Hz, 
H3), 5.74 (1H, dd, J = 17.8, 1.5 Hz, H4-trans), 5.32 (2H, s, H11), 5.20 (1H, dd, J = 11.3, 1.5 Hz, 
H4-cis); 13C NMR (101 MHz, DMSO-d6): δC 138.4, 137.2, 130.2, 129.4, 129.1, 128.0, 127.6, 
126.4, 122.4, 120.5, 120.4, 114.2, 111.1, 110.2, 49.6; IR (cm-1): ν 3135 (CH), 2829 (CH); Anal. 
Calcd for C17H15N2: C, 87.52; H, 6.48; N, 6.00. Found: C, 87.39; H, 6.67; N, 5.95. 
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Synthesis of 3-vinyl-1H-indole – 140   
 
In a Schlenk flask, methyltriphenylphosphonium iodide (2.14g, 5.3 mmol) was dissolved in 
dry THF (13 mL). The solution was cooled to -78 oC and nbutyllithium (2.9 mL, 4.6mmol) was 
added over 10 minutes. The yellow solution was warmed to 0 oC and was left to stir for 1 
hour before being cooled to -78 oC. In a separate Schlenk flask, 1H-indole-3-carboxylate 
(0.67 g, 4.6 mmol) was dissolved in THF (7 mL) and to the solution sodium 
bis(trimethylsilyl)amide (2.3 mL, 4.6 mmol) was added. This solution was transferred into 
the first Schlenk flask and the red solution was allowed to stir at room temperature for 1 
hour. The reaction was poured into water (30 mL) and extracted with ethyl acetate (2 x 20 
mL). The combined organic layers were dried over MgSO4, filtered and the solvent removed 
under pressure to leave the crude product as yellow oil. The product was purified using 
column chromatography (Petrol: Diethyl ether 7: 3, column diameter = 4 cm, silica = 20 cm) 
to give 3-vinyl-1H-indole (0.636 g, 4.4 mmol, 95%) as a yellow powder.  
MP: 78.4-80.7 oC (literature – 80-81 oC); Rf = 0.76 (Pet:EA, 1:1); 1H NMR (300 MHz, CDCl3) δH 
8.02 (1H, br s, NH), 7.85 – 7.80 (1H, m), 7.32 – 7.28 (1H, m), 7.18 (1H, s, H1), 7.18 – 7.09 (2H, 
m), 6.83 (1H, ddd, J = 17.7, 11.2, 0.5 Hz, H3), 5.65 (1H, dd, J = 17.7, 1.5 Hz, H4-trans), 5.11 
(1H, dd, J = 11.2, 1.5 Hz, H4-cis); 13C NMR (400 MHz, CDCl3) δ 136.8 (C
10), 129.5, 125.7 (C5), 
123.6, 122.6, 120.4, 120.2 C9), 115.9 (C2), 111.4 (C6), 110.9 (C4); IR (cm-1): ν 3660 (NH), 2981 
(CH sp2). 
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1-tosyl-1H-indole-3-carbaldehyde – 144   
 
Into a Schlenk flask, was placed 1H-indole-3-carbaldehyde (5.0 g, 34.5 mmol) and DCM (100 
mL). The resulting stirred solution was cooled to 0 oC before triethylamine (12 mL, 86.2 
mmol) was added dropwise via syringe. To the stirred solution, p-toluenesulfonyl chloride 
(7.23 g, 37.9 mmol) in DCM was added dropwise over a period of 20 minutes. The solution 
was stirred at 0 oC for a further one hour before warming to room temperature over 18 
hours. The solution was washed into a separating funnel with DCM (20 mL) and washed with 
water (2 x 100 mL) and brine (100 mL). The organic extracts were dried over MgSO4, filtered 
and the solvent removed under reduced pressure to give the crude product as a pale orange 
oil. The product was purified by recrystallisation from hot ethyl acetate (150 mL) to give 1-
tosyl-1H-indole-3-carbaldehyde (8.38 g, 28 mmol, 82%) as orange crystals.  
MP: 145.3 – 148.8 oC; oC; Rf: 0.83 (EA:Petrol, 4:1); 
1H NMR (300 MHz, CDCl3) δH 10.11 (1H, s, 
H3), 8.29-8.26 (1H, m), 8.19 – 8.16 (1H, m), 8.16 (1H, s, H1), 7.89 – 7.85 (1H, m), 7.78 (2H, d, J 
= 8.4 Hz, H11), 7.36 – 7.25 (2H, m), 7.22 (2H, d, J = 8.4 Hz, H12), 2.29 (3H, s, H14); 13C NMR 
(400 MHz, CDCl3) δ 185.3 C3, 146.1, 136.2, 135.4, 134.1, 130.3, 130.2, 127.2, 127.1, 126.2, 
124.9, 122.5, 122.2, 113.1, 21.5 C14; IR (cm-1): ν 3140 (CH), 1663 (C=O); Anal. Calcd for 
C16H13NO3S: C, 64.20; H, 4.38; N, 4.68. Found: C, 63.97; H, 4.52; N, 4.72. 
.  
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tert-butyl 3-formyl-1H-indole-1-carboxylate – 145   
 
In a Schlenk flask, 1H-indole-3-carbaldehyde (4.0 g, 27.4 mmol) was dissolved in DCM (120 
mL). The stirred solution was cooled to 0 oC before triethylamine (5.8 mL, 41.1 mmol) was 
added dropwise via a syringe. To the solution, di-tert-butyl dicarbonate (6.92 mL, 30.14 
mmol) was added via syringe over 10 minutes. The solution was stirred at 0 oC for one hour 
before warming to room temperature for 18 hours. The solution was washed into a 
separating funnel with DCM (20 mL) and washed with water (2 x 100 mL) and brine (100 
mL). The organic extracts were dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the crude product as a white solid. The product was purified by 
recrysatllisation from refluxing ethyl acetate (120 mL) to give tert-butyl 3-formyl-1H-indole-
1-carboxylate (5.87 g, 21.9 mmol, 87%) as a white powder.  
MP: 126.2-129.0 oC; Rf: 0.75 (Pet:EA, 1:1); 
1H NMR (300 MHz, CDCl3) δH 10.04 (1H, s, H
3), 
8.24 – 8.21 (1H, m, H8), 8.17 (1H, s, H1), 8.13 (1H, d, J = 8.1 Hz, H5), 7.43 – 7.32 (2H, m, H6/7), 
1.64 (9H, s, H12); 13C NMR (400 MHz, CDCl3) δC 185.9 (C
3), 148.9 (C10), 136.6 (C1), 136.1 (C9), 
126.2 (C6), 126.2 (C2), 124.7 (C7), 122.2 (C8), 121.7 (C4), 115.2 (C5), 85.8 (C11), 28.2 (C12); IR: ν 
2980 (CH sp2), 2884 (CH sp3), 1740 (CO); Anal. Calcd for C14H15NO3: C, 68.56; H, 6.16; N, 5.71. 
Found: C, 68.56; H, 6.15; N, 5.87. 
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1-tosyl-3-vinyl-1H-indole – 146   
 
A Schlenk flask was charged with methyltriphenylphosphonium iodide (1.29 g, 3.2 mmol) 
dissolved in dry THF (25 mL) under a nitrogen atmosphere. The solution was cooled to -78 oC 
and nbutyllithium (1.81 mL, 2.97 mmol) was added dropwise via syringe over 10 minutes. 
The solution was warmed to 0 oC and left to stir for 2 hours. In a separate Schlenk flask, 1-
tosylindoline-3-carbaldehyde (0.8 g, 2.7 mmol) was dissolved in THF (5 mL). The indole 
solution was transferred via cannula to the Schlenk flask containing the solution of 
methyltriphenylphosphonium iodide and the solution was stirred for 18 hours. The reaction 
poured into water (50 mL) and extracted with ether (3 x 40 mL). The organic layers were 
washed with brine (20 mL), dried over MgSO4, filtered and the solvent was removed under 
reduced pressure to leave the crude product as an orange oil. The crude product was 
purified by column chromatography (Petrol: Ethyl acetate; 10: 1, 2 cm diameter column) to 
give 1-tosyl-3-vinyl-1H-indole (0.56 g, 3.9 mmol, 70%) as a pale yellow powder.  
MP: 90.3 – 94.6 oC; Rf: 0.86 (Pet:EA, 1:1); 
1H NMR (300 MHz, CDCl3) δH 7.93 – 7.90 (1H, m), 
7.69 (2H, d, J = 8.4 Hz, H12), 7.70-7.65 (1H, m), 7.53 (1H, s, H1), 7.29-7.19 (2H, m), 7.29 – 7.17 
(2H, m), 7.15 (2H, d, J = 8.4 Hz, H13), 6.70 (1H, app ddd, J =17.9, 11.3, 0.7 Hz), 5.72 (dd, 1H, J 
= 17.9, 1.2 Hz, H4-trans), 5.28 (1H, dd, J = 11.3, 1.2 Hz, H4-cis), 2.26 (3H, s, H15); 13C NMR (400 
MHz, CDCl3) δC 145.1, 135.6, 135.2, 130.0 (C
12), 129.1, 127.6, 126.9 (C13), 125.0, 124.2, 
123.6, 121.0, 120.5, 115.4, 113.8, 21.7 (C15); IR (cm-1): ν 3119 (CH-sp2), 3072 (CH-sp3); Anal. 
Calcd for C17H15NO2S: C, 68.66; H, 5.08; N, 4.71. Found: C, 68.70; H, 5.21; N, 4.61. 
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tert-butyl 3-vinyl-1H-indole-1-carboxylate – 147   
 
A Schlenk flask was charged with methyltriphenylphosphonium iodide (3.0 g, 7.43 mmol) 
and put under a nitrogen atmosphere before being dissolved in dry THF (25 mL). The 
solution was cooled to -78 oC and nbutyllithium (4.3 mL, 6.81 mmol) was slowly added 
dropwise via syringe over 10 minutes. The solution was warmed to 0 oC and left to stir for 2 
hours. In a separate Schlenk flask, tert-butyl 3-formyl-1H-indole-1-carboxylate (1.52 g, 6.19 
mmol) was dissolved in THF (15 mL). The indole solution was transferred, via cannula, to the 
flask containing the methyltriphenylphosphonium iodide solution and allowed to stir for 18 
hours. The reaction was quenched by pouring into water (50 mL) and extracted with ether 
(3 x 60 mL). The organic layers were washed with brine (30 mL), dried over MgSO4, filtered 
and the solvent was removed under reduced atmosphere to leave the crude product as a 
pale yellow oil. The crude product was purified by column chromatography (Petrol: Ethyl 
acetate, 10: 1, column diameter = 3 cm, silica = 20 cm) to give tert-butyl 3-vinyl-1H-indole-1-
carboxylate (0.195 g, 0.8 mmol, 13%) as a pale oil.  
MP: Oil at room temperature; Rf: 0.90 (Pet:EA, 1:1); 
1H NMR (300 MHz, CDCl3) δH 8.08 (1H, 
d, J = 8.1 Hz, H6), 7.72 – 7.68 (1H, m, H9), 7.53 (1H, s, H1), 7.28 – 7.15 (2H, m H7/8), 6.72 (1H, 
dd, J = 17.8, 11.3 Hz, H3), 5.72 (d, J = 17.8 Hz, H4-trans), 5.23 (1H, d, J = 11.3 Hz, H4-cis), 1.58 
(9H, s, H13); 13C NMR (400 MHz, CDCl3) δ 149.2 (CO), 136.0, 128.8, 128.3, 124.7, 124.1, 123.0, 
120.1, 119.3, 115.5, 114.5, 83.9 (C12), 28.3 (C13); IR (cm-1): ν 3119 (CH sp2), 2974 (CH sp3), 
1730 (CO); MS (pAPCI): 188.1 (100%, (M-tBu+H)+), 244.1 (93%, (M+H)+), 487.3 (4%, 
(2M+H)+); HRMS (pAPCI): calcd C15H18NO2 [M+H]
+: 244.1332; observed: 244.1334. 
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(3aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione – 148  
Method A: 
 
Into a round bottomed flask, 1-tosyl-3-vinyl-1H-indole (2.0 g, 6.7 mmol) and DCM (10 mL) 
was added. To the stirred solution, N-methylmalemide (0.75 g, 6.7 mmol) was added and 
the solution was stirred at 40 oC for 48 hours. The solvent was removed under reduced 
pressure to leave the crude product as orange oil. The product was purified by column 
chromatography (Petrol : Ethyl acetate, 4 : 1, column diameter = 4 cm, silica = 15 cm) to give 
(3aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione (2.01 g, 5.0 mmol, 76%) as a white powder. 
Method B: 
 
In a boiling tube, 3-vinyl-1H-indole (0.2 g, 1.4 mmol) and DCM (7 mL) was added. To the 
stirred solution, N-methylmaleimide (0.16 g, 1.4 mmol) was added and the sealed tube was 
heated at 70 oC for 3 hours. The solution was cooled to room temperature and triethylamine 
(0.48 mL, 3.5 mmol) and p- toluenesulfonic anhydride (0.64 g, 1.96 mmol) were added to 
the reaction. The reaction was stirred at room temperature for 2 hours before the solution 
was poured into water (20 mL) and extracted with DCM (2 x 10 mL). The combined organic 
layers were dried over MgSO4, filtered and the solvent removed under reduced pressure to 
leave the crude product as an orange oil. The product was purified by column 
chromatography (Petrol: Ethyl acetate, 4: 1, column diameter = 2 cm, silica = 15 cm) to give 
(3aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione (0.405 g, 0.99 mmol, 70%) as a white powder. 
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Method C: 
 
Into a Schlenk flask was added NMM (17 mg, 0.15 mmol), 1-(3,5-bis(trifluoromethyl)phenyl)-
3-((1R)-(6-methoxyquinolin-4-yl)((2R,4R,5S)-5-vinylquinuclidin-2-yl)methyl)thiourea (18 mg, 
20 mol%) and DCM (1 mL), The solution was cooled to -55 oC before a pre-cooled solution of 
3-vinyl-1H-indole (25 mg, 0.18 mmol) in DCM (0.5 mL) was added. The solution was stirred 
at -55 oC for 48 h before a solution of p-toluenesulfonic anhydride (245 mg, 0.75 mmol) in 
DCM (1.5 mL) was added. The solution was warmed to room temperature and stirred for 20 
hours. The solution was poured into NaHCO3 and extracted with DCM (3 x 5 mL). The 
combined organic extracts were dried over MgSO4, filtered and the solvent removed under 
reduced pressure to leave the crude product as an orange oil. The product was purified by 
column chromatography (Petrol: DCM: Et2O, 2: 1: 1, column diameter = 1 cm, silica = 14 cm) 
to give (3aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione (74%, 45 mg, 0.11 mmol) as a white solid.  
MP: 204.2 – 208.0 oC; Rf: 0.09 (Pet:EA, 1:1); 
1H NMR (300 MHz, CDCl3) δH 7.72 (2H, d, J = 8.0 
Hz, H15), 7.61 (1H, d, J = 8.5 Hz, H6), 7.21 – 7.19 (2H, d, J = 8.0, H16), 7.21-7.16 (1H, m), 6.92 
(1H, app t, J = 7.5 Hz), 6.01 – 5.96 (1H, m, H9), 4.47 (1H, dd, J = 7.0, 3.3 Hz, H8), 3.99 (1H, app 
t, J = 8.1 Hz, H10), 3.12 (1H, app t, J =8.1 Hz, H12), 2.99-2.92 (1H, m, H11), 2.76 (3H, s, H13), 
2.30 (3H, s, H18), 2.11 (1H, ddd, J = 18.0, 6.4, 2.4 Hz, H11); 13C NMR (400 MHz, CDCl3) δC 178.9 
C=O, 174.2 C=O, 144.7, 144.6, 137.4, 134.3, 130.4, 129.9, 127.5, 126.4, 123.9, 121.0, 115.4, 
112.9, 61.6 C8, 43.3 C10, 37.2 C12, 25.3 C11, 25.1 C13, 21.7 C18; IR (cm-1): ν 2981 (CH- sp2), 2889 
(CH-sp3), 1694 (CO); MS (pNSI): 409.2 (61%, (M+H)+), 426.1 (100%, (M+(NH4))
+), 834.3 (52%, 
(2M+(NH4))
+); HRMS (pNSI): calcd C22H21N2O4S [M+H]
+: 409.1217; observed: 409.1218. 
The ee of the product was determined by HPLC using an AD-H column (n-hexane/iPrOH 
80:20, flow rate 0.75 mL/min, tmaj = 35.1 min, tmin = 77.2 min, >95% ee). [α]D
25 = +180 (c = 
0.16 in CHCl3).            
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2-phenyl-11-tosyl-11,11a-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-
1,3(2H)-dione – 151  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol) 
and DCM (7 mL) and the solution was cooled to -78 oC. To the stirred solution was added 4-
phenyl-3H-1,2,4-triazole-3,5(4H)-dione (60 mg, 0.34 mmol) and the resulting solution was 
stirred at -78 oC for 3.5 hours before the solvent was removed under reduced pressure to 
leave the crude product as a pale red solid. The product was purified by column 
chromatography (Petrol : Ether: DCM 2: 1: 1, column diameter = 1 cm, silica = 20 cm) to give 
2-phenyl-11-tosyl-11,11a-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-
1,3(2H)-dione (88%, 140 mg, 0.30 mmol) as a pale red powder. 
Mp: 160.1 – 162.8 oC; Rf: 0.14 (Pet:Et2O:DCM 2:1:1); 
1H NMR (300 MHz, CDCl3): δH 7.86 (2H, 
d, J = 8.4 Hz), 7.63 – 7.55 (2H, m), 7.51 – 7.46 (2H, m), 7.46 – 7.42 (1H, m), 7.42 – 7.39 (1H, 
m), 7.38 – 7.34 (2H, m), 7.26 – 7.22 (2H, m), 7.09 (1H, app td, J = 7.5, 1.0 Hz).6.26 (1H, td, J = 
2.6, 1.8 Hz, H1), 6.18 (1H, app dt, J = 5.3, 2.7 Hz, H9),4.56 – 4.46 (1H, app td, J = 17.6, 2.8 Hz, 
H8), 4.39 (1H, ddd, J = 17.6, 5.2, 1.9 Hz, H8), 2.37 (3H, s, H21); 13C NMR (75 MHz, CDCl3): δC 
152.7 (CO), 150.8 (CO), 144.7, 143.7, 135.6, 134.8, 131.5, 130.4, 129.6, 128.9, 128.5, 128.1, 
126.8, 125.7, 125.2, 120.9, 117.4, 113.8, 74.8 (C1), 44.6 (C8), 21.4 (C21); IR (cm-1): ν 3070 (CH), 
2926 (CH), 1719 (CO); MS (pNSI): 473.1 (100%, (M+H)+), 522.2 (30%); HRMS (pNSI): calcd for 
C25H21N4O4S [M+H]
+: 473.1278; observed: 473.1277. 
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(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione and (3aS*,5S*,10bS*)-5-((R*)-
hydroxy(perfluorophenyl)methyl)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 165  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol) 
DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol) and the resulting 
solution was heated at reflux for 48 hours. The reaction was cooled to -78 oC and 2,3,4,5,6-
pentafluorobenzaldehyde (0.04 mL, 0.34 mmol) was added followed by DMAC (1M in 
hexane, 0.34 mL, 0.34 mmol). The reaction was stirred at -78 oC for 15 minutes before being 
allowed to warm to room temperature. The reaction was stirred at room temperature for 
18 hours. The reaction was poured into saturated sodium bicarbonate solution (10 mL) and 
extracted with DCM (2 x 10mL). The combined organic layers were dried with MgSO4, 
filtered and the solvent was removed under reduced pressure to give the crude product as a 
pale brown solid. The product was purified by column chromatography (Petrol : Ethyl 
acetate 3 : 1, column diameter = 2 cm, silica = 15 cm) to give a separable 5:1 mixture of 
(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione and (3aS*,5S*,10bS*)-5-((R*)-
hydroxy(perfluorophenyl)methyl)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (72 %, 149 mg, 0.25 mmol). 
Major Diastereomer: Mp: 120.4-121.7 oC; Rf: 0.24 (Pet:EA 3:1); 
1H NMR (300 MHz, CDCl3): δH 
δ 7.85 (3H, app d, J = 8.4 Hz), 7.31 – 7.22 (4H, m), 7.22 – 7.14 (1H, m), 5.13 (1H, d, J = 8.1Hz, 
H20), 4.99 (1H, d, J = 7.5 Hz, H10), 3.71 – 3.52 (2H, m, H13 + H11), 3.01 (3H, s, H19), 2.38 (3H, s, 
H33), 2.20 – 2.10 (1H, m, H12), 1.67 (1H, app td, J = 13.8, 5.3 Hz, H12); 13C NMR (400 MHz, 
CDCl3): δC 177.7 C=O, 173.3 C=O, 145.3, 137.4, 135.4, 129.8, 129.7, 129.6, 127.2, 125.3, 
123.9, 120.1, 119.9, 115.2, 70.2 C20, 41.5 C10, 39.1 C11, 36.9 C13, 28.7 C19, 25.2 C12, 21.7 C33; 
IR(neat): υmax/cm
-1 3371, 2981, 2889, 1690;MS (pNSI): 605.1 (40%, (M+H)+), 622.1 (88%, 
(M+NH4)
+), 627.1 (100%, (M+Na)+), 643.1 (17%), 709.1 (15%); HRMS (pNSI): calcd for 
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C29H21F5N2NaO5S [M+Na]
+: 627.0984; observed: 627.0968. Note: 13C NMR missing peaks due 
to C-F coupling.  
The ee of the product was determined by HPLC using an AD-H column (n-hexane/iPrOH 
80:20, flow rate 0.75 mL/min, tmaj = 16.4 min, tmin = 17.9 min, >95% ee). [α]D
25 = +56 (c = 0.60 
in CHCl3). 
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(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-10-tosyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 167  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol) and the resulting 
solution was heated at reflux for 48 hours. The reaction was cooled to 0 oC before PTAD (60 
mg, 0.34 mmol) was added. The reaction was stirred at 0 oC for 4 hours. The solvent was 
removed under reduced pressure to leave the crude product as a pale red powder. The 
product was purified by column chromatography (Petrol : Ethyl acetate 4 : 1, column 
diameter = 1 cm, silica = 14 cm) to give (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-
triazolidin-1-yl)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione (76%, 150 mg, 0.26 mmol) as a white powder. 
Mp: 183.4 – 187.7 oC; Rf: 0.05 (Pet:EA 1:1); 
1H NMR (400 MHz, CDCl3): δH 7.84 (2H, d, J =8.4 
Hz), 7.67 (1H, d, J = 8.2 Hz), 7.52 (1H, d, J = 7.6 Hz), 7.46-7.31 (5H, m), 7.29-7.19 (2H, m), 
7.17 (2H, d, J = 8.3 Hz), 5.55 (1H, app t, J = 4.7 Hz, H13), 5.08 (1H, d, J = 7.7 Hz, H10), 3.66 (1H, 
ddd, J = 10.5, 7.7, 5.8 Hz, H11), 2.96 (3H, s, H19), 2.49 (1H, app dt, J = 14.8, 5.3 Hz, H12), 2.28 
(3H, s, H38), 2.14 (1H, ddd, J = 14.8, 10.5, 5.5 Hz, H12); 13C NMR (400 MHz, CDCl3): δC 177.4 
C=O, 173.4 C=O, 153.6, 152.8, 145.5, 137.0, 135.3, 132.3, 130.8, 130.0, 129.3, 128.5, 127.5, 
126.9, 125.7, 125.6, 124.3, 119.4, 115.4, 114.9, 47.8 C13, 40.3 C10, 39.0 C11, 28.4 C19, 25.4 C12, 
21.7 C38; IR(neat): υmax/cm
-1 3665, 2984, 2884, 1699; MS (pNSI): 601.2 (100%, (M+NH4)
+), 
1184.3 (13%, (2M+NH4)
+); HRMS (pNSI): calcd for C30H29N6O6S [M+NH4]
+: 601.1864; 
observed: 601.1861. 
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(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 171  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol). The resulting solution 
was heated at reflux for 48 hours. The reaction was allowed to cool to room temperature, 
nitrosobenzene (40mg, 0.34 mmol) was added, and the solution was stirred at room 
temperature for 18 hours. The solvent was removed under reduced pressure to leave the 
crude product as a pale yellow solid which was purified by column chromatography (Petrol : 
Ethyl acetate 4 : 1, column diameter = 1 cm, silica = 16 cm) to give (3aS*,5S*,10bS*)-5-
(hydroxy(phenyl)amino)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione as a yellow powder (71%, 128 mg, 0.24 mmol). 
Mp: 196.8-199.5 oC; Rf: 0.64 (Pet:EA, 1:1); 
1H NMR (500 MHz, DCM-d2): δH 7.94 (1H, d, J = 
8.4 Hz), 7.69 (2H, d, J = 8.2 Hz), 7.60 (1H, d, J = 7.9 Hz), 7.32-7.25 (3H, m) , 7.23 (2H, d, J = 8.2 
Hz), 7.18-7.13 (3H, m), 7.02 (1H, t, J = 7.3 Hz), 5.06 (1H, d, J = 8.0 Hz, H10), 4.75 (1H, app. t, J 
= 5.9 Hz, H13), 4.72 (1H, s, OH), 3.64 (1H, app. q, J = 7.2 Hz, H11), 2.95 (3H, s, H19), 2.43 (1H, 
app dt, J = 13.6, 6.4 Hz, H12), 2.35 (3H, s, H33), 2.06 (1H, ddd, J = 13.6, 7.2, 4.9, H12); 13C NMR 
(400 MHz, DCM-d2): δC 178.1 C=O, 173.6 C=O, 150.7, 145.3, 137.5, 134.9, 131.4, 129.7, 
128.9, 128.9, 126.8, 125.2, 124.2, 122.6, 121.7, 120.2, 117.2, 115.4, 58.0 C13, 40.5 C10, 39.5 
C11, 25.0 C19, 23.3 C12, 21.4 C33; IR(neat): υmax/cm
-1 3661, 2990, 2886, 1690; MS (pNSI): 407.1 
(66%, (M-(C6H5NOH))
+), 516.2 (49%, (M+H)+), 533.2 (100%, (M+NH4)
+), 1031.3 (57%, 
(2M+H)+), 1053.3 (13%, (2M+Na)+); HRMS (pNSI): calcd for  C28H26N3O5S [M+H]
+: 516.1588; 
observed: 516.1584. 
Note: 1H NMR run at 35 oC, broad signals observed at room temperature. 
The ee of the product was determined by HPLC using an AD-H column (n-hexane/iPrOH 
80:20, flow rate 0.75 mL/min, tmaj = 23.4 min, tmin = 56.1 min, >95% ee). [α]D
25 = +42 (c = 0.50 
in CHCl3). 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 173 
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol). The resulting solution 
was heated at reflux for 48 hours. The reaction was allowed to cool to room temperature, 1-
methyl-2-nitrosobenzene (42 mg, 0.17 mmol) was added and the solution was stirred at 
room temperature for 18 hours. The solvent was removed under reduced pressure to leave 
the crude product as a pale yellow solid. The product was purified by column 
chromatography (Petrol : Ethyl acetate 4 : 1, column diameter = 1 cm, silica = 14 cm) to give 
(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (71%, 128 mg, 0.24 mmol) as a yellow 
powder. 
Mp: 193.0-196.7 oC; Rf: 0.59 (Pet:EA 1:1); 
1H NMR (400 MHz, DCM-d2): δH 7.89 (1H, d, J = 8.3 
Hz), 7.65 (2H, d, J = 8.4 Hz), 7.40 (1H, d, J = 7.9 Hz), 7.28 (1H, d, J = 7.7 Hz) 7.21-7.18 (3H, m), 
7.13-6.99 (4H, m), 5.04 (1H, d, J = 8.1 Hz, H10), 4.87 (1H, s, OH), 4.27 (1H, app. t, J = 5.4 Hz, 
H12), 3.73 (1H, app td, J = 8.0, 6.1 Hz, H11), 2.91 (3H, s), 2.58 (1H, app dt, J = 12.9, 6.2 Hz, H12), 
2.32 (3H, s, H28), 2.25 (3H, s, H36), 1.95 (1H, ddd, J = 12.9, 7.8, 4.5 Hz, H12); 13C NMR (400 
MHz, DCM-d2): δC 178.2 C=O, 173.6 C=O, 149.3, 145.3, 137.3, 134.9, 131.6, 130.9, 129.7, 
129.7, 129.2, 126.8, 126.2, 125.0, 124.9, 124.1, 121.4, 120.5, 115.3, 57.3 C13, 40.6 C10, 39.4 
C11, 25.0 C19, 24.6 C28, 21.4 C12, 18.3 C36; IR(neat): υmax/cm
-1 3662, 2990, 2886, 1701; MS 
(pNSI): 407.1 (98%, (M-((o-CH3)-C6H4NOH))
+), 530.2 (52%, (M+H)+), 547.2 (65%, (M+NH4)
+), 
1059.3 (100%, (2M+H)+); HRMS (pNSI): calcd for C29H28N3O5S [M+H]
+: 530.1744; observed: 
530.1743. 
The ee of the product was determined by HPLC using an AD-H column (n-hexane/iPrOH 
80:20, flow rate 0.75 mL/min, tmaj = 17.8 min, tmin = 22.8 min, >95% ee). [α]D
25 = +44 (c = 0.50 
in CHCl3). 
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6-(hydroxy(phenyl)amino)-2-phenyl-11-tosyl-5,6-dihydro-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione – 177  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol) 
and DCM (5 mL) and the solution was cooled to -78 oC. To this solution PTAD (70 mg, 0.34 
mmol) was added and the reaction was stirred at -78 oC for 3.5 hours. The reaction was 
warmed to room temperature, nitrosobenzene (44 mg, 0.34 mmol) was added and the 
reaction was stirred for 18 hours. The solvent was removed under reduced pressure to leave 
the crude product as a pale yellow oil. The product was purified by column chromatography 
(column diameter = 1 cm, silica = 16 cm, eluent = Petrol: Ether: DCM 2: 1: 1) to give 6-
(hydroxy(phenyl)amino)-2-phenyl-11-tosyl-5,6-dihydro-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione (72%, 54 mg, 0.09 mmol) 
as a white powder.  
Mp: 176.1 – 180.0 oC; Rf: 0.48 (Pet:Et2O 2:1); 
1H NMR (400 MHz, CDCl3): δH 8.03 (1H, d, J = 
8.3 Hz), 7.62 (2H, d, J = 8.1 Hz), 7.56 (2H, d, J = 7.6 Hz), 7.46 (2H, app t, J = 7.7 Hz), 7.42-7.36 
(1H, m), 7.23-7.07 (7 H, m), 7.05-6.99 (2H, m), 6.59 (1H, d, J = 7.4 Hz), 5.81 (1H, br s, OH), 
5.18 (1H, d, J = 13.5 Hz, H12), 4.59 (1H, s, H13), 3.23 (1H, d, J = 13.5 Hz, H12), 2.30 (3H, s, H36);  
13C NMR (101 MHz, DMSO-d6): δC 152.7 C=O, 152.2, 150.5 C=O, 146.0, 134.9, 132.9, 132.5, 
131.8, 130.4, 129.8, 129.3, 129.2, 128.5, 127.3, 127.3, 125.5, 125.4, 122.5, 119.8, 117.6, 
116.6, 108.6, 55.9 C13, 44.6 C12, 21.6 C36; IR(neat): υmax/cm
-1 2981, 2884, 1714; MS (pAPCI): 
138.1 (100%), 157.0 (95%), 213.1 (50%), 248.1 (86%), 279.1 (62%), 317.1 (33%), 333.1 (29%), 
471.1 (31%), 564.2 (11%), 580.2 (10%, (M+H)+); HRMS (pAPCI): calcd for C31H26N5O5S 
[M+H]+: 580.1649; observed: 580.1640. 
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6-(hydroxy(o-tolyl)amino)-2-phenyl-11-tosyl-5,6-dihydro-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione – 178  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol) 
and DCM (5 mL) and the solution cooled to -78 oC. To this solution PTAD (70 mg, 0.34 mmol) 
was added and the reaction was stirred at -78 oC for 3.5 hours. The reaction was warmed to 
room temperature and 1-methyl-2-nitrosobenzene (42 mg, 0.34 mmol) was added and the 
reaction was stirred for 18 hours. The solvent was removed under reduced pressure to leave 
the crude product as a pale yellow oil. The product was purified by column chromatography 
(column diameter = 1 cm, silica = 14 cm, eluent = Petrol: Ether: DCM 2: 1: 1) to give 6-
(hydroxy(o-tolyl)amino)-2-phenyl-11-tosyl-5,6-dihydro-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione as a white powder (78%, 
60 mg, 0.10 mmol). 
Mp: 149.7 – 153.1 oC; Rf:  0.32 (Pet:Et2O:DCM 2:1:1); 
1H NMR (300 MHz, CDCl3): δH 7.99 (d, 
1H, J = 8.3 Hz), 7.61-7.58 (m, 5H), 7.43-7.40 (m, 1H), 7.47 (2H, app t, J = 7.7 Hz), 7.40-7.37 
(m, 1H), 7.18 (2H, app t, J = 7.8 Hz), 7.11 (d, 2H, J = 8.2 Hz), 6.97 (2H, app q, J = 7.2 Hz), 6.85 
(d, 1H, J =7.5 Hz), 6.50 (d, 1H, J = 7.8 Hz), 5.93 (s, 1H, OH), 5.24 (d, 1H, J = 13.5 Hz, H12), 4.44 
(s, 1H, H13), 3.11 (d, 1H, J = 13.5 Hz, H12), 2.29 (s, 3H, H27), 1.91 (s, 3H, H39); 13C NMR (101 
MHz, CDCl3): δC 153.3 C=O, 150.3 C=O, 148.7, 145.4, 135.1, 133.7, 132.0, 131.7, 131.3, 
130.6, 129.6, 129.3, 128.7, 127.9, 127.2, 127.0, 126.8, 125.9, 124.9, 124.8, 122.6, 118.0, 
116.8, 107.0, 59.1 C13, 44.5 C12, 21.7 C27, 17.8 C39; IR(neat): υmax/cm
-1 3068, 2981, 1713; MS 
(pAPCI): 138.1 (100%), 157.0 (82%), 262.1 (55%), 279.1 (76%), 317.1 (50%), 391.3 (37%), 
471.1 (21%), 594.2 (10%, (M+H)+); HRMS (pAPCI): calcd for C32H28N5O5S [M+H]
+: 594.1806; 
observed: 594.1801. 
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(3aS*,5S*,10bS*)-5-(diethylamino)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 188  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (60 mg, 0.20 mmol), 
DCM (3 mL) and 1-methyl-1H-pyrrole-2,5-dione (22 mg, 0.20 mmol) was added and the 
resulting solution was heated at reflux for 48 hours. The reaction was cooled to 0 oC and N-
bromosuccinimide (36 mg, 0.20 mmol) was added. The reaction was stirred at 0 oC for 45 
minutes before diethylamine (50 µL, 0.40 mmol) was added and the reaction was stirred at 
0 oC for 45 minutes before the solvent was removed under reduced pressure to leave the 
crude product as a pale yellow solid. The product was purified by column chromatography 
(Petrol: Ether: DCM 2: 1: 1, column diameter = 1.5 cm, silica = 17 cm) to give 
(3aS*,5S*,10bS*)-5-(diethylamino)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (75 mg, 0.16 mmol, 78%) as a yellow powder. 
Mp: 168.8 – 171.5 oC; Rf: 0.37 (Pet:Et2O:DCM 2:1:1); 
1H NMR (400 MHz, CDCl3): δH 7.99 (1H, 
d, J = 7.7 Hz), 7.92 (1H, d, J = 8.3 Hz), 7.58 (2H, d, J = 8.2 Hz, H18), 7.24 (1H, t, J = 7.7 Hz), 7.15 
(1H, t, J = 7.6 Hz), 7.11 (2H, d, J = 8.2 Hz, H19), 5.02 – 4.98 (1H, m, H2), 3.99 – 3.93 (1H, m, H8), 
3.50 (1H, app dt, J = 8.2, 5.1 Hz, H6), 2.93 (3H, s, H21), 2.45 – 2.31 (3H, m), 2.29 (3H, s, H4), 
1.88 – 1.80 (1H, m, H7), 0.94 (3H, t, J = 7.1 Hz, H10); 13C NMR (101 MHz, CDCl3): δC 178.4 (CO), 
173.9 (CO), 144.7, 138.4, 134.6, 130.1, 129.9, 129.4 (C18), 126.9, 126.8 (C19), 125.2, 123.8, 
122.3, 116.0, 51.5, 43.4 (C9), 40.4, 39.4, 25.3, 21.6, 21.2, 14.1 (C10); IR (cm-1): ν 2919 (CH), 
2850 (CH), 1703 (CO); MS (pAPCI): 407.1 (100%, (M-(N(Et2))
+), 480.2 (63%, (M+H)+), 959.4 
(21%, (2M+H)+); HRMS (pAPCI): calcd for C26H30N3O4S [M+H]
+: 480.1952; observed: 
480.1946. 
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6-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-phenyl-11-tosyl-5,6-dihydro-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione - 193 
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol) 
and DCM (5 mL).he resulting solution was cooled to -78 oC and then PTAD (70 mg, 0.34 
mmol) was added. The reaction was stirred at -78 oC for 3.5 hours. The reaction was 
warmed to 0 oC and a further equivalent of PTAD (60 mg, 0.34 mmol) was added.The 
reaction was stirred 0 oC for 4 hours, resulting in the formation of a white precipitate. The 
reaction mixture was filtered and 6-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-phenyl-11-
tosyl-5,6-dihydro-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione (29%, 
61 mg, 0.094 mmol) was recovered as a white powder. 
Mp: 227.8-230.6 oC; 1H NMR (400 MHz, DMSO-d6): δH 10.76 (s, 1H, NH), 7.91 (d, 1H, J = 7.8 
Hz), 7.61 (d, 2H, J = 8.3 Hz), 7.48-7.24 (m, 15H), 5.52 (s, 1H, H19), 4.76 (d, 1H, J = 13.8 Hz, 
H12), 3.86 (d, 1H, J = 13.8 Hz, H12), 2.24 (s, 3H, H42); 13C NMR (101 MHz, DMSO-d6) δC 154.3, 
153.5, 150.6, 149.5, 146.0, 135.1, 133.3, 133.0, 131.7, 131.5, 130.4, 129.6, 129.5, 129.4, 
128.8, 128.1, 127.6, 127.5, 126.9, 125.9, 125.4, 119.3, 116.8, 104.1, 48.8 C13, 43.3 C12, 21.6 
C42; IR(neat): υmax/cm
-1 2971, 2883, 1714; MS (pNSI): 263.0 (36%), 345.0 (51%), 371.1 (42%), 
665.2 (89%, (M+NH4)
+), 670.1 (100%, (M+Na)+); HRMS (pNSI): calcd for C33H25N7NaO6S 
[M+Na]+: 670.1479; observed: 670.1475. 
Note – No Rf data due to poor solubility in DCM.  
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(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 199  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol) and the resulting solution was 
heated at reflux for 48 hours. The reaction was cooled to room temperature and 
nitrosobenzene (36 mg, 0.34 mmol) was added. The reaction was stirred at room 
temperature for 4 hours before the solvent was removed under reduced pressure to leave 
the crude product as a white solid. The product was purified by tritriation from DCM to give 
(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione as a white powder (151 mg, 0.30 mmol) in a 89% yield.  
Mp: 203.7-206.9 oC; Rf: 0.15 (Pet:EA 2:1);
 1H NMR (300 MHz, DMSO-d6): δH 11.26 (1H, s), 
8.45 (1H, s), 7.88 (1H, d, J = 8.3 Hz). 7.76 (2H, d, J = 8.2 Hz), 7.42 (1H, d, J = 7.8 Hz), 7.33 (2H, 
d, J = 8.2 Hz), 7.29-7.04 (5H, m), 6.89 (1H, t, J = 7.2 Hz), 5.17 (1H, d, J = 7.8 Hz, H10), 4.88 (1H, 
app t, J = 4.4 Hz, H13), 3.65 (1H, app td, J = 8.8, 5.9 Hz, H11), 2.32 (3H, s, H32), 2.36-2.27 (1H, 
m, H12), 1.81 (1H, ddd, J = 14.0, 9.4, 5.0 Hz, H12); 13C NMR (400 MHz, DMSO-d6): δC 179.4 
C=O, 174.7 C=O, 152.0, 144.7, 136.4, 135.0, 131.5, 129.8, 128.9, 128.4, 126.6, 124.4, 123.4, 
121.2, 120.7, 120.6, 117.0, 114.4, 56.8 C13, 41.5 C10, 40.6 C11, 25.2 C12, 20.9 C32; IR(neat): 
υmax/cm
-1 3452, 2981, 1715; MS (pNSI): 393.1 (100%, (M-(C6H5NOH)
+), 502.1 (14%, (M+H)+), 
519.2 (96%, (M+NH4)
+), 524.1 (17%, (M+Na)+), 1003.3 (40%, (2M+H)+), 1025.3 (15%, 
(2M+Na)+); HRMS (pNSI): calcd for C27H24N3O5S [M+H]
+: 502.1431; observed: 502.1428. 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 200  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol) was added and the resulting 
solution was heated at reflux for 48 hours. The reaction was cooled to room temperature 
and 1-methyl-2-nitrosobenzene (41 mg, 0.34 mmol) was added. The reaction was stirred at 
room temperature for 4 hours before the solvent was removed under reduced pressure to 
leave the crude product as a pale yellow solid. The product was purified by column 
chromatography (Petrol : Ether: DCM 2 : 1 : 1, column diameter = 2 cm, silica = 14 cm) to 
give (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (82%, 143 mg, 0.28 mmol) as a yellow powder. 
Mp: 171.1-174.0 oC; Rf: 0.13 (Pet:EA 2:1); 
1H NMR (400 MHz, CDCl3): δ 7.90 (1H, d, J = 8.4 
Hz), 7.73 (2H, d, J = 8.2 Hz), 7.77 (1H, s), 7.35 (2H, dd, J = 15.7, 7.9 Hz), 7.20 (3H, app d, J = 
8.2 Hz), 7.09 (2H, d, J = 7.5 Hz), 7.07 – 7.00 (2H, m), 5.17 (1H, d, J = 8.1 Hz, H10), 4.75 (1H, s, 
OH), 4.39 (1H, app t, J = 5.1 Hz, H13), 3.80 (1H, app q, J = 8.3, 5.7 Hz, H11), 2.64 (1H, app dt, J 
= 13.1, 5.5 Hz, H12), 2.34 (3H, s, H32), 2.26 (3H, s, H27), 1.96 (1H, ddd, J = 15.9, 7.9, 3.7 Hz, 
H12); 13C NMR (75 MHz, CDCl3): δC 178.3 C=O, 173.4 C=O, 149.3, 144.7, 137.4, 135.8, 131.3, 
130.9, 129.8, 129.6, 129.5, 129.0, 127.0, 126.3, 125.1, 124.7, 123.7, 121.5, 120.1, 115.3, 57.3 
C13, 42.0 C10, 40.8 C11, 26.0 C12, 21.4 C32, 18.3 C27; IR(neat): υmax/cm
-1 3294, 2981, 1713; MS 
(pAPCI): 293.1 (16%), 332.1 (13%), 342.1 (16%), 393.1 (100%, (M-(o-(CH3)C6H4NOH)
+), 489.1 
(54%, (M-H2O)
+), 516.2 (26%, (M+H)+); HRMS (pAPCI): calcd for C28H26N3O5S [M+H]
+: 
516.1588; observed: 516.1576. 
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(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 201  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The resulting solution was 
heated at reflux for 48 hours. The reaction was cooled to 0 oC and pentafluorobenzaldehyde 
(67 mg, 0.34 mmol) and DMAC (1M in hexane, 0.34 mL, 0.34 mmol) were added. The 
solution was stirred at 0 oC for 1 hour and then warmed to room temperature for 18 hours. 
The reaction was poured into sodium bicarbonate (15 mL) and extracted with DCM. The 
combined organic layers were dried with MgSO4, filtered and the solvent was removed 
under reduced pressure to give the crude product as an off white solid. The product was 
purified by column chromatography (diameter = 1.5 cm, silica = 15 cm, eluent = Pet: EA 2: 1) 
to give (3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (71 %, 0.1427 g, 0.24 mmol) as an off 
white solid.  
Mp: 181.3-185.1 oC; Rf: 0.22 (Pet:EA 2:1); 
1H NMR (400 MHz, CDCl3): δH 8.03 (1H, br, NH), 
7.81 (3H, app d, J = 7.9 Hz), 7.28 (1H, d, J = 8.0 Hz), 7.25 – 7.22 (3 H, m), 7.16 (1H, app t, J = 
7.6 Hz), 5.08 (1H, d, J = 8.3 Hz, H19), 5.05 (1H, d, J = 7.4 Hz, H10), 3.61 – 3.66 (1H, m, H13), 3.49 
– 3.57 (1H, m, H11), 2.34 (3H, s, H32), 2.09 (1H, dd, J = 14.0, 4.5 Hz, H12), 1.74 (1H, app td, J = 
13.9, 5.3 Hz, H12); 13C NMR (101 MHz, CDCl3): δC 177.4 C=O, 173.0 C=O, 145.3, 137.4, 135.5, 
129.8, 129.7, 129.1, 127.1, 125.5, 123.9, 120.2, 120.0, 115.3, 70.2 C19, 42.5 C10, 40.3 C11, 
36.8 C13, 28.5 C12, 21.7 C32; IR(neat): υmax/cm
-1 3240, 2981, 1717; MS (pAPCI): 157.0 (79%), 
221.1 (61%), 393.1 (15%, (M-(C6F5COH)
+), 443.1 (51%), 573.1 (8%, (M-H2O)
+), 591.1 (100%, 
(M+H)+); HRMS (pAPCI): calcd for C28H20F5N2O5S [M+H]
+: 591.1008; observed: 591.1001. 
Note: 13C NMR missing peaks due to C-F coupling. 
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(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 202  
 
To a stirred round bottomed flask was added 1-tosyl-3-vinyl-1H-indole (100 mg, 0.34 mmol), 
DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The resulting solution was 
heated at reflux for 48 hours. The reaction was cooled to 0 oC and PTAD was added. The 
solution was stirred at 0 oC for 4 hours and the solvent was removed under reduced 
pressure to give the crude product as pale red. The product was purified by column 
chromatography (diameter = 1.5 cm, silica = 17 cm, eluent = Pet: EA 1: 1) to give 
(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (23 %, 0.044 g, 0.08 mmol) as an off 
white solid. 
Mp: 206.4-209.7 oC; Rf = 0.10 (Pet:EA 2:1); 
1H NMR (400 MHz, DMSO-d6): δC 11.37 (1H, s, 
NH), 10.77 (1H, s, NH), 7.82 (2H, d, J = 8.3 Hz), 7.72 (1H, d, J = 7.9 Hz), 7.48 – 7.43 (2H, m), 
7.42 – 7.35 (4H, m), 7.28 (2H, d, J = 8.5 Hz), 7.25 – 7.18 (2H, m), 5.46 (1H, app t, J = 4.9 Hz, 
H13), 5.19 (1H, d, J = 7.7 Hz, H10), 3.77 – 3.65 (1H, m, H11), 2.41 (1H, app dt, J = 9.8, 5.1 Hz, 
H12), 2.26 (3H, s, H37), 2.24 – 2.16 (1H, m, H12); 13C NMR (101 MHz, CDCl3): δH 178.8 C=O, 
173.6 C=O, 153.6, 152.4, 145.4, 136.9, 135.3, 132.2, 130.9, 129.9, 129.2, 128.4, 127.5, 126.9, 
125.7, 125.6, 124.2, 119.3, 115.1, 114.8, 47.3 C13, 41.5 C10, 40.2 C11, 28.8 C12, 21.7 C37; 
IR(neat): υmax/cm
-1 3194, 2981, 2980, 1699; MS (pNSI): 587.2 (100% (M+NH4)
+), 592.1 (30% 
(M+Na)+); HRMS (pNSI): calcd for C29H27N6O6S [M+NH4]
+: 587.1707; observed: 587.1706. 
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5-methoxy-1-tosyl-1H-indole-3-carbaldehyde – 205  
 
To a stirred round bottomed flask was added 5-methoxy-1H-indole-3-carbaldehyde (0.70 g, 
4.00 mmol) and DCM (20 mL) and the solution was cooled to 0 oC. To the stirred solution 
was added triethylamine (1.40 mL, 10.0 mmol) and the resulting solution was stirred at 0 oC 
for 1 hour. To the stirred solution was added p-toluenesulfonyl chloride (0.84 g, 4.40 mmol) 
in DCM (10 mL) and the solution was stirred at room temperature for 18 hours. The reaction 
was poured into water (50 mL) and extracted with DCM (3 x 20 mL). The combined organic 
extracts were dried over MgSO4, filtered and the solvent was removed under reduced 
pressure to leave the crude product as a pale orange solid. The product was purified using 
column chromatography (Petrol: Ether: DCM 2: 1: 1, column diameter = 2 cm, silica = 15 cm) 
to give 5-methoxy-1-tosyl-1H-indole-3-carbaldehyde (1.14 g, 3.48 mmol, 87 %) as a pale 
brown powder. 
Mp: 126.1 – 128.4 oC; Rf: 0.71 (Pet:Et2O:DCM 2:1:1); 
1H NMR (300 MHz, CDCl3): δH 10.07 (1H, 
s, H3), 8.19 (1H, s, H1), 7.86 – 7.83 (1H, m, H8), 7.84 (2H, d, J = 8.5 Hz, H11), 7.72 (1H, d, J = 2.6 
Hz, H5), 7.29 (2H, d, J = 8.5 Hz, H12), 7.02 (1H, dd, J = 9.1, 2.6 Hz, H7), 3.86 (3H, s, H16), 2.38 
(3H, s, H14); 13C NMR (101 MHz, CDCl3): δC 185.6 (C
3), 157.8 (C6), 146.2, 136.8, 134.4, 130.4, 
129.8, 127.4, 127.2, 122.3, 116.2, 114.2, 104.1, 55.8 (C16), 21.8 (C14); IR (cm-1): ν 3128 (CH), 
2832 (CH), 1671 (CO); Anal. Calcd for C17H15NO4S: C, 61.99; H, 4.59; N, 4.25. Found: C, 61.77; 
H, 4.70; N, 4.29. 
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5-methoxy-1-tosyl-3-vinyl-1H-indole – 206  
 
In a Schlenk flask, methyltriphenylphosphonium iodide (1.35 g, 3.34 mmol) was dissolved in 
dry THF (30 mL). The solution was cooled to -78 oC and nBuLi (1.2 mL, 3.03 mmol) was added 
over 5 minutes. The yellow solution was warmed to 0 oC and was allowed to stir for 1 hour 
before being cooled to -78 oC. To the stirred solution, 5-methoxy-1-tosyl-1H-indole-3-
carbaldehyde (1.00 g, 3.03 mmol) in DCM (10 mL) was added and the solution was stirred at 
room temperature for 3 hours.  The reaction was poured into water (40 mL) and extracted 
with ethyl acetate (3 x 20 mL). The combined organic layers were dried over MgSO4, filtered 
and the solvent removed under pressure to leave the crude product an orange oil. The 
product was purified using column chromatography (Petrol: Ethyl acetate 2: 1, column 
diameter = 2 cm, silica = 16 cm) to give 5-methoxy-1-tosyl-3-vinyl-1H-indole (0.79 g, 2.42 
mmol, 80 %) as a brown powder.  
Mp: 101.4 – 103.9 oC; Rf: 0.66 (Pet:EA 2:1); 
1H NMR (300 MHz, CDCl3): δH 7.87 (1H, d, J = 9.0 
Hz, H10), 7.73 (2H, d, J = 8.4 Hz, H13), 7.55 (1H, s, H1), 7.19 (2H, d, J = 8.3 Hz, H14), 7.14 (1H, d, 
J = 2.5 Hz, H6), 6.93 (1H, dd, J = 9.0, 2.5 Hz, H9), 6.72 (1H, dd, J = 17.9, 11.3 Hz, H3), 5.73 (1H, 
dd, J = 17.9, 1.1 Hz, H4-trans), 5.32 (dd, J = 11.3, 1.1 Hz, H4-trans), 3.82 (3H, s, H8), 2.31 (3H, 
s, H16); 13C NMR (101 MHz, CDCl3): δC 156.7 (C
7), 145.0, 135.1, 130.3, 130.1, 130.0, 127.6, 
126.9, 124.9, 121.1, 115.2, 114.7, 113.7, 103.2, 55.8 (C8), 21.7 (C16); IR (cm-1): ν 3128 (CH), 
2832 (CH), 1671 (CO); MS (pNSI): 328.1 (100%, (M+H)+), 350.1 (15%, (M+Na)+), 672.2 
(2M+NH4)
+); HRMS (pNSI): calcd for C18H18NO3S [M+H]
+: 328.1002; observed: 328.1007. 
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(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-7-methoxy-2-methyl-10-tosyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione and (3aS*,5S*,10bS*)-5-
((R*)-hydroxy(perfluorophenyl)methyl)-7-methoxy-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 208  
 
To a stirred round bottomed flask was added 5-methoxy-1-tosyl-3-vinyl-1H-indole (112 mg, 
0.34 mmol), DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol). The 
reaction was heated at reflux for 48 hours. The reaction was cooled to -78 oC and 
pentafluorobenzaldehyde (0.04 mL, 0.34 mmol) and DMAC (1M in hexane, 0.34 mL, 0.34 
mmol) were added. The solution was stirred at -78 oC for 15 minutes and then at room 
temperature for 18 hours. The solvent was removed under reduced pressure to give the 
crude product as an off white solid. The product was purified by column chromatography 
(column diameter = 2 cm, silica = 15 cm, eluent = Petrol: Ethyl acetate 3: 1) to give a 8:1 
mixture of (3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-7-methoxy-2-methyl-
10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione and 
(3aS*,5S*,10bS*)-5-((R*)-hydroxy(perfluorophenyl)methyl)-7-methoxy-2-methyl-10-tosyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (70%, 0.151 mg) as a white 
powder. 
Major Diastereomer:  Mp: 136.7-139.0 oC; Rf: 0.40 (Pet:EA 2:1); 
1H NMR (400 MHz, CDCl3): δH 
7.76 (2H, d, J = 8.3 Hz), 7.69 (1H, d, J = 9.1 Hz), 7.22 (2H, d, J = 8.3 Hz), 6.83 (1H, dd, J = 9.1, 
2.5 Hz), 6.72 (1H, d, J = 2.5 Hz), 5.08 (1H, d, J = 8.3 Hz, H23), 4.87 (1H, d, J = 7.4 Hz, H10), 3.71 
(3H, s, H20), 3.58 – 3.47 (2H, m, H23 + H11), 2.94 (3H, s, H28), 2.34 (3H, s, H36), 2.11 – 2.04 (1H, 
m, H12), 1.60 (1H, app td, J = 13.9, 5.3 Hz, H12); 13C NMR (101 MHz, CDCl3): δC 177.7 C=O, 
173.2 C=O, 156.8, 145.2, 135.2, 132.0, 130.9, 130.3, 129.8, 127.0, 120.6, 116.2, 114.0, 102.6, 
70.2 C21, 55.6 C20, 41.5 C10, 39.0 C11, 36.9 C13, 28.6 C12, 25.3 C28, 21.7 C36; IR(neat): υmax/cm
-1 
2981, 2884, 1709; ; MS (pAPCI): 157.0 (80%), 221.1 (92%), 281.1 (49%) 475.1 (94%), 635.1 
(100%, (M+H)+); HRMS (pAPCI): calcd for C30H24F5N2O6S [M+H]
+: 635.1270; observed: 
635.1266.  
Note: 13C NMR missing peaks due to C-F coupling. 
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(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-7-methoxy-10-tosyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 209  
 
To a stirred round bottomed flask was added 5-methoxy-1-tosyl-3-vinyl-1H-indole (112 mg, 
0.34 mmol), DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The reaction was 
heated at reflux for 48 hours. The reaction was cooled to 0 oC and PTAD (60 mg, 0.34 mmol) 
was added. The reaction was stirred at 0 oC for 4 hours before the solvent was removed 
under reduced pressure to give the crude product as a pale red solid. The product was 
purified by column chromatography (column diameter = 2 cm, silica = 16 cm, eluent = Pet: 
EA 1: 1) to give (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-7-methoxy-10-
tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (75%, 0.152 mg, 0.25 
mmol) as a pale yellow powder. 
Mp: 189.9-193.3 oC; Rf: 0.07 (Pet:EA 1:1);
 1H NMR (400 MHz, CDCl3): δH 9.31 (1H, br s, NH), 
8.60 (1H, br s, NH), 7.67 (2H, d, J = 7.5 Hz), 7.55 (1H, d, J = 8.8 Hz), 7.38-7.23 (5H, m), 7.00 
(2H, d, J = 7.8 Hz), 6.90 (1H, s), 6.80 (1H, d, J = 8.9 Hz), 5.53 (1H, br s, H13), 5.18 (1H, d, J = 6.7 
Hz, H10), 3.74-3.69 (1H, m, H11), 3.64 (3H, s, H39), 2.48-2.55 (1H, m, H12), 2.17 (3H, s, H37), 
2.12-2.02 (1H, m, H12); 13C NMR (101 MHz, CDCl3): δC 179.0 C=O, 173.9 C=O, 156.9, 153.7, 
152.7, 145.2, 135.1, 132.7, 131.5, 131.0, 129.8, 129.2, 128.4, 128.0, 127.2, 125.6, 115.9, 
115.5, 114.3, 101.9, 55.7 C39, 47.6 C13, 41.6 C10, 40.1 C11, 28.8 C12, 21.6 C37; IR(neat): 
υmax/cm
-1 2972, 2885, 1781, 1709; MS (pNSI): 617.2 (69%, (M+NH4)
+), 622.1 (100%, 
(M+Na)+), 644.1 (48%); HRMS (pNSI): calcd for C30H29N6O7S [M+NH4]
+: 617.1813; observed: 
617.1817. 
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3-Formyl-N,N-dimethyl-1H-indole-1-sulfonamide – 211  
 
To a stirred round bottomed flask was added 1H-indole-3-carbaldehyde (3.0 g, 20.7 mmol) 
and THF (70 mL) and the solution was cooled to 0 oC. To the stirred solution was added 
sodium hydride (1.7 g, 41.4 mmol) in THF (30 mL) and the resulting solution was stirred at 0 
oC for 1 hour. To the stirred solution was added dimethylsulfamoyl chloride (2.4 mL, 20.7 
mmol) and the solution was stirred at room temperature for 18 hours. The reaction was 
poured into water (100 mL) and extracted with DCM (3 x 60 mL). The combined organic 
extracts were dried over MgSO4, filtered and the solvent was removed under reduced 
pressure to leave the crude product as a pale red pink solid. The product was purified by 
recrystallization from ethyl acetate to give 3-formyl-N,N-dimethyl-1H-indole-1-sulfonamide 
(97%, 5.07 g, 20.1 mmol) as a pink powder. 
Mp:  149.0 – 150.9 oC; Rf: 0.63 (Pet:EA, 1:1); 
1H NMR (300 MHz, CDCl3): δH 10.08 (1H, s, H
3), 
8.31 (1H, app dd, J = 7.2, 1.4 Hz, H5), 8.09 (1H, s, H1), 7.94 – 7.88 (1H, m), 7.40 (2H, app ddd, 
J = 5.9, 3.3, 1.6 Hz, H6/7), 2.91 (6H, s, H10); 13C NMR (101 MHz, CDCl3): δC 185.5 (C
3), 137.3, 
136.0 (C9), 126.1, 125.9 (C4), 124.9, 122.6, 120.8 (C2), 113.6, 38.6 (C10); IR (cm-1): ν 3124 (CH), 
2945 (CH), 1662 (CO); Anal. Calcd for C11H12N2O3S: C, 52.37; H, 4.79; N, 11.10. Found: C, 
52.23; H, 4.91; N, 10.92. 
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N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide – 212  
 
In a Schlenk flask, methyltriphenylphosphonium iodide (7.00 g, 17.4 mmol) was dissolved in 
dry THF (75 mL). The solution was cooled to -78 oC and nBuLi (6.4 mL, 15.9 mmol) was added 
over 10 minutes. The yellow solution was warmed to 0 oC and was left to stir for 1 hour 
before being cooled to -78 oC. To the stirred solution, 3-formyl-N,N-dimethyl-1H-indole-1-
sulfonamide (4.00 g, 15.9 mmol) was added and the solution was stirred at room 
temperature for 3 hours.  The reaction was poured into water (70 mL) and extracted with 
ethyl acetate (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered and 
the solvent removed under pressure to leave the crude product as yellow oil. The product 
was purified using column chromatography (Petrol: Diethyl ether 4: 1, column diameter = 3 
cm, silica = 14 cm) to give N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (3.11 g, 12.4 mmol, 
78 %) as a pale orange powder.  
Mp:  68.7 – 67.8 oC; Rf: 0.63 (Pet:EA 2:1); 
1H NMR (300 MHz, CDCl3): δH 7.98 (1H, dd, J = 8.0, 
1.4 Hz), 7.85 (1H, dd, J = 7.7, 1.5 Hz), 7.35 (2H, app ddd, J = 7.0, 5.3, 1.6 Hz), 6.83 (1H, dd, J = 
17.8, 11.2 Hz, H4-cis), 5.84 (1H, dd, J = 17.8, 1.2 Hz, H4-trans), 5.38 (1H, dd, J = 11.3, 1.2 Hz, 
H4-cis), 2.86 (6H, s, H11); 13C NMR (101 MHz, CDCl3): δC 136.1 (C
10), 128.2, 127.8, 125.2, 
124.7, 123.1, 120.4, 118.8, 114.9, 114.0, 38.6 (C4); IR (cm-1): ν 3123 (CH), 2945 (CH); Anal. 
Calcd for C12H14N2O2S: C, 57.58; H, 5.64; N, 11.19. Found: C, 57.68; H, 5.75; N, 11.05. 
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(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-N,N-dimethyl-1,3-dioxo-
1,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide – 215  
 
To a stirred round bottomed flask was added N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide 
(85 mg, 0.34 mmol), DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol). 
The reaction was heated at reflux for 48 hours. The reaction was cooled to -78 oC and 
pentafluorobenzaldehyde (66 mg, 0.34 mmol) and DMAC (1M in hexane, 0.34 mL, 0.34 
mmol) were added and the reaction was stirred for 1 hour. The reaction was poured into a 
solution of sodium bicarbonate (10 mL) and extracted with DCM (3 x 10 mL). The combined 
organic extracts were dried with MgSO4, filtered and the solvent was removed under 
reduced pressure to leave the crude product as a pale pink solid. The product was purified 
by column chromatography (diameter = 2cm, silica = 17 cm, eluent = Pet: EA 2:1) to give 
(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-N,N-dimethyl-1,3-dioxo-
1,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide (77%, 0.145 g, 0.26 
mmol) as a pale pink solid.  
Mp: 255.8-257.2 oC; Rf: 0.30 (Pet:EA 2:1);
 1H NMR (400 MHz, CDCl3): δH 7.77 (1H, d, J = 8.3 
Hz), 7.39 (1H, d, J = 7.8 Hz), 7.33-7.28 (1H, m), 7.21 (1H, app t, J = 7.8 Hz), 5.14 (1H, d, J = 8.0 
Hz, H19), 4.80 (1H, d, J = 7.3 Hz, H10), 3.67-3.62 (1H, m, H13), 3.48 (1H, ddd, J = 12.8, 7.2, 5.0 
Hz, H11), 2.98 (6H, s, H26), 2.93 (3H, s, H30), 2.49 (1H, br s, OH), 2.06 (1H, app dd, J = 14.9, 4.1 
Hz, H12), 1.59 (1H, app dt, J = 13.8, 6.9 Hz, H12); 13C NMR (101 MHz, CDCl3): δC 177.8, 173.4, 
137.2, 130.0, 129.3, 125.0, 123.5, 120.0, 118.2, 114.6, 70.3 C19, 41.5 C10, 39.2 C13, 38.2 C26, 
36.7 C11, 28.6 C12, 25.2 C30; IR(neat): υmax/cm
-1 3415, 2972, 2884, 1713; MS (pNSI): 371.1 
(22%), 558.1 (81% (M+H)+), 580.1 (100%, (M+Na)+), HRMS (pNSI): calcd C24H20O5N3F5S 
[M+H]+: 558.1117; observed: 558.1118.  
Note: 13C NMR missing peaks due to C-F coupling. 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-N,N,2-trimethyl-1,3-dioxo-1,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide – 216  
 
To a stirred bottomed flask was added N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (85 
mg, 0.34 mmol), DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol). The 
solution was heated at reflux for 48 hours. The reaction was cooled to room temperature 
and 1-methyl-2-nitrosobenzene (41 mg, 0.34 mmol) was added. The reaction was stirred for 
3 hours at room temperature before the solvent was removed under reduced pressure to 
give the crude product. The crude product was purified by column chromatography (column 
diameter = 2 cm, silica = 16 cm, eluent = Petrol : Ethyl Acetate 2 : 1) to give 
(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-N,N,2-trimethyl-1,3-dioxo-1,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide (74%, 0.122 g, 0.25 mmol) as an off 
white solid.  
Mp: 169.3 – 171.9 oC; Rf: 0.32 (Pet:Ea 2:1);
 1H NMR (400 MHz, CDCl3): δH 7.84 (1 H, d, J = 8.4 
Hz), 7.60 (1H, d, J = 7.9 Hz), 7.50 (1H, d, J = 8.0 Hz), 7.28 (1H, app t, J = 7.8 Hz), 7.21-7.16 (2H, 
m), 7.13 (1H, d, J = 8.1 Hz), 7.07-7.03 (1H, m), 4.98-4.96 (2H, m, H10 + OH), 4.35-4.31 (1H, m, 
H13), 3.69 (1H, app t, J = 7.7 Hz, H11) , 2.93 (9H, s, H33 + H21), 2.60 (1H, app dt, J = 13.1, 6.2 Hz, 
H12), 2.33 (3H, s, H29), 1.97 (1H, ddd, J = 13.1, 7.7, 4.6 Hz, H12); 13C NMR (101 MHz, CDCl3): δC 
178.4 C=O, 173.8 C=O, 149.2, 137.4, 131.9, 131.1, 129.6, 128.4, 126.6, 125.3, 124.7, 123.7, 
121.5, 120.4, 118.8, 115.0, 57.5 C13, 40.5 C10, 39.4 C11, 38.4 C33, 25.2 C21, 24.7 C12, 18.7 C29; 
IR(neat): υmax/cm
-1 3426, 2981, 1712; MS (pAPCI): 221.1 (9%), 251.1 (13%), 360.1 (100%, (M-
MeC6H4NOH)
+), 465.2 (15%, (M-H2O)
+), 483.2 (15%, (M+H)+); HRMS (pAPCI): calcd for 
C24H27N4O5S1 [M+H]
+: 483.1697; observed: 483.1685. 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-N,N-dimethyl-1,3-dioxo-1,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide – 217  
 
To a round bottomed flask was added N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide (85 
mg, 0.34 mmol), DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The reaction 
was heated at reflux for 48 hours and then cooled to room temperature. 1Methyl-2-
nitrosobenzene (41 mg, 0.34 mmol) was added and the reaction is stirred for 4.5 hours. The 
solvent was removed to give the crude product as pale yellow solid. The crude product was 
purified by trituration from DCM to give (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-N,N-
dimethyl-1,3-dioxo-1,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide 
(45%, 72 mg, 0.15 mmol) as a white solid. 
Mp: 199.9-201.0 oC; Rf: 0.64 (Pet:EA 3:1);
 1H NMR (300 MHz, DMSO-d6): δH 11.15 (1H, s, 
NH), 8.38 (1H, s, OH), 7.88 (1H, d, J = 8.4 Hz), 7.36 (1H, d, J = 7.9 Hz), 7.31-7.20 (2H, m), 7.13 
(3H, app dt, J = 14.3, 7.3 Hz), 7.01 (d, J = 7.3 Hz, 1H), 4.98 (1H, d, J = 7.8 Hz, H10), 4.38 (1H, 
app t, J = 4.8 Hz, H13), 3.73 (1H, app q, J = 7.8 Hz, H11), 2.70 (6H, s, H26), 2.45 – 2.37 (1H, m, 
H12)2.36 (s, 3H, H30), 1.77-1.65 1.77 (1H, m, H12); 13C NMR (101 MHz, DMSO-d6) δC 180.4 
C=O, 175.5 C=O, 151.6, 137.2, 133.2, 131.1, 129.3, 129.1, 126.6, 124.4, 124.3, 123.4, 121.8, 
121.1, 118.6, 115.3, 56.5 C13, 42.2 C10, 41.1 C11, 38.7 C26, 26.6 C12, 18.9 C30; IR(neat): 
υmax/cm
-1 3426, 2981, 1712; MS (pAPCI): 237.1 (60%), 346.1 (100%, (M-MeC6H4NOH)
+), 
451.1 (25%, (M-H2O)
+), 469.2 (22%, (M+H)+); HRMS (pAPCI): calcd C23H25N4O5S1 [M+H]
+: 
469.1540; observed: 469.1537. 
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6-(hydroxy(o-tolyl)amino)-N,N-dimethyl-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11(1H)-sulfonamide – 218  
 
To a stirred round bottomed flask was added N,N-dimethyl-3-vinyl-1H-indole-1-sulfonamide 
(85 mg, 0.34 mmol), DCM (5 mL) and cooled to -78 oC. To this solution PTAD (60 mg, 0.34 
mmol) was added and the reaction stirred at -78 oC for 1 hour. 1-Methyl-2-nitrosobenzene 
(41 mg, 0.34 mmol) was added and the reaction was stirred 4 hours before the solvent was 
removed under reduced pressure to give the crude product. The crude product was purified 
by column chromatography (column diameter = 2 cm, silica = 16 cm, eluent = Petrol : Ethyl 
Acetate 2 : 1) to give 6-(hydroxy(o-tolyl)amino)-N,N-dimethyl-1,3-dioxo-2-phenyl-2,3,5,6-
tetrahydro-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11(1H)-sulfonamide (76%, 0.141 
g) as an off white solid. 
Mp: 168.5 – 172.8 oC; Rf: 0.25 (Pet:EA 2:1);
 1H NMR (300 MHz, CDCl3): δH 7.87 (1H, d, J = 8.3 
Hz), 7.73 (1H, d, J = 8.1 Hz), 7.60 (2H, d, J =7.4 Hz), 7.51 (2H, t, J = 7.6 Hz), 7.46-7.38 (1H, m), 
7.30-7.18 (2H, m), 7.04 (2H, t, J = 7.5 Hz), 6.90 (1H, d, J = 7.6 Hz), 6.71 (1H, d, J = 7.8 Hz), 5.76 
(1H, s, H13), 5.37 (1H, d, J = 14.1 Hz, H12), 4.66 (1H, s, OH), 3.46 (1H, d, J = 14.1 Hz, H12), 2.90 
(6H, s, H32), 1.94 (3H, s, H28); 13C NMR (101 MHz, CDCl3): δC 153.5 C=O, 150.5 C=O, 148.7, 
135.1, 132.1, 131.9, 131.2, 130.6 129.4, 128.7, 127.1, 126.9, 126.8, 125.9, 124.4, 124.2, 
122.7, 118.1, 115.9, 104.7, 59.4 C13, 44.7 C12, 38.7 C32, 17.9 C28;  IR(neat): υmax/cm
-1 3322, 
2971, 1707; MS (pNSI): 339.1 (33%), 424.1 (94%, (M-MeC6H4NOH)
+), 547.2 (72%, (M+H)+), 
569.2 (100%, (M+Na)+); HRMS (pNSI): calcd C27H27N6O5S1 [M+H]
+: 547.1758; observed: 
547.1761. 
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(3aS*,5S*,10bS*)-10-benzyl-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 224  
 
Into a round bottomed flask, 1-benzyl-3-vinyl-1H-indole (100 mg, 0.43 mmol) and DCM (5 
mL) and 1-methyl-1H-pyrrole-2,5-dione (48 mg, 0.43 mmol) were added. The reaction was 
cooled to 0 oC and stirred for 2 hours. To the stirred reaction 2-nitrosotoluene (52 mg, 0.43 
mmol) was added and the reaction was stirred for a further 2 hours. The solvent was 
removed and to give the crude product as a yellow solid. The reaction was purified by 
column chromatography (column diameter – 2cm, silica – 14cm, eluent – Petrol: Ethyl 
Acetate 3: 1) to give (3aS*,5S*,10bS*)-10-benzyl-5-(hydroxy(o-tolyl)amino)-2-methyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (73%, 0.1411 g, 0.30 
mmol) as a pale yellow solid. 
Mp: 114.7-116.9 oC; Rf: 0.32 (Pet:EA 2:1);
 1H NMR (400 MHz, C6D6): δH 7.74-7.69 (1H, m), 
7.66 (1H, d, J = 7.9 Hz), 7.07-6.86 (9H, m), 6.78 (2H, d, J = 8.1 Hz), 6.13 (1H, d, J = 17.4 Hz, 
H35), 5.28 (1H, d, J = 17.4 Hz, H35), 4.51 (1H, s, OH), 4.40 (1H, dd, J = 6.6, 4.4 Hz, H13), 3.34 
(1H, d, J = 7.9 Hz, H10), 2.80 (1H, td, J = 7.7, 5.3 Hz, H11), 2.43 (3H, s, H19), 2.35 (1H, ddd, J = 
13.3, 7.0, 5.4 Hz, H12), 2.14 (3H, s, H28), 1.74 (1H, ddd, J = 13.3, 7.5, 4.3 Hz, H12); 13C NMR 
(101 MHz,C6D6-d6): δC 177.4 C=O, 174.7 C=O, 150.1, 138.5, 138.0, 130.7, 130.4, 129.6, 
128.7,, 127.2, 126.4, 126.3, 126.1, 124.7, 122.4, 121.7, 120.3, 120.3, 111.9, 110.1, 58.2 C13, 
47.4 C35, 39.2 C10, 39.1 C11, 24.3 C19, 24.0 C12, 18.4 C28; IR(neat): υmax/cm
-1 3439, 2981, 1704; 
MS (pAPCI): 343.1 (100%, (M-MeC6H4NOH)
+), 359.1 (18%), 448.2 (18%, (M-H2O)
+), 466.2 
(4%, (M+H)+); HRMS (pAPCI): calcd C29H28N3O3 [M+H]
+: 466.2125; observed: 466.2115. 
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(3aS*,5S*,10bS*)-10-benzyl-5-((S*)-1-hydroxy-2,2-dimethylpropyl)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 227  
and  
(3aS*,5R*,10bS*)-10-benzyl-2-methyl-5-((S*)-1-methyl-2,5-dioxopyrrolidin-3-yl)-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 228  
 
To a stirred round bottomed flask was added 1-benzyl-3-vinyl-1H-indole (100 mg, 0.43 
mmol) and DCM (5 mL). The reaction was cooled to 0 oC, 1-methyl-1H-pyrrole-2,5-dione (48 
mg, 0.43 mmol) was added and the reaction was stirred at 0 oC for 2 hours. The reaction was 
cooled to -78 0C and pivaldehyde (0.05 mL, 0.43 mmol) and DMAC (1M in hexane, 0.43 mL, 
0.43 mmol) were added and the solution stirred for 1 hour. The solution was poured into a 
solution of NaHCO3 (10 mL) and extracted with DCM (3 x 10 mL). The combined organic 
layers were dried with MgSO4, filtered and the solvent was removed to give the crude 
product as a pale brown solid. The reaction was purified by column chromatography 
(column diameter – 2cm, silica – 15cm, eluent – Petrol: Ethyl Acetate 3: 1) to give 
(3aS*,5S*,10bS*)-10-benzyl-5-((S*)-1-hydroxy-2,2-dimethylpropyl)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (29%, 54 mg, 0.13 mmol) as an off-
white solid and (3aS*,5R*,10bS*)-10-benzyl-2-methyl-5-((S*)-1-methyl-2,5-dioxopyrrolidin-
3-yl)-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (15%, 28 mg, 0.06 
mmol) as a brown solid. 
(3aS*,5S*,10bS*)-10-benzyl-5-((S*)-1-hydroxy-2,2-dimethylpropyl)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
Mp: 99.4 – 101.9 oC; Rf: 0.63 (Pet: EA 1: 1); 
1H NMR (400 MHz, CDCl3): δH 7.58 (1H, d, J = 7.8 
Hz), 7.31 (1H, d, J = 8.2 Hz), 7.24-7.17 (4H, m), 7.14-7.09 (1H, m), 6.91-6.87 (2H, m), 6.06 
(1H, d, J = 17.3 Hz, H25), 5.60 (1H, d, J = 17.3 Hz, H25), 4.00 (1H, d, J = 1.5 Hz, H17), 3.97 (1H, d, 
J = 7.7 Hz, H10), 3.68 (1H, ddd, J = 10.7, 7.7, 5.2 Hz, H24), 3.45-3.43 (1H, m, H11), 2.97 (3H, s, 
H20), 2.61-2.55 (1H, m, H12), 1.89 (1H, ddd, J = 13.8, 10.7, 5.3 Hz, H12), 1.16 (9H, s, H23); 13C 
NMR (101 MHz, CDCl3): δC δ 179.3 C=O, 175.6 C=O, 138.2, 138.1, 129.6, 129.0, 127.4, 126.0, 
125.1, 122.5, 119.8, 118.9, 114.0, 110.5, 80.7 C17, 47.6 C25, 40.4 C13, 39.3 C10, 35.9 C21, 33.4 
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C11, 27.5 C23, 26.5 C12, 25.1 C20; IR(neat): υmax/cm
-1 3440, 2971, 1707; MS (pNSI): 431.2 
(100%, (M+H)+); HRMS (pNSI): calcd C27H31N2O3 [M+H]
+: 431.2329; observed: 431.2328. 
(3aS*,5R*,10bS*)-10-benzyl-2-methyl-5-((S*)-1-methyl-2,5-dioxopyrrolidin-3-yl)-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione  
Mp: 126.2 – 130.0 oC; Rf:0.21 (Pet: EA 1: 1); 
1H NMR (400 MHz, CDCl3): δH 7.50 (1H, d, J = 8.0 
Hz), 7.32-7.21 (4H, m), 7.20-7.16 (1H, m), 7.11-7.08 (1H, m), 6.86 (2H, d, J = 7.9 Hz), 6.12 
(1H, d, J = 17.4 Hz, H30), 5.55 (1H, d, J = 17.4 Hz, H30), 4.11 (1H, d, J = 8.5 Hz, H10), 4.05 (1H, 
dt, J = 9.1, 4.4 Hz, H29), 3.68 (1H, dd, J = 9.9, 4.6 Hz, H25), 3.37 (1H, dt, J = 9.1, 4.9 Hz, H11), 
3.01 (3H, s, H28), 2.94 (3H, s, H20), 2.69 (1H, dd, J = 18.9, 9.5 Hz, H21), 2.31-2.25 (2H, m, H12 + 
H25), 1.46 (1H, ddd, J = 13.0, 10.7, 5.8 Hz, H12); 13C NMR (101 MHz, CDCl3): δC 178.3, 177.5, 
176.7, 175.3, 138.1, 137.8, 129.6, 129.0, 127.6, 125.9, 124.9, 122.7, 120.4, 119.3, 111.4, 
110.6, 47.3 C30, 42.8 C17, 39.5 C11, 38.9 C10, 31.4 C25, 31.1 C13, 25.4 C20, 25.0 C28,  23.9 C12; 
IR(neat): υmax/cm
-1 3029, 2928, 1693; MS (pNSI): 456.2 (66%, (M+H)+), 478.2 (73%, (M+Na)+), 
933.4 (100%, (2M+Na)+); HRMS (pNSI): calcd C27H26N3O4 [M+H]
+: 456.1918; observed: 
4561.1914. 
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Benzyl 3-formyl-1H-indole-1-carboxylate – 229  
 
To a solution of 1H-indole-3-carbaldehyde (1.0 g, 6.9 mmol) in DCM (20 mL) at 0 oC was 
added triethylamine (1.8 mL, 17.3 mmol) dropwise. The solution was stirred at room 
temperature for 1 hour before benzyl chloroformate (1.4 mL, 8.3 mmol) was added. The 
solution was stirred for 18 hours after which it was poured into water and extracted with 
DCM (3 x 20 mL). The organic fractions were combined, dried over MgSO4, filtered and the 
solvent was removed under reduced pressure to give the crude product as an orange 
powder. The crude product was purified by column chromatography (column diameter = 2.5 
cm, eluent = Petrol: Ethyl acetate 2: 1) to give benzyl 3-formyl-1H-indole-1-carboxylate (1.74 
g, 6.35 mmol, 92%) as a pale orange powder.  
MP: 90.6 – 91.9 oC; Rf: 0.68 (Pet:EA, 2:1); 
1H NMR (300 MHz, CDCl3) δH 10.06 (1H, s, H
3), 8.30 
– 8.25 (1H, m), 8.23 (1H, s, H1), 8.17 (1H, d, J = 8.0 Hz), 7.50 (2H, app dd, J = 7.7, 1.8 Hz), 7.42 
(3H, app ddd, J = 6.6, 5.1, 1.5 Hz), 7.38 (1H, app t, J = 1.6 Hz), 7.37 – 7.34 (1H, m), 5.49 (2H, s, 
H11); 13C NMR (101 MHz, CDCl3) δC 185.8 C
3, 150.2 C10, 136.1, 136.1, 134.3, 129.3, 129.0, 
128.9, 126.5, 126.1, 125.0, 122.3, 122.3, 115.2, 69.9 C11; IR (cm-1): ν 3127, 3008, 1733; MS 
(pNSI): 280.1 (100%, (M+H)+), 302.1 (96%, (M+Na)+), 581.2 (25%, (2M+Na)+); HRMS (pNSI): 
calcd for C17H14NO3 [M+H]
+: 280.0968; observed: 280.0970. 
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Benzyl 3-vinyl-1H-indole-1-carboxylate – 230  
 
In a Schlenk flask, methyltriphenylphosphonium iodide (2.38 g, 5.90 mmol) was dissolved in 
dry THF (30 mL). The solution was cooled to -78 oC and nBuLi (2.15 mL, 5.35 mmol) was 
added over 10 minutes. The yellow solution was warmed to 0 oC and was left to stir for 1 
hour before being cooled to -78 oC. To the stirred solution, benzyl 3-formyl-1H-indole-1-
carboxylate (1.50 g, 5.35 mmol) was added and the solution was stirred at room 
temperature for 3 hours.  The reaction was poured into water (50 mL) and extracted with 
ethyl acetate (3 x 40 mL). The combined organic layers were dried over MgSO4, filtered and 
the solvent removed under pressure to leave the crude product as yellow oil. The product 
was purified using column chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 2 
cm, silica = 15 cm) to give benzyl 3-vinyl-1H-indole-1-carboxylate (1.14 g, 4.07 mmol, 76 %) 
as a yellow powder.  
MP: 42.6 – 44.9 oC; Rf: 0.73 (Pet:EA, 2:1); 
1H NMR (300 MHz, CDCl3) δH 8.33 (1H, d, J = 7.1 
Hz), 7.91 – 7.86 (1H, m), 7.84 (1H, s, H1), 7.58- 7.55 (2H, m), 7.52 – 7.44 (m, 4H), 7.43 – 7.36 
(1H, m), 6.87 (1H, dd, J = 17.8, 11.3 Hz, H3), 5.92 (1H, d, J = 17.8 Hz, H4-trans), 5.51 (2H, s, 
H12), 5.44 (1H, d, J = 11.3 Hz, H4-cis); 13C NMR (101 MHz, CDCl3) δC 150.8 C
11, 135.1, 128. 9, 
128.9, 128.8, 128.6, 128.4, 128.0, 125.1, 123.6, 123.4, 120.2, 120.2, 115.5, 115.0, 68.9 C12; IR 
(cm-1): ν 3153, 2962, 1729; MS (pAPCI): 181.1 (50%), 260.1 (100%), 278.1 (25%, (M+H)+); 
HRMS (pAPCI): calcd for C18H16NO2 [M+H]
+: 278.1176; observed: 278.1173. 
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(3aS*,5S*,10bS*)-5-methoxy-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione – 233  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-
methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (120 
mg, 0.24 mmol), platinum (IV) oxide (53 mg, 0.24 mmol) and methanol (5 mL). The resulting 
suspension was placed under an atmosphere of H2 and stirred at room temperature for 18 
hours. The suspension was filtered through celite and the solvent was removed under 
reduced pressure to leave the crude product as an orange solid, The crude product was 
purified by column chromatography (Petrol: Ethyl acetate 1: 1, column diameter = 2cm, 
silica = 13 cm) to give (3aS*,5S*,10bS*)-5-methoxy-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60%, 41 mg, 0.14 mmol) as a pale 
yellow powder. 
Mp: 139.4 – 142.7 oC; Rf: 0.25 (Pet:EA 1:1); 1H NMR (400 MHz, DCM-d2): δH 8.91 (1H, s), 
7.56 (1H, d, J = 7.8 Hz), 7.34 (1H, d, J = 7.7 Hz), 7.14 (1H, app t, J = 7.5 Hz), 7.09 (1H, app t, J = 
7.4 Hz), 4.73 (1H, app t, J = 2.7 Hz), 4.14 (1H, d, J = 8.8 Hz), 3.31 – 3.25 (1H, m), 3.22 (3H, s), 
2.94 (1H, app t, J = 2.4 Hz), 2.90 (3H, s), 1.88 (1H, ddd, J = 14.2, 6.9, 2.2 Hz);13C NMR (101 
MHz, DCM-d2): δC 178.9, 176.1, 136.4, 128.8, 126.6, 122.3, 120.1, 118.2, 111.9, 111.3, 69.4, 
56.1, 39.,5 37.3, 27.4, 25.1; IR(neat): υmax/cm
-1 3398, 2931, 2870, 1689; MS (pNSI): 285.0 
(29%), 355.1 (100%), 371.1 (57%), 560.0 (21%);HRMS (pNSI): calcd C15H13N2O2 [M-OMe]
+: 
253.0972; observed: 253.0974. 
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(3aS*,5S*,10bS*)-5-ethoxy-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione – 234  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-
methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (100 
mg, 0.20 mmol), platinum (IV) oxide (45 mg, 0.20 mmol) and ethanol (5 mL). The resulting 
suspension was placed under an atmosphere of H2 and stirred at room temperature for 18 
hours. The suspension was filtered through celite and the solvent was removed under 
reduced pressure to leave the crude product as an yellow solid, The crude product was 
purified by column chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 2cm, 
silica = 15 cm) to give (3aS*,5S*,10bS*)-5-ethoxy-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (24%, 20 mg, 0.04 mmol) as a brown 
powder. 
Mp: 100.6 – 102.8 oC; Rf: 0.16 (Pet:EA 2:1); 1H NMR (400 MHz, DCM-d2): δH 8.78 (1H, s), 
7.54 (1H, d, J = 7.7 Hz), 7.35 (1H, d, J = 7.7 Hz), 7.17 – 7.12 (1H, m), 7.09 (1H, app t, J = 7.0 
Hz), 4.83 (1H, app t, J = 2.8 Hz), 4.16 (1H, d, J = 8.8 Hz), 3.55 (1H, app td, J = 6.9, 1.8 Hz), 3.32 
– 3.26 (2H, m), 2.93 – 2.91 (1H, m), 2.90 (3H, s), 1.88 (1H, ddd, J = 14.3, 7.1, 2.7 Hz), 0.97 
(1H, t, J = 7.0 Hz); 13C NMR (101 MHz, DCM-d2): δC 178.9, 176.0, 136.3, 128.8, 126.5, 122.3, 
120.1, 118.1, 112.5, 111.3, 67.4, 63.5, 39.5, 37.3, 27.9, 25.0, 15.2; IR(neat): υmax/cm
-1 3300, 
2969, 1690;MS (pAPCI): 108.1 (24%), 298.1 (6%, (M)+), 299.1 (5%, (M+H)+); HRMS (pAPCI): 
calcd C17H19N2O3 [M+H]
+: 299.1390; observed: 299.1387. 
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Benzyl-5-methoxy-3-vinyl-1H-indole-1-carboxylate – 239  
 
In a Schlenk flask, 5-methoxy-3-vinyl-1H-indole (1.15 g, 6.61 mmol) was dissolved in THF (30 
mL) and the solution was cooled to 0 oC. To the stirred solution, sodium 
bis(trimethylsilyl)amide (7.27 mL, 7.27 mmol) was added and the solution was stirred for 30 
minutes before benzyl chloroformate (0.90 mL, 6.61 mmol) was added. The solution was 
stirred for 30 minutes at room temperature before being added to water (50 mL) and 
extracted with ethyl acetate (3 x 30 mL). The combined organic washings were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure to give the crude 
product as an orange oil. The product was purified using column chromatography (Petrol: 
Ethyl acetate 5: 1, column diameter = 2.0 cm, silica = 15 cm) to give benzyl 5-methoxy-3-
vinyl-1H-indole-1-carboxylate (1.78 g, 4.7 mmol, 71%) as a yellow powder.   
MP: Oil at room temperature; Rf: 0.82 (Pet:EA, 5:1); 
1H NMR (400 MHz, δH 8.09 (1H, s), 7.66 
(1H, s, H1), 7.50 (2H, d, J = 7.2 Hz), 7.45 – 7.37 (1H, m), 7.25 (1H, d, J = 2.5 Hz), 6.96 (1H, dd, J 
= 9.0, 2.2 Hz), 6.79 (1H, dd, J = 17.8, 11.4 Hz, H3), 5.80 (1H, d, J = 17.8 Hz, H4-trans), 5.42 (2H, 
s, H12), 5.34 (1H, d, J = 11.4 Hz, H4-cis), 3.85 (3H, s, H6); 13C NMR (101 MHz, CDCl3) δC 156.4 
C11, 135.2, 129.7, 128.9, 128.9, 128.7, 128.6, 128.0, 124.1, 124.1, 120.0, 116.1, 114.8, 113.3, 
103.3, 68.8 C12, 55.8 C6; IR (cm-1): ν 2955, 2834, 1726; MS (pAPCI): 181.1 (32%), 260.1 
(100%), 308.1 (28%, (M+H)+); HRMS (pAPCI): calcd for C19H18NO3 [M+H]
+: 308.1281; 
observed: 308.1277. 
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5-methoxy-3-vinyl-1H-indole – 240  
 
In a Schlenk flask, methyltriphenylphosphonium iodide (3.54 g, 8.70 mmol) was dissolved in 
dry THF (34 mL). The solution was cooled to -78 oC and nBuLi (3.1 mL, 7.87 mmol) was added 
over 10 minutes. The yellow solution was warmed to 0 oC and was left to stir for 1 hour 
before being cooled to -78 oC. In a separate Schlenk flask, 5-methoxy-1H-indole-3-
carbaldehyde (1.38 g, 7.87 mmol) was dissolved in THF (10 mL) and to the solution sodium 
bis(trimethylsilyl)amide (7.87 mL, 7.87 mmol) was added. This solution was transferred into 
the first Schlenk flask and the red solution was allowed to stir at room temperature for 1 
hour. The reaction was poured into water (50 mL) and extracted with ethyl acetate (2 x 30 
mL). The combined organic layers were dried over MgSO4, filtered and the solvent removed 
under pressure to leave the crude product as yellow oil. The product was purified using 
column chromatography (Petrol: Diethyl ether 2: 1, column diameter = 2.5 cm, silica = 16 
cm) to give 5-methoxy-3-vinyl-1H-indole (1.38 g, 7.6 mmol, 97%) as a yellow powder.  
MP: 190.0 – 192.8 oC; Rf: 0.49 (Pet:Et2O, 2:1); 
1H NMR (300 MHz, CDCl3) δH 8.28 (1H, s), 7.66 
(1H, d, J = 2.4 Hz), 7.29 (1H, d, J = 8.8 Hz), 7.24 (1H, d, J = 2.7 Hz), 7.20 – 7.10 (2H, m), 7.18 
(d, J = 2.5 Hz, 1H), 7.15 (dd, J = 4.5, 2.1 Hz, 2H), 7.10 (s, 1H), 5.95 (1H, dd, J = 17.8, 1.5 Hz), 
5.46 (1H, dd, J = 11.2, 1.5 Hz), 4.07 (3H, s); 13C NMR (101 MHz, CDCl3) δC 154.4, 132.5, 130.8, 
126.4, 126.1, 114.2, 113.0, 112.0, 109.1, 102.0, 55.9 C6; IR (cm-1): ν 3410, 2925, 2836; MS 
(pNSI): 174.1 (100%, (M+H)+), 520.3 (100%, (3M+H)+); HRMS (pNSI): calcd for C11H12NO 
[M+H]+: 174.0913; observed: 174.0912 
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 241  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (94 mg, 0.34 
mmol), DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The resulting 
solution was heated at reflux for 24 hours. The reaction was allowed to cool to room 
temperature and to the stirred solution nitrosobenzene (36 mg, 0.34 mmol) was added and 
the solution was stirred for 18 hours. The solvent was removed under reduced pressure to 
leave the crude product as a pale yellow solid. The product was purified by column 
chromatography (Petrol: Ethyl acetate 3: 1, column diameter = 2 cm, silica = 14 cm) to give 
benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (74%, 124 mg, 0.25 mmol) as a yellow 
powder. 
Mp: 105.7 – 109.2 oC; Rf: 0.34 (Pet:EA 2:1); 
1H NMR (400 MHz, CD2Cl2) δH 8.10 (1H, br d, J = 
8.1 Hz), 7.70 (1H, br d, J = 7.3 Hz), 7.49 (2H, br d, J = 6.6 Hz), 7.39 (3H, br app q, J = 6.9, 6.4 
Hz), 7.35 – 7.25 (3H, br m), 7.22 – 7.13 (3H, br m), 7.01 (1H, br app t, J = 6.7 Hz), 5.55 (1H, d, 
J = 11.8 Hz, H29), 5.41 (1H, d, J = 11.8 Hz, H29), 4.88 (1H, br d, J = 6.8 Hz, H10), 4.87 (1H, br s, 
OH), 4.80 – 4.77 (1H, br m, H13), 3.54 – 3.41 (1H, br m, H11), 2.85 (3H, s, H19), 2.40 – 2.25 (1H, 
br m, H12), 2.08 – 1.93 (1H, br m, H12); 13C NMR (101 MHz, CD2Cl2) δC 178.4 C=O, 174.6 C=O, 
151.6, 151.0, 137.0, 135.0, 130.0, 129.0, 128.9, 128.8, 128.8, 127.6, 125.0, 123.3, 122.3, 
120.0, 118.3, 117.1, 115.1, 69.5 C29, 57.7 C13, 40.2 C10, 39.2 C11, 24.9 C12, 22.6 C19; IR(neat): 
υmax/cm
-1  3433, 2953, 1699; MS (pNSI): 387.1 (97%, (M-N(OH)Ph)+), 494.2 (100%, (M-H)+), 
518.2 (30%, (M+Na)+), 991.4 (15%, (2M+H)+), 1013.3 (10%, (2M+Na)+); HRMS (pNSI): calcd 
C29H25N3O5Na [M+Na]
+: 518.1686; observed: 518.1676. 
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 242  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (94 mg, 0.34 
mmol), DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The resulting 
solution was heated at reflux for 24 hours. The reaction was allowed to cool to room 
temperature and to the stirred solution 1-methyl-2-nitrosobenzene (41 mg, 0.34 mmol) was 
added and the solution was stirred for 18 hours. The solvent was removed under reduced 
pressure to leave the crude product as a pale yellow solid. The product was purified by 
column chromatography (Petrol: Ethyl acetate 3 : 1, column diameter = 2 cm, silica = 16 cm) 
to give benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylateas (78%, 135 mg, 0.26 
mmol) as a yellow powder. 
Mp: 128.4 – 131.5 oC; Rf: 0.45 (Pet:EA 3:1);
 1H NMR (400 MHz, CDCl3) δH 8.11 (1H, d, J = 8.3 
Hz), 7.59 (1H, d, J = 7.8 Hz), 7.55 (1H, d, J = 8.1 Hz), 7.50-7.48 (2H, m), 7.45-7.38 (3H, m), 
7.29-7.23 (1H, m), 7.20 (1H, app t, J = 7.6 Hz), 7.14 (1H, d, J = 7.6 Hz), 7.10 (1H, d, J = 7.8 Hz), 
7.05 (1H, d, J = 7.3 Hz), 5.56 (1H, d, J = 11.8 Hz, H32), 5.46 (1H, d, J = 11.8 Hz, H32), 5.02 (1H, s, 
OH), 4.93 (1H, d, J = 7.6 Hz, H10), 4.38 (1H, t, J = 5.2 Hz, H13), 3.63 (1H, app q, J = 6.9 Hz, H11), 
2.91 (3H, s, H19), 2.59 (1H, app dt, J = 12.3, 6.0 Hz, H12), 2.29 (3H, s, H28), 1.92 (1H, ddd, J = 
12.5, 7.5, 4.6 Hz, H12); 13C NMR (101 MHz, CDCl3) δC 178.5 C=O, 174.6 C=O, 151.7 C
21, 149.2 
C29, 136.8, 134.8, 131.1, 129.9, 129.0, 129.0, 128.9, 128.9, 127.7, 126.6, 125.3, 125.0, 123.3, 
121.5, 120.1, 118.1, 115.3, 69.6 C32, 57.4 C C13, 40.4 C10, 39.1 C11, 25.2 C19, 24.1 C12, 18.6 C28; 
IR(neat): υmax/cm
-1 3450, 2954, 1699; MS (pNSI): 343.1 (40%), 387.1 (82%, (M-(N(OH)2-
Tol))+), 508.2 (100%, (M-(H2)+H)
+), 532.2 (59%, (M+Na)+); HRMS (pNSI): calcd C30H27N3O5Na 
[M+Na]+: 532.1843; observed: 532.1834. 
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(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 243  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (189 mg, 0.68 
mmol), 1-methyl-1H-pyrrole-2,5-dione (76 mg, 0.68 mmol) and DCM (10 mL). The reaction 
mixture was heated at reflux for 24 hours. The reaction was cooled to 0 °C and then 4-
phenyl-1,2,4-triazolidine-3,5-dione (120 mg, 0.68 mmol) was added. The reaction was 
stirred at 0 °C for 1 hour then at room temperature for 18 hours. The solvent was removed 
under reduced pressure to leave the crude product as an orange powder. The product was 
purified by column chromatography (Petrol: Ethyl acetate 1: 1, column diameter = 2 cm, 
silica = 20 cm) to give (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-
methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate 
(54%, 207 mg, 0.37 mmol) as an off-white powder and (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-
phenyl-1,2,4-triazolidin-1-yl)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-
a]carbazole-10(1H)-carboxylate (27%, 76 mg, 0.19 mmol) as a white powder.   
Mp: 202.3-203.9 °C; Rf: 0.15 (Pet: EA 1:1); 
1H NMR (400 MHz, CDCl3) δH 8.38 (1H, s, NH), 8.07 
(1H, d, J = 8.4 Hz), 7.51 (1H, app dt, J = 7.6, 0.9 Hz), 7.49 – 7.37 (4H, m), 7.39 – 7.33 (6H, m), 
7.30 (1H, ddd, J = 8.6, 7.3, 1.3 Hz), 7.21 (1H, app td, J = 7.5, 1.0 Hz), 5.53 (1H, app t, J = 5.2 
Hz, H27), 5.44 (1H, d, J = 11.8 Hz, H35), 5.38 (1H, d, J = 11.8 Hz, H35), 4.89 (1H, d, J = 8.0 Hz, 
H11), 3.50 (1H, ddd, J = 9.6, 8.0, 5.5 Hz, H11), 2.87 (3H, s, H20) 2.41 (1H, app dt, J = 14.2, 5.5 
Hz, H12), 2.14 (1H, ddd, J = 14.2, 9.5, 5.5 Hz, H12); 13C NMR (101 MHz, CDCl3) δC 177.4 C=O, 
173.6 C=O, 153.6 C=O, 152.2 C=O, 151.3 C=O, 136.9, 134.5, 130.9, 130.8, 129.3, 129.1, 
128.9, 128.9, 128.4, 126.1, 125.8, 125.3, 123.8, 118.8, 115.7, 113.8, 69.8 C35, 47.5 C13, 40.0 
C10, 38.4 C11, 27.5 C12, 25.2 C20; IR (neat): νmax cm
-1 3462, 2969, 1699; MS (pNSI): 199.2 
(16%), 387.1 (19%, (M-PTAD)+), 564.2 (59%, (M+H)+), 581.2 (100%, (M+NH4)
+), 643.2 (15%), 
1144.4 (39%, (2M+NH4)
+); HRMS (pNSI): calcd C31H26N5O6 [M+H]
+: 564.1878; observed: 
564.1873. 
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 244  
 
To a stirred Schlenk flask was added benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (209 
mg, 0.68 mmol), DCM (10 mL) and 1-methyl-1H-pyrrole-2,5-dione (76 mg, 0.68 mmol). The 
resulting solution was heated at reflux for 18 hours. The reaction was cooled to room 
temperature and 1-methyl-2-nitrosobenzene (82 mg, 0.68 mmol) was added. The solution 
was stirred at room temperature for 3 hours. The solvent was removed under reduced 
pressure to leave the crude product as a pale yellow solid. The product was purified by 
column chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 2 cm, silica = 15 cm) 
to give benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (74%, 279 mg, 0.50 
mmol) as a pale yellow powder. 
Mp: 107.6 – 110.1°C; Rf: 0.29 (Pet:EA 2:1); 
1H NMR (400 MHz, CD2Cl2) δH 7.93 (1H, d, J = 9.1 
Hz), 7.54 (1H, dd, J = 8.1, 1.3 Hz), 7.49 – 7.45 (2H, m), 7.43 – 7.35 (3H, m), 7.19 (1H, ddd, J = 
7.6, 6.9, 1.9 Hz), 7.10 – 7.01 (2H, m), 6.88 (1H, d, J = 2.6 Hz), 6.80 (1H, dd, J = 9.1, 2.6 Hz), 
5.52 (1H, d, J = 11.9 Hz, H32), 5.37 (1H, d, J = 11.9 Hz, H32), 5.18 (1H, s, OH), 4.87 (1H, d, J = 
8.1 Hz, H10), 4.33 – 4.29 (1H, m, H13), 3.65 (3H, s, H37), 3.67 – 3.61 (1H, m, H11), 2.86 (3H, s, 
H28), 2.61 (1H, app dt, J = 13.4, 5.9 Hz, H12), 2.22 (3H, s, H27), 1.86 (1H, ddd, J = 13.4, 8.5, 4.3 
Hz, H12); 13C NMR (101 MHz, CD2Cl2) δC 178.4 C=O, 174.4 C=O, 156.1 C
1, 151.6 C29, 149.8 C20, 
135.0, 134.9, 131.2, 130.8, 130.6, 130.4, 128.8, 128.8, 128.5, 126.4, 125.3, 121.7, 117.5, 
115.7, 113.6, 102.0, 69.3 C32, 57.8 C13, 55.4 C38, 40.5 C10, 38.9 H11, 25.0 C28, 24.9 C12, 18.2 
C27; IR(neat): υmax/cm
-1 = 3370, 2965, 2887,  1699; MS (pNSI): 207.1 (39%), 417.1 (34%, (M-
(N(OH)2-Tol))+), 438.2 (100%, (M-(H2)+H)
+), 1075.4 (15%, (2(M-(H2)+H)
+); HRMS (pNSI): calcd 
C31H28N3O6 [M-(H2)+H]
+:538.1976; observed: 538.1973.  
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-methoxy-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 245  
 
To a stirred Schlenk flask was added benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (209 
mg, 0.68 mmol), DCM (10 mL) and 1H-pyrrole-2,5-dione (66 mg, 0.68 mmol). The resulting 
solution was heated at reflux for 18 hours. The reaction was cooled to room temperature 
and nitrosobenzene (72 mg, 0.68 mmol) was added and the reaction was stirred for 2.5 
hours. The solvent was removed under reduced pressure to leave the crude product as a 
pale orange oil. The product was purified by column chromatography (Petrol: Ethyl acetate 
2: 1, column diameter = 1 cm, silica = 16 cm,) to give benzyl (3aS*,5S*,10bS*)-5-
(hydroxy(phenyl)amino)-7-methoxy-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-
a]carbazole-10(1H)-carboxylate (79%, 317 mg, 0.54 mmol) as a pale orange powder.  
Mp: 134.2 – 136.9 °C; Rf: 0.34 (Pet:EA 3:2);  
1H NMR (400 MHz, CD2Cl2) δH 8.42 (1H, br s, NH), 7.94 (1H, d, J = 9.0 Hz), 7.47 – 7.44 (2H, m), 
7.40 – 7.34 (3H, m), 7.30 – 7.27 (2H, m), 7.19 – 7.17 (2H, m), 7.01 – 6.98 (1H, m), 6.93 (1H, 
br s), 6.81 (1H, d, J = 9.0 Hz),  5.49 (1H, d, J = 11.9 Hz, H28), 5.39 (1H, br s, OH), 5.34 (1H, d, J = 
11.9 Hz, H28), 4.92 (1H, br d, J = 6.2 Hz, H10), 4.74 (1H, br s, H13), 3.64 (3H, s, H34), 3.57 – 3.51 
(1H, br m, H11), 2.39 – 2.35 (1H, br m, H12), 1.91 – 1.89 (1H, br m, H12); 13C NMR (101 MHz, 
CD2Cl2) δC 178.6 C=O, 174.4 C=O, 156.2 C
1, 151.5, 151.0, 135.0, 131.4, 130.3, 129.0, 128.9, 
128.8, 128.8, 128.4, 122.6, 117.5, 117.4, 116.0, 113.5, 102.3, 69.4 C28, 57.9 C13, 55.6 C34, 
41.5 C10, 40.5 C11, 24.0 C12; IR(neat): υmax/cm
-1 = 3233, 2952, 1708; MS (pNSI): 403.1 (37%, 
(M-(N(OH)Ph))+), 510.2 (100%, (M-(H2)+H)
+), 532.1 (26%, (M-(H2)+Na)
+); HRMS (pNSI): calcd 
C29H24N3O6 [M-(H2)+H]
+:510.1654; observed: 510.1660.    
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 246 
 
To a stirred Schlenk flask was added benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (209 
mg, 0.68 mmol), DCM (10 mL) and 1H-pyrrole-2,5-dione (66 mg, 0.68 mmol). The resulting 
solution was heated at reflux for 18 hours. The reaction was cooled to room temperature 
and 1-methyl-2-nitrosobenzene (82 mg, 0.68 mmol) was added. The solution was stirred at 
room temperature for 3.5 hours. The solvent was removed under reduced pressure to leave 
the crude product as a pale yellow solid. The product was purified by column 
chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 2 cm, silica = 14 cm) to give 
benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (76%, 255 mg, 0.52 mmol) as a pale 
yellow powder. 
Mp: 193.0 – 195.6 °C; Rf: 0.20 (Pet:EA 2:1); 
1H NMR (400 MHz, CD2Cl2) δH 7.92 (1H, d, J = 9.7 
Hz), 7.81 (1H, s, NH), 7.53 (1H, d, J = 7.8 Hz), 7.46 (2H, dd, J = 7.8, 1.6 Hz), 7.42 – 7.33 (3H, 
m), 7.21 – 7.15 (1H, m), 7.09 – 7.00 (2H, m), 6.84 – 6.75 (2H, m). 5.50 (1H, d, J = 11.9 Hz, 
H31), 5.35 (1H, d, J = 11.9 Hz, H31), 5.16 (1H, s, OH), 4.96 (1H, d, J = 7.6 Hz, H10), 4.37 (1H, app 
t, J = 4.9 Hz, H13), 3.71 (1H, app td, J = 8.7, 5.6 Hz, H11), 3.64 (3H, s, H37), 2.64 (1H, app dt, J = 
13.6, 5.6 Hz, H12), 2.21 (3H, s, H27), 1.88 (1H, ddd, J = 13.6, 9.3, 4.3 Hz, H12); 13C NMR (101 
MHz, DMSO-d6) δC 180.6 C=O, 176.4 C=O, 155.6, 151.8, 151.7, 135.8, 131.6, 130.8, 130.7, 
130.2, 129.1, 129.1, 129.0, 126.7, 124.8, 122.3, 117.2, 115.2, 113.5, 102.7, 69.1 C31, 57.3 C13, 
55.5 C37, 41.9 C10, 40.3 C11, 27.2 C12, 18.5 C27; IR(neat): υmax/cm
-1 = 3457, 3367, 2981, 2886, 
1712; MS (pNSI): 403.1 (100%, (M-(N(OH)-2-Tol))+), 524.1 (75%, (M-(H2)+H)
+), 548.2 (16%, 
(M+Na)+), 1073.4 (5%, (2M+Na)+); HRMS (pNSI): calcd C30H27N3O6Na [M+Na]
+: 548.1792; 
observed: 548.1785. 
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 247 
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (189 mg, 0.68 
mmol), 1H-pyrrole-2,5-dione (66 mg, 0.68 mmol) and DCM (10 mL).  The resulting solution 
was heated at reflux for 24 hours. The reaction was allowed to cool to room temperature 
and to the stirred solution nitrosobenzene (73 mg, 0.68 mmol) was added and the solution 
was stirred for 18 hours. The solvent was removed under reduced pressure to leave the 
crude product as a yellow powder.  The product was purified by column chromatography 
(Petrol: Ethyl acetate 2: 1, column diameter = 2 cm, silica = 20 cm) to give benzyl 
(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-
a]carbazole-10(1H)-carboxylate (70%, 230 mg, 0.48 mmol) as a yellow powder. 
Mp: 177.1-177.8 °C; Rf: 0.38 (Pet:EA 2:1); 
1H NMR (500 MHz, CD2Cl2) δH 8.20 (1H, s, NH), 8.11 
(1H, d, J = 8.3 Hz), 7.66 (1H, d, J = 7.8 Hz), 7.50 (2H, dd, J = 7.9, 1.6 Hz), 7.43-7.36 (3H, m), 
7.33 (2H, app t, J = 7.8 Hz), 7.28 (1H, app t, J = 7.8 Hz), 7.22 (2H, d, J = 8.0 Hz), 7.16 (1H, app 
t, J = 7.5 Hz), 7.02 (1H, app t, J = 7.3 Hz), 5.55 (1H, d, J = 11.9 Hz, H28), 5.40 (1H, d, J = 11.9 Hz, 
H28), 5.19 (1H, s, OH), 4.96 (1H, br d, J = 8.1 Hz, H10), 4.82 (1H, app t, J = 5.7 Hz, H13), 3.56 
(1H, br app q, J = 7.4 Hz, H11), 2.35 (1H, br app dd, J = 13.4, 6.7 Hz, H12), 2.00 – 1.92 (1H, br 
m, H12); 13C NMR (101 MHz, CD2Cl2) δC 178.5 C=O, 174.5 C=O, 151.6 C
25, 150.7, 136.9, 134.9, 
129.7, 129.0, 128.9, 128.9, 128.8, 127.6, 125.1, 123.3, 122.6, 119.8, 118.0, 117.3, 115.2, 69.5 
C28, 57.7 C13, 41.4 C10, 40.6 C11, 23.0 C12; IR(neat): υmax/cm
-1 = 3418, 3329, 2970, 1705; MS 
(pNSI): 199.2 (87%), 373.1 (68%, (M-(N(OH)Ph))+), 480.2 (100%, (M-(H2)+H)
+); HRMS (pNSI): 
calcd C28H23N3O5Na [M+Na]
+: 504.1530; observed: 504.1522. 
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 248  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (94 mg, 0.34 
mmol), DCM (5 mL) and 1H-pyrrole-2,5-dione (33 mg, 0.34 mmol). The resulting solution 
was heated at reflux for 24 hours. The reaction was allowed to cool to room temperature 
and to the stirred solution 1-methyl-2-nitrosobenzene (41 mg, 0.34 mmol) was added and 
the solution was stirred for 4 hours. The solvent was removed under reduced pressure to 
leave the crude product as a pale yellow solid. The product was purified by column 
chromatography (Petrol: Ethyl acetate 3: 2, column diameter = 2 cm, silica = 16 cm) to give 
benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (83%, 140 mg, 0.28 mmol) as a yellow 
powder. 
Mp: 181.4 – 183.9 oC; Rf: 0.48 (Pet:EA 3:2); 
1H NMR (400 MHz, DMSO-d6) δH 11.26 (1H, s, 
NH), 8.41 (1H, s, OH), 7.93 (1H, d, J = 8.3 Hz), 7.51 (2H, d, J = 7.0 Hz), 7.45-7.33 (4H, m), 7.18-
7.08 (3H, m), 7.03-6.91 (3H, m), 5.56 (1H, d, J = 12.1 Hz, H31), 5.32 (1H, d, J = 12.1 Hz, H31), 
4.96 (1H, d, J = 8.0 Hz, H10), 4.34 (1H, app t, J = 3.7 Hz, H13), 3.73 (1H, app q, J = 8.7 Hz, H11), 
2.50-2.44 (1H, m, H12), 2.17 (3H, s, H27), 1.74-1.64 (1H, m, H12); 13C NMR (101 MHz, DMSO-
d6) δC 180.6 C=O, 176.5 C=O, 151.6, 136.2, 135.7, 131.1, 130.8, 130.0, 129.2, 129.1, 129.1, 
128.2, 126.6, 124.7, 124.5, 122.9, 122.2, 120.6, 117.5, 114.4, 69.2 C31, 57.1 C13, 41.8 C10, 
40.2 C11, 26.7 C12, 18.6 C27; IR(neat): υmax/cm
-1 3495, 3325, 2953, 1711; MS (pNSI): 373.1 
(51%, (M-(N(OH)2-Tol))+), 494.2 (16%, (M-(H2)+H)
+), 518.2 (21%, (M+Na)+); HRMS (pNSI): 
calcd C29H25N3O5Na [M+Na]
+: 518.1686; observed: 518.1681. 
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benzyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 249  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (189 mg, 0.68 
mmol), DCM (10 mL) and 1H-pyrrole-2,5-dione (66 mg, 0.68 mmol). The resulting solution 
was heated at reflux for 24 hours. The reaction was cooled to 0 oC and 4-phenyl-1,2,4-
triazolidine-3,5-dione (120 mg, 0.68 mmol) was added. The solution was stirred at 0 oC for 1 
hour. The solvent was removed under reduced pressure to leave the crude product as an off 
white solid. The product was purified by column chromatography (Petrol: Ethyl acetate 1: 1, 
column diameter = 2 cm, silica = 13 cm) to give benzyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-
phenyl-1,2,4-triazolidin-1-yl)-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-
10(1H)-carboxylate (58%, 216 mg, 0.39 mmol) as a pale pink powder. 
Mp: 174.6 – 177.1 °C; Rf: 0.06 (Pet:EA 1:1); 
1H NMR (400 MHz, CD2Cl2) δH  8.78 (1H, s, NH), 
8.05 (1H, d, J = 8.3 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.44 – 7.38 (6H, m), 7.38 – 7.30 (4H, m), 7.30 
– 7.24 (1H, m), 7.20 (1H, app t, J = 7.5 Hz),  5.51 (1H, app t, J = 5.3 Hz, H26), 5.45 (1H, d, J = 
11.9 Hz, H34), 5.31 (1H, d, J = 11.9 Hz, H34), 4.98 (1H, d, J = 7.9 Hz, H10), 3.46 (1H, app q, J = 
8.1 Hz, H11), 2.36 – 2.30 (1H, m, H12), 2.18 (1H, ddd, J = 13.9, 8.6, 5.3 Hz,H12); 13C NMR (101 
MHz, CD2Cl2) δC 178.1, 173.8, 153.7, 152.4, 151.4, 136.8, 134.7, 131.1, 130.6, 129.1, 128.9, 
128.8, 128.8, 128.4, 126.2, 125.7, 125.6, 123.7, 119.0, 115.5, 114.2, 69.7 C34, 47.7 C13, 41.0 
C10, 39.5 C11, 26.8 C12; IR(neat): υmax/cm
-1 = 3169, 2975, 1699; MS (pNSI): 279.1 (38%), 373.1 
(13%, (M-PTAD)+), 550.2 (21%, (M+H)+), 567.2 (100% (M+NH4)
+), 1116.4 (39%, (2M+NH4)
+), 
1666.5 (6%, (3M+NH4)
+); HRMS (pNSI): calcd C30H24N5O6 [M+H]
+: 550.1721; observed: 
550.1719.   
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benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-methoxy-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 250  
 
To a stirred Schlenk flask was added benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (209 
mg, 0.68 mmol), DCM (10 mL) and 1-methyl-1H-pyrrole-2,5-dione (76 mg, 0.68 mmol). The 
resulting solution was heated at reflux for 18 hours. The reaction was cooled to room 
temperature and nitrosobenzene (72 mg, 0.68 mmol) was added and the reaction was 
stirred for 1.5 hours. The solvent was removed under reduced pressure to leave the crude 
product as a pale orange oil. The product was purified by column chromatography (Petrol: 
Ethyl acetate 2: 1, column diameter = 1 cm, silica = 16 cm,) to give benzyl (3aS*,5S*,10bS*)-
5-(hydroxy(phenyl)amino)-7-methoxy-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (73%, 218 mg, 0.44 mmol) as an 
orange powder.  
Mp: 106.8 – 110.2 °C; Rf: 0.65 (Pet:EA 2:1); 
1H NMR (400 MHz, CD2Cl2) δH 7.97 (1H, br d, J = 
8.3 Hz), 7.49 – 7.47 (2H, m), 7.41 – 7.37 (3H, m), 7.33 – 7.30 (2H, m), 7.21 – 7.19 (2H, m), 
7.05 – 7.00 (2H, m), 6.85 (1H, br d, J = 8.4 Hz), 5.53 (1H, d, J = 11.9 Hz, H28), 5.39 (1H, d, J = 
11.9 Hz, H28), 5.02 (1H, br s, OH), 4.91 – 4.87 (1H, m, H10), 4.75 (1H, br s, H13), 3.68 (3H, s, 
H34), 3.50 (1H, br s, H11), 2.86 (3H, s, H25), 2.36 (1H, br s, H12), 2.01 (1H, br s, H12); 13C NMR 
(101 MHz, CD2Cl2) δC 178.3 C=O, 174.5 C=O, 156.3 C
1, 151.5 C26, 151.1, 135.0, 131.5, 130.7, 
129.0, 128.9, 128.8, 128.8, 128.4, 122.4, 117.7, 117.2, 115.9, 113.4, 102.4, 69.4 C28, 57.9 C13, 
55.6 C34, 40.3 C10, 39.2 C11, 24.9 C25, 23.4 C12; IR(neat): υmax/cm
-1 = 3408, 2969, 2890, 1699; 
MS (pNSI): 417.1 (100%, (M-(N(OH)Ph))+), 524.2 (68%, (M-(H2)+H)
+), 548.2 (16%, (M+Na)+), 
1073.4 (4%, (2M+Na)+); HRMS (pNSI): calcd C30H27N3O6Na [M+Na]
+: 548.1792; observed: 
548.1785. 
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benzyl (R*)-6-(hydroxy(phenyl)amino)-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate – 251  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (189 mg, 0.68 
mmol) and DCM (10 mL). The solution was cooled to -78 oC and 4-phenyl-1,2,4-triazolidine-
3,5-dione (120 mg, 0.68 mmol) was added. The reaction was stirred at -78 oC for 5 hours. 
The reaction was warmed to room temperature, nitrosobenzene (73 mg, 0.68 mmol) was 
added and the reaction was stirred for 3 hours. The solvent was removed under reduced 
pressure to leave the crude product as a pale yellow oil. The product was purified by column 
chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 1 cm, silica = 16 cm,) to give 
benzyl (R*)-6-(hydroxy(phenyl)amino)-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate (72%, 274 mg, 0.49 mmol) as 
a white powder.  
Mp: 101.2 – 103.1°C; Rf: 0.53 (Pet:EA 2:1; 
1H NMR (400 MHz, CD2Cl2) δH 8.09 (1H, d, J = 8.2 
Hz), 7.51 – 7.38 (8H, m), 7.38 – 7.24 (5H, m), 7.23 – 7.07 (4H, m), 6.87 (1H, d, J = 7.9 Hz), 
6.36 (1H, s, OH), 5.52 (1H, d, J = 12.1 Hz, H32), 5.39 (1H, d, J = 12.1 Hz, H32), 5.22 (1H, dd, J = 
14.0, 1.7 Hz, H12), 4.97 – 4.89 (1H, m, H13), 3.66 (1H, dd, J = 14.0, 3.4 Hz, H12); 13C NMR (101 
MHz, CD2Cl2) δC 147.2, 147.0, 146.6, 145.6, 131.0, 130.1, 127.3, 126.2, 125.4, 125.2, 124.9, 
124.9, 124.9, 124.8, 124.8, 122.4, 122.3, 120.7, 120.5 119.7, 115.8, 114.5, 110.5, 97.2, 66.2 
C32, 55.1 C13, 39.6 C12; IR(neat): υmax/cm
-1 = 3337, 3063, 1716; MS (pAPCI): 395.1 (100%), 
451.1 (59%, (M-(N(OH)Ph))+), 542.2 (5%, (M-(H2O)+H)
+), 558.2 (1%, (M-H)+), 560.2 (1%, 
(M+H)+); HRMS (pAPCI): calcd C32H26N5O5 [M+H]
+: 560.1928; observed: 560.1913.  
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benzyl (R*)-6-(hydroxy(o-tolyl)amino)-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate – 252  
 
To a stirred Schlenk flask was added benzyl 3-vinyl-1H-indole-1-carboxylate (94 mg, 0.34 
mmol) and DCM (10 ml). The reaction mixture was cooled to -78 °C and 4-phenyl-1,2,4-
triazolidine-3,5-dione (60 mg, 0.34 mmol) was added. The reaction mixture was stirred at -
78 °C for 5 hours, 1-methyl-2-nitrosobenzene was added (41 mg, 0.34 mmol) and the 
reaction stirred at room temperature for 18 hours. The solvent was removed under reduced 
pressure to leave the crude product as a yellow powder. The product was purified by 
column chromatography (Petrol: Ethyl acetate 3: 1, column diameter = 2 cm, silica = 20 cm) 
to give benzyl (R*)-6-(hydroxy(o-tolyl)amino)-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate  (68%, 132 mg, 0.23 mmol) as 
an off white powder.  
Mp: 163.8-165.1 °C; Rf: 0.49 (Pet:EA 3:1); 
1H NMR (400 MHz, CD2Cl2) δH 8.01 (1H, d, J = 8.3 
Hz), 7.65 (1H, dd, J = 8.1, 1.3 Hz), 7.54 – 7.38 (7H, m), 7.35 (3H, dd, J = 5.0, 2.1 Hz), 7.19 (2H, 
app dtd, J = 8.5, 7.2, 6.7, 1.4 Hz), 6.99 (2H, app tdd, J = 7.5, 3.4, 1.2 Hz), 6.90 (1H, dd, J = 7.7, 
1.4 Hz), 6.75 (1H, d, J = 7.8 Hz), 5.87 (1H, s, OH), 5.48 (1H, d, J = 11.9 Hz, H33), 5.34 (1H, d, J = 
11.9 Hz, H33), 5.19 (1H, dd, J = 14.1, 2.3 Hz, H12), 4.63 (1H, app t, J = 2.3 Hz, H13), 3.52 (1H, dd, 
J = 14.1, 2.3 Hz, H12), 1.94 (3H, s, H25); 13C NMR (101 MHz, CDCl3) δC 151.9, 150.3, 150.0, 
148.8, 134.6, 133.6, 131.6, 131.1, 130.6, 130.0, 129.4, 128.9, 128.9, 128.8, 128.8, 127.0, 
126.6, 126.0, 125.7, 124.4, 123.6, 122.7, 117.9, 114.6, 101.7, 70.1 C33, 58.6 C13, 43.5 C12, 
17.7 C25; IR(neat): υmax/cm
-1 = 3291, 2981, 1782, 1737, 1699; MS (pNSI): 199.2 (100%), 407.2 
(79%), 451.1 (81%, (M-(N(OH)2-Tol))+), 572.2 (25%, (M-H)+), 596.2 (65%, (M+Na)+); HRMS 
(pNSI): calcd C33H27N5O5Na [M+Na]
+:596.1904; observed: 596.1898.  
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benzyl (R*)-6-(hydroxy(phenyl)amino)-8-methoxy-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-
1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate – 253  
 
To a stirred Schlenk flask was added benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (209 
mg, 0.68 mmol) and DCM (10 mL). The solution was cooled to -78 oC and 4-phenyl-1,2,4-
triazolidine-3,5-dione (120 mg, 0.68 mmol) was added. The reaction was stirred at -78 oC for 
1.5 hours. The reaction was warmed to room temperature, nitrosobenzene (73 mg, 0.68 
mmol) was added and the reaction was stirred for 20 hours. The solvent was removed under 
reduced pressure to leave the crude product as a pale yellow oil. The product was purified 
by column chromatography (Petrol: Ethyl acetate 2: 1, column diameter = 1 cm, silica = 16 
cm) to give benzyl (R*)-6-(hydroxy(phenyl)amino)-8-methoxy-1,3-dioxo-2-phenyl-2,3,5,6-
tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate (78%, 
312 mg, 0.53 mmol) as a white powder.  
Mp: 110.4 – 113.2 °C; Rf: 0.20 (Pet:EA 2: 1); 
1H NMR (400 MHz, CD2Cl2) δH 7.88 (1H, d, J = 9.1 
Hz), 7.42 – 7.38 (5H, m), 7.36 – 7.32 (3H, m), 7.29 – 7.26 (2H, m), 7.24 – 7.20 (2H, m), 7.13 
(2H, d, J = 8.1 Hz), 7.05 (1H, app t, J = 7.3 Hz). 6.76 (1H, dd, J = 9.1, 2.6 Hz), 6.24 (1H, s, OH), 
6.10 (1H, d, J = 2.5 Hz), 5.43 (1H, d, J = 12.0 Hz, H28), 5.32 – 5.29 (1H, m, H28), 5.25 – 5.18 (1H, 
m, H12), 4.84 – 4.80 (1H, m, H13), 3.64 (1H, dd, J = 14.0, 3.3 Hz, H12), 3.55 (3H, s, H38); 13C 
NMR (101 MHz, CD2Cl2) δC 156.5, 151.1, 150.3, 149.4, 134.8, 131.2, 130.3, 129.2, 129.0, 
129.0, 128.70, 128.7, 128.7, 128.6, 128.2, 126.9, 126.2, 124.6, 119.7, 115.3, 113.2, 101.0, 
100.5, 69.9 C28, 59.1 C13, 55.5 C38, 44.0 C12; IR(neat): υmax/cm
-1 = 3336, 2935, 1716; MS 
(pNSI): 481.1 (17%, (M-(N(OH)Ph))+), 588.2 (100%, (M-(H2)+H)
+), 612.2 (15%, (M+Na)+); 
HRMS (pNSI): calcd C33H27N5O6Na [M+Na]
+: 612.1854; observed: 612.1838. 
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benzyl (R*)-6-(hydroxy(o-tolyl)amino)-8-methoxy-1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-
1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate – 254  
 
To a stirred Schlenk flask was added benzyl 5-methoxy-3-vinyl-1H-indole-1-carboxylate (209 
mg, 0.68 mmol) and DCM (10 mL). The solution was cooled to -78 oC and 4-phenyl-1,2,4-
triazolidine-3,5-dione (120 mg, 0.68 mmol) was added. The reaction was stirred at -78 oC for 
1.5 hours. The reaction was warmed to room temperature, 1-methyl-2-nitrosobenzene (73 
mg, 0.68 mmol) was added and the reaction was stirred for 24 hours. The solvent was 
removed under reduced pressure to leave the crude product as a pale orange oil. The 
product was purified by column chromatography (Petrol: Ethyl acetate 2: 1, column 
diameter = 2 cm, silica = 17 cm) to give benzyl (R*)-6-(hydroxy(o-tolyl)amino)-8-methoxy-
1,3-dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-
b]indole-11-carboxylate (82%, 338 mg, 0.56 mmol) as an off white powder.  
Mp: 181.1 – 183.0 °C; Rf: 0.55 (Pet:EA 2:1); 
1H NMR (400 MHz, DMSO-d6) δH 8.70 (1H, s), 7.84 
(1H, d, J = 9.0 Hz), 7.55 – 7.48 (2H, m), 7.46 – 7.41 (3H, m), 7.41 – 7.33 (4H m), 7.33 – 7.29 
(2H, m), 7.13 – 7.03 (2H, m), 6.97 (1H, app td, J = 7.4, 1.3 Hz), 6.83 (1H, dd, J = 9.1, 2.6 Hz). 
6.38 (1H, s, OH), 5.43 (1H, d, J = 12.1 Hz, H35), 5.33 (1H, d, J = 12.1 Hz, H35), 4.80 (1H, dd, J = 
13.7, 1.8 Hz, H12), 4.71 (1H, dd, J = 3.3, 1.8 Hz, H13), 3.68 – 3.61 (1H, dd, J = 13.7, 3.3 Hz, H12), 
3.58 (s, 3H, H41), 2.30 (s, 3H, H27); 13C NMR (101 MHz, CD2Cl2) δC 156.3, 151.6, 150.8, 150.3, 
149.8, 135.3, 131.6, 130.9, 130.3, 130.0, 129.7, 129.2, 129.1, 129.1, 128.9, 128.0, 127.4, 
127.1, 126.8, 125.2, 121.8, 115.3, 113.2, 103.1, 101.9, 69.9 C35, 55.9 C13, 55.6 C41, 43.9 C12, 
18.2 C27; IR(neat): υmax/cm
-1 = 3212, 2939, 1720; MS (pNSI): 481.2 (100%, (M-N(OH)2-Tol)+), 
602.2 (34%, (M-(H2)+H)
+), 626.2 (100%, (M+Na)+); HRMS (pNSI): calcd C34H29N5O6Na 
[M+Na]+: 626.2010; observed: 626.2006. 
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(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 255  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-
methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (120 
mg, 0.25 mmol), platinum (IV) oxide (57 mg, 0.25 mmol) and THF (5 mL). The resulting 
suspension was placed under an atmosphere of H2 and stirred at room temperature for 5 
hours. The suspension was filtered through celite and the solvent was removed under 
reduced pressure to leave the crude product as a yellow solid, The crude product was 
purified by trituration from DCM to give (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-
methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (75%, 68 mg, 0.19 
mmol) as a pale yellow powder. 
Mp: 157.2 – 161.9 oC; Rf: 0.17 (Pet:EA 1:1);  
1H NMR (400 MHz, DMSO-d6) δH 11.06 (1H, s), 8.20 (1H, s), 7.35 (1H, d, J = 8.0 Hz), 7.26 (1H, 
d, J = 8.0 Hz), 7.24 – 7.19 (2H, m), 7.17 – 7.08 (2H, m), 6.98 (1H, app ddd, J = 8.2, 7.0, 1.2 Hz), 
6.91 – 6.81 (1H, m), 6.81 (1H, app ddd, J = 8.0, 6.9, 1.0 Hz), 4.88 (1H app t, J = 4.9 Hz, H13), 
4.27 (1H, d, J = 8.8 Hz, H10), 3.64 (1H, app td, J = 8.8, 6.1 Hz, H11), 2.81 (3H, s, H19), 2.33 (1H, 
app dt, J = 13.7, 6.1 Hz, H12), 1.84 (1H, ddd, J = 13.7, 8.8, 4.9 Hz, H12); 13C NMR (101 MHz, 
DMSO-d6) δC 179.8 C=O, 176.3 C=O, 153.3, 137.0, 130.0, 129.0, 126.3, 121.5, 121.2, 119.9, 
119.0, 117.2, 111.7, 110.0, 57.4 C13, 39.6 C10, 39.3 C11, 25.8 C19, 25.1 C12; IR(neat): υmax/cm
-1 
3374, 3306, 2919, 1683; MS (pAPCI): 108.0 (28%), 251.1 (100%), 253.1 (68%, (M-
(N(OH)Ph)+H)+), 344.1 (13%, (M-(OH)+H)+), 361.1 (3%, (M+H)+); HRMS (pAPCI): calcd 
C21H20N3O3 [M+H]
+: 362.1499; observed: 362.1501. 
Note H1 NMR ran at 40 oC 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 256  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-
methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (100 
mg, 0.20 mmol), platinum (IV) oxide (45 mg, 0.20 mmol) and THF (5 mL). The resulting 
suspension was placed under an atmosphere of H2 and stirred at room temperature for 7 
hours. The suspension was filtered through celite and the solvent was removed under 
reduced pressure to leave the crude product as a yellow solid. The crude product was 
purified by column chromatography (Petrol: Ethyl acetate 1: 1, column diameter = 2cm, 
silica = 16 cm) to give (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (87%, 65 mg, 0.17 mmol) as a pale 
orange powder. 
Mp: 179.3 – 181.0 oC; Rf: 0.60 (Pet:EA 1:1); 
1H NMR (400 MHz, DMSO-d6) δH 11.08 (1H, s, 
NH), 8.28 (1H, s, OH), 7.50 (1H, d, J = 8.0 Hz), 7.29 (1H, d, J = 8.1 Hz), 7.14 – 7.10 (1H, m), 
6.91 – 6.87 (4H, m), 6.67 (1H, app t, J = 7.4 Hz), 4.29 (1H, d, J = 8.2 Hz, H10), 4.27 (1H, app t, J 
= 3.9 Hz, H13), 3.83 – 3.74 (1H, m, H11), 2.81 (3H, s, H20), 2.65 – 2.56 (1H, m, H12), 1.98 (3H, s, 
H28), 1.67 (1H, ddd, J = 13.6, 10.5, 3.9 Hz, H12); 13C NMR (101 MHz, DMSO-d6) δC 180.0 C=O, 
176.3 C=O, 152.2, 136.7, 130.7, 130.5, 130.3, 126.5, 126.5, 124.5, 122.4, 121.2, 119.3, 118.9, 
111.7, 109.7, 58.3 C13, 40.0 C10, 38.6 C11, 27.3 C12, 25.1 C20, 18.3 C28; IR(neat): υmax/cm
-1 
3379, 2955, 2873, 1691; MS (pAPCI): 108.1 (98%), 251.1 (100%), 253.1 (61%, (M-(N(OH)2-
Tol)+H)+), 271.1 (6%, (M-(N(OH)-2-Tol)+OH2)
+), 358.2 (13%, (M-OH)+); HRMS (pAPCI): calcd 
C22H22N3O3 [M+H]
+: 376.1656; observed: 376.1658. 
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(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 257  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-
triazolidin-1-yl)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-
10(1H)-carboxylate (110 mg, 0.20 mmol), platinum (IV) oxide (46 mg, 0.20 mmol) and THF (5 
mL). The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a yellow solid. The product 
was purified by trituration from DCM to give (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-
triazolidin-1-yl)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
(91 %, 79 mg, 0.18 mmol) as an off-white solid. 
 
Mp: 262.4 – 264.0 oC; 1H NMR (400 MHz, DMSO-d6) δH 11.43 (1H, s, NH), 10.67 (1H, br s, 
NH), 7.52 – 7.42 (4H, m), 7.39-7.37 (2H, m), 7.21 (1H , d, J = 7.9 Hz), 7.06 (1H, app t, J = 7.6 
Hz), 6.94 (1H, app t, J = 7.5 Hz), 5.39 (1H, app t, J = 6.1 Hz, H21), 4.33 (1H, d, J = 8.0 Hz, H10), 
3.72 (1H, app q, J = 6.8 Hz, H11), 2.81 (3H, s, H20), 2.35 – 2.31 (2H, m, H12); 13C NMR (101 
MHz, DMSO-d6) δC 178.9 C=O, 175.8 C=O, 152.7 C=O, 152.7 C=O, 137.2, 132.3, 130.7, 129.5, 
128.5, 126.7, 125.3, 122.2, 119.9, 118.4, 112.3, 107.3, 48.1 C13, 39.5 C10, 38.3 C11, 27.7 C12, 
25.3 C20; IR(neat): υmax/cm
-1 3229, 1693; MS (pAPCI): 178.1 (35%), 253.1 (100%, (M-
(PTAD)+H)+); HRMS (ASAP) calcd C15H13N2O2 [M-PTAD+H]
+: 253.0972; observed: 253.0969. 
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(R*)-6-(hydroxy(o-tolyl)amino)-2-phenyl-6,11-dihydro-1H,5H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione – 258  
 
To a stirred Schlenk flask was added benzyl (R*)-6-(hydroxy(o-tolyl)amino)-1,3-dioxo-2-
phenyl-2,3,5,6-tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-
carboxylate (140 mg, 0.24 mmol), platinum (IV) oxide (55 mg, 0.24 mmol) and THF (5 mL). 
The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a white solid. The crude 
product was purified by trituration from DCM to give (R*)-6-(hydroxy(o-tolyl)amino)-2-
phenyl-6,11-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione 
(44 %, 46 mg, 0.11 mmol) as a white powder.  
Mp: 188.1 – 189.6 °C; 1H NMR (400 MHz, DMSO-d6) δH 11.65 (1H, s, NH), 8.58 (1H, s, OH), 
7.59 – 7.51 (5H, m), 7.47 – 7.42 (1H, m), 7.36 (1H, d, J = 8.0 Hz), 7.17 – 7.13 (1H, m), 6.96 – 
6.91 (3H, m), 6.79 – 6.69 (2H, m), 4.69 (1H, d, J = 12.8 Hz, H12), 4.58 (1H, br s, H13), 3.62 (1H, 
dd, J = 12.8, 3.3 Hz, H12), 2.06 (3H, s, H28); 13C NMR (101 MHz, DMSO-d6) δC 151.4 C
20, 150.4 
C=O, 146.8 C=O, 134.0, 131.8, 131.2, 130.6, 129.8, 129.7, 128.9, 127.0, 126.7, 126.0, 125.1, 
122.6, 121.0, 120.1, 118.1, 112.2, 92.3, 57.8 C13, 43.5 C12, 18.2 C28; IR(neat): υmax/cm
-1 = 
3426, 3380, 2950, 1712; MS (pAPCI): 108.1 (100%), 317.1 (37%, (M-(N(OH)2-Tol)+H)+), 422.2 
(4%, (M-(H2O)+H)
+), 438.2 (6%, (M-H)+); HRMS (pAPCI): calcd C25H20N5O3 [M-H]
+: 438.1561; 
observed: 438.1553. 
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(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-methoxy-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 259  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-
methoxy-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-
carboxylate (130 mg, 0.25 mmol), platinum (IV) oxide (57 mg, 0.25 mmol) and THF (5 mL). 
The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as an orange solid. The crude 
product was purified by column chromatography (Petrol: Ethyl acetate 3: 2, column 
diameter = 2cm, silica = 14 cm) to give (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-
methoxy-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (70%, 
69 mg, 0.18 mmol) as a pale yellow powder.  
Mp: 149.1 – 151.2 °C; Rf: 0.19 (Pet:EA 3:2); 
1H NMR (400 MHz, DMSO-d6) δH 10.95 (1H, s, 
NH), 8.29 (1H, s, OH), 7.23 – 7.19 (2H, m), 7.18 (1H, d, J = 2.8 Hz), 7.14 – 7.10 (2H, m), 6.87 – 
6.83 (1H, m), 6.57 (1H, dd, J = 8.7, 2.5 Hz), 6.51 (1H, d, J = 2.5 Hz), 4.83 (1H, app t, J = 4.8 Hz, 
H13), 4.24 (1H, d, J = 8.2 Hz, H10), 3.64 (1H, app td, J = 9.1, 6.1 Hz, H11), 3.48 (3H, s, H27), 2.80 
(3H, s, H28), 2.35 (1H, ddd, J = 13.7, 6.1, 4.8 Hz, H12), 1.83 (1H, ddd, J = 13.7, 9.1, 4.8 Hz, H12); 
13C NMR (101 MHz, DMSO-d6) δC 179.9 C=O, 176.3 C=O, 153.6 C
1, 153.4, 132.0, 130.6, 129.0, 
126.6, 121.2, 117.4, 112.3, 111.5, 109.5, 101.7, 57.7 C13, 55.5 C27, 39.5 C10, 39.1 C11, 27.1 C28, 
25.1 C12; IR(neat): υmax/cm
-1 =  3394, 2937, 2833, 1690; MS (pAPCI): 283.1 (100%, (M-
(N(OH)Ph)+H)+), 374.1 (18%, (M-(H2O)+H)
+), 390.1 (2%, (M-H)+), 392.2 (1%, (M+H)+); HRMS 
(pAPCI): calcd C22H22N3O4 [M+H]
+: 392.1605; observed: 392.1597. 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 260  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-
methoxy-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-
carboxylate (108 mg, 0.20 mmol), platinum (IV) oxide (46 mg, 0.20 mmol) and THF (5 mL). 
The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a white solid. The crude 
product was purified by column chromatography (Petrol: Ethyl acetate 1: 1, column 
diameter = 2 cm, silica = 15 cm) to give (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-
methoxy-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (70%, 
57 mg, 0.14 mmol) as an off white powder.  
Mp: 139.7 – 142.5 °C; Rf: 0.36 (Pet:EA 1:1); 
1H NMR (400 MHz, DMSO-d6) δH  10.89 (1H, s, 
NH), 8.36 (1H, s, OH), 7.52 (1H, d, J = 8.0 Hz), 7.15 – 7.11 (2H, d, J = 8.7 Hz), 6.93 – 6.85 (2H, 
m), 6.49 (1H, dd, J = 8.7, 2.4 Hz), 6.23 – 6.17 (1H, m), 4.28 (1H, d, J = 8.2 Hz, H10), 4.22 (1H, 
app t, J = 3.8 Hz, H13), 3.78 (1H, ddd, J = 10.8, 8.2, 6.1 Hz, H11), 3.45 (3H, s, H27), 2.81 (3H, s, 
H29), 2.70 – 2.63 (1H, m, H12), 1.89 (3H, s, H28), 1.66 (1H, ddd, J = 14.1, 10.8, 3.8 Hz, H12); 13C 
NMR (101 MHz, DMSO-d6) δC 180.1 C=O, 176.3 C=O, 153.2 C
1, 152.5 C20, 131.6, 131.1, 130.7, 
130.4, 126.8, 126.5, 124.7, 122.7, 112.2, 111.4, 109.2, 100.6, 58.8 C13, 55.3 C27, 39.6 C10, 
38.4 C11, 28.3 C12, 25.1 C29, 18.1 C28; IR(neat): υmax/cm
-1 = 3384, 2954, 2866, 1693; MS 
(pAPCI): 283.1 (100%, (M-(N(OH)2-Tol)+H)+), 388.2 (34%, (M-(H2O)+H)
+), 404.2 (13%, (M-
H)+), 406.2 (11%, (M+H)+); HRMS (pAPCI): calcd C23H24N3O4 [M+H]
+: 406.1761; observed: 
406.1750. 
  
  
                                                                                                                                        Chapter 6 - Experimental 
181 | P a g e  
 
(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 261  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-1,3-
dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (90 mg, 0.18 
mmol), platinum (IV) oxide (41 mg, 0.18 mmol) and THF (5 mL). The resulting suspension 
was placed under an atmosphere of H2 and stirred at room temperature for 10 hours. The 
suspension was filtered through celite and the solvent was removed under reduced 
pressure to leave the crude product as an yellow solid, The crude product was purified by 
column chromatography (Petrol: Ethyl acetate 1: 1, column diameter = 2 cm, silica = 14 cm) 
to give (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (41%, 26 mg, 0.07 mmol) as a yellow powder. 
Mp: 150.0 – 153.1 oC; Rf: 0.33 (Pet:EA 1:1); 
1H NMR (400 MHz, DMSO-d6) δH 11.22 (1H, s, 
NH), 11.09 (1H, s, NH), 8.24 (1H, s, OH), 7.33 (1H, d, J = 8.1 Hz), 7.27 – 7.23 (1H, m), 7.20 
(2H, app d, J = 7.3 Hz), 7.12 (2H, d, J = 7.7 Hz), 7.00 – 6.95 (1H, m), 6.85 (1H, app t, J = 7.2 
Hz), 6.80 (1H app t, J = 7.3 Hz),4.89 (1H, app t, J = 4.9 Hz, H13), 4.25 (1H, d, J = 8.1 Hz, H10), 
3.63 – 3.52 (1H, m, H11), 2.27 (1H, app dt, J = 13.6, 5.6 Hz, H12), 1.80 (1H, ddd, J = 13.6, 9.2, 
4.8 Hz, H12); 13C NMR (101 MHz, DMSO-d6) δC 181.2 C=O, 177.6 C=O, 153.3, 137.0, 130.3, 
129.0, 126.3, 121.4, 121.1, 119.9, 118.9, 117.2, 111.7, 109.9, 57.4 C13, 40.9 C10, 40.6 C11, 
25.7 C12; IR(neat): υmax/cm
-1 3302, 2924, 1706; MS (pAPCI): 108.1 (18%), 237.1 (100), 239.1 
(46%, (M-(N(OH)Ph)+H)+); HRMS (pAPCI): calcd C14H11N2O2 [M-(N(OH)Ph)+H]
+: 239.0815; 
observed: 239.0810. 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 262  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-1,3-
dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (120 mg, 0.24 
mmol), platinum (IV) oxide (54 mg, 0.24 mmol) and THF (5 mL). The resulting suspension 
was placed under an atmosphere of H2 and stirred at room temperature for 6 hours. The 
suspension was filtered through celite and the solvent was removed under reduced 
pressure to leave the crude product as a yellow solid, The crude product was purified by 
column chromatography (Petrol: Ethyl acetate 2: 3, column diameter = 2cm, silica = 17 cm) 
to give (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (70%, 61 mg, 0.17 mmol) as an off white solid. 
Mp: 149.9 – 153.2 oC; Rf: 0.52 (Pet:EA 2:3); 
1H NMR (400 MHz, CD2Cl2) δH 8.81 (1H, s, NH), 
8.21 (1H, s, NH), 7.56 (1H, d, J = 8.0 Hz), 7.30 (1H, d, J = 7.9 Hz), 7.18 (2H, d, J = 6.9 Hz), 7.06 
(1H, app t, J = 7.6 Hz), 7.03 – 6.99 (2H, m), 6.91 – 6.85 (1H, m),5.36 (1H, s, OH), 4.51 (1H, app 
t, J = 4.5 Hz, H13), 4.19 (1H, d, J = 8.6 Hz, H10), 3.80 (1H, app td, J = 9.3, 6.4 Hz, H11), 2.74 (1H, 
app dt, J = 13.6, 5.5 Hz, H12), 2.15 (3H, s, H27), 1.83 (1H, ddd, J = 13.6, 10.1, 4.1 Hz, H12); 13C 
NMR (101 MHz, DMSO-d6) δC 181.5 C=O, 177.6 C=O, 152.2, 136.7, 130.6, 130.5, 130.5, 
126.5, 126.5, 124.5, 122.4, 121.1, 119.3, 118.9, 111.6, 109.5, 58.3 C13, 55.5 C10, 40.9 C11, 
27.3 C12, 18.3 C27; IR(neat): υmax/cm
-1 3372, 3298, 1683; MS (nNSI) = 186.0 (100%), 237.1 
(97%, (M-(N(OH)-2-Tol)-H)-), 358.1 (35%, (M-H2)
-), 394.1 (23%); HRMS (nNSI): calcd 
C21H18N3O3 [M-H]
-: 360.1354; observed: 360.1348. 
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(3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 263  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-
triazolidin-1-yl)-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-
carboxylate (110 mg, 0.20 mmol), platinum (IV) oxide (46 mg, 0.20 mmol) and THF (5 mL). 
The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a white solid. The crude 
product was purified by trituration from DCM to give (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-
phenyl-1,2,4-triazolidin-1-yl)-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-
dione (64%, 53 mg, 0.13 mmol) as a white powder.  
Mp: 212.6 – 213.9 °C; 1H NMR (400 MHz, DMSO-d6) δH 11.39 (1H, s, NH), 11.36 (1H, s, NH), 
10.66 (1H, s, OH), 7.51 – 7.44 (4H, m), 7.41 – 7.37 (2H, m), 7.23 (1H, d, J = 7.8 Hz), 7.07 (1H, 
app t, J = 7.5 Hz), 6.96 (1H, app t, J = 7.5 Hz), 5.42 (1H, app t, J = 6.0 Hz, H26), 4.29 (1H, d, J = 
8.0 Hz, H10), 3.69 (1H, app q, J = 6.8 Hz, H11), 2.37 – 2.21 (2H, m, H12); 13C NMR (101 MHz, 
DMSO-d6) δC 180.3 C=O, 177.1 C=O, 152.7 C=O, 152.6 C=O, 137.2, 132.3, 131.0, 129.5, 
128.5, 126.7, 125.3, 122.2, 119.9, 118.4, 112.3, 107.1, 55.5 C13, 48.1 C10, 40.9 C11, 27.5 C12; 
IR(neat): υmax/cm
-1 = 3310, 3155, 3077, 1719, 1674; MS (pAPCI): 239.1 (100%, (M-
(PTAD)+H)+), 414.1 (2%, (M-H)+); HRMS (pAPCI): calcd C22H16N5O4 [M-H]
+: 414.1197; 
observed: 414.1185. 
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(R*)-6-(hydroxy(phenyl)amino)-2-phenyl-6,11-dihydro-1H,5H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione – 264  
 
To a stirred Schlenk flask was added benzyl (R*)-6-(hydroxy(phenyl)amino)-1,3-dioxo-2-
phenyl-2,3,5,6-tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-
carboxylate (110 mg, 0.20 mmol), platinum (IV) oxide (46 mg, 0.20 mmol) and THF (5 mL). 
The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a yellow solid. The product 
was purified by trituration from DCM to give (R*)-6-(hydroxy(phenyl)amino)-2-phenyl-6,11-
dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione (65%, 55 mg, 
0.13 mmol) as an off-white solid. 
 
Mp: 174.3 – 175.2 oC; 1H NMR (400 MHz, DMSO-d6) δH
 11.63 (1H, s, NH), 8.61 (1H, s, OH), 
7.54 – 7.38 (6H, m), 7.18 (2H, app t, J = 7.8 Hz), 7.10 (2H, app d, J = 7.8 Hz), 7.00 – 6.96 (2H, 
m), 6.91 – 6.83 (2H, m), 5.18 – 5.15 (1H, m, H13), 4.48 (1H, dd, J = 13.0, 2.0 Hz, H12), 3.77 (1H, 
dd, J = 13.0, 4.2 Hz, H12); 13C NMR (101 MHz, DMSO-d6) δC 152.6 C
16, 149.6 C=O, 146.6 C=O, 
134.2, 131.7, 129.8, 129.6, 128.9, 128.9, 127.0, 125.8, 122.3, 121.1, 120.2, 118.5, 118.3, 
112.3, 92.4, 57.4 C13, 43.4 C12; IR(neat): υmax/cm
-1 3431, 3054, 1698;MS (pAPCI): 317.1 
(100%, (M-(N(OH)Ph)+H)+), 407.1 (5%, (M-H2O)
+); HRMS (pAPCI) calcd C24H19N5O3 [M-H]
+: 
424.1404; observed: 424.1398. 
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(3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-methoxy-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 265  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-
methoxy-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate 
(131 mg, 0.25 mmol), platinum (IV) oxide (57 mg, 0.25 mmol) and THF (5 mL). The resulting 
suspension was placed under an atmosphere of H2 and stirred at room temperature for 5 
hours. The suspension was filtered through celite and the solvent was removed under 
reduced pressure to leave the crude product as an orange solid. The crude product was 
purified by column chromatography (Petrol: Ethyl acetate 1: 1, column diameter = 2 cm, 
silica = 15 cm) to give (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-7-methoxy-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60%, 57 mg, 0.15 mmol) as a pale 
orange powder.  
Mp: 146.2 – 147.9 °C; Rf. 0.22 (Pet:EA 1:1); 
1H NMR (400 MHz, DMSO-d6) δH 11.21 (1H, s, 
NH), 10.89 (1H, s, NH), 8.26 (1H, s, OH), 7.23 – 7.16 (3H, m), 7.11 (1H, d, J = 7.8 Hz), 6.85 (1H, 
app t, J = 7.2 Hz), 6.57 (1H, dd, J = 8.7, 2.4 Hz), 6.52 (1H, d, J = 2.3 Hz), 4.84 (1H, app t, J = 5.2 
Hz, H13), 4.23 (1H, d, J = 9.6 Hz, H10), 3.58 (1H, ddd, J = 14.3, 9.6, 7.5 Hz, H11), 3.49 (3H, s, 
H27), 2.33 (1H, app dt, J = 14.3, 5.2 Hz, H12), 1.82 (1H, ddd, J = 14.3, 9.6, 5.2 Hz, H12); 13C NMR 
(101 MHz, DMSO-d6) δC 181.3 C=O, 177.6 C=O, 153.6 C
1, 153.4 C20, 132.0, 130.9, 129.0, 
126.6, 121.2, 117.4, 112.3, 111.4, 109.4, 101.7, 57.7 C13, 55.6 C27, 41.0 C10, 40.5 C11, 27.0 C12; 
IR(neat): υmax/cm
-1 =  3328, 3070, 2944, 1704; MS (pAPCI): 269.1 (100%, (M-(N(OH)Ph)+H)+), 
360.1 (3%, (M-(H2O)+H)
+); HRMS (pAPCI): calcd C21H18N3O3 [M-(H2O)+H]
+: 360.1343; 
observed: 360.1334. 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 266  
 
To a stirred Schlenk flask was added benzyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-
methoxy-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate 
(98 mg, 0.19 mmol), platinum (IV) oxide (43 mg, 0.19 mmol) and THF (4.2 mL). The resulting 
suspension was placed under an atmosphere of H2 and stirred at room temperature for 5 
hours. The suspension was filtered through celite and the solvent was removed under 
reduced pressure to leave the crude product as a yellow solid.  The product was purified by 
column chromatography (Petrol: Ethyl Acetate 1: 1, column diameter = 2 cm, silica = 20 cm) 
to give (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-7-methoxy-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (85%, 63 mg, 0.16 mmol) as a yellow 
solid. 
 
Mp: 336.8 – 339.0 oC; Rf: 0.28 (Pet:EA 1:1); 
1H NMR (400 MHz, DMSO-d6) δH 11.24 (1H, s, 
NH), 10.85 (1H, s, OH), 8.34 (1H, s), 7.52 (1H, d, J = 8.0 Hz), 7.15 – 7.11 (2H, m), 6. 90 – 6.88 
(2H, m), 6.49 (1H, dd, J = 8.7, 2.4 Hz), 6.22 (1H, s),  4.27 (1H, d, J = 8.3 Hz, H10), 4.23 (1H, app 
t, J = 4.0 Hz, H13), 3.76 – 3.68 (1H, m, H11), 3.46 (3H, s, H27), 2.65 (1H, app dt, J = 13.0, 5.2 Hz, 
H12), 1.90 (3H, s, H17), 1.66 (1H, app td, J = 13.9, 12.5, 3.8 Hz, H12); 13C NMR (101 MHz, 
DMSO-d6) δC 181.6 C=O, 177.6 C=O, 153.2 C
1, 152.5 C16, 131.6, 131.1, 130.4, 126.8, 126.5, 
124.7, 122.7, 122.6, 112.2, 111.4, 109.1, 100.6, 58.8 C27, 55.3 C13, 40.9 C10, 39.7 C11, 28.2 C12, 
18.1 C28; IR(neat): υmax/cm
-1 3450, 3367, 1782, 1714; MS (pAPCI): 108.1 (100%), 374.1 (12%, 
(M-(H2O)+H)
+), 390.1 (3%, (M-H)+), 392.2 (2%, (M+H)+; HRMS (pAPCI) calcd C22H22N3O4 
[M+H]+: 392.1605; observed: 392.1596 
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(R*)-6-(hydroxy(phenyl)amino)-8-methoxy-2-phenyl-6,11-dihydro-1H,5H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione – 267  
 
To a stirred Schlenk flask was added benzyl (R*)-6-(hydroxy(phenyl)amino)-8-methoxy-1,3-
dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-
11-carboxylate (118 mg, 0.20 mmol), platinum (IV) oxide (46 mg, 0.20 mmol) and THF (5 
mL). The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a yellow solid. The product 
was purified by trituration from DCM to give (R*)-6-(hydroxy(phenyl)amino)-8-methoxy-2-
phenyl-6,11-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione 
(38%, 35 mg, 0.08 mmol) as an off-white solid. 
 
Mp: 173.7 – 176.4 oC; Rf: 0.18 (Pet:EA 3:1); 
1H NMR (400 MHz, DMSO-d6) δH  11.44 (1H, s, 
NH) 8.62 (1H, s, OH), 7.54 – 7.47 (4H, m), 7.44 – 7.41 (1H, m) 7.25 – 7.18 (3H, m), 7.12 (2H, 
d, J = 7.7 Hz), 6.90 (1H, app t, J = 6.8 Hz), 6.56 (1H, d, J = 8.7 Hz), 6.26 (1H, s), 5.12 (1H, br s, 
H12), 4.51 (1H, d, J = 13.0 Hz, H12), 3.81 (1H, dd, J = 13.0, 3.3 Hz, H12), 3.49 (3H, s, H27); 13C 
NMR (101 MHz, DMSO-d6) δC 154.3 C
1, 152.9, 149.7, 146.4, 131.8, 130.1, 129.6, 129.6, 
128.9, 128.9, 127.0, 126.3, 122.3, 118.4, 112.9, 110.7, 100.8, 92.3, 57.7 C13, 55.5 C27, 44.3 
C12; IR(neat): υmax/cm
-1 3362, 3000, 1758, 1700; MS (pAPCI): 213.1 (70%), 347.1 (100%,(M-
(N(OH)Ph)+H)+); HRMS (pAPCI): calcd C25H20N5O4 [M-H]
+: 454.1510; observed: 454.1502. 
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(R*)-6-(hydroxy(o-tolyl)amino)-8-methoxy-2-phenyl-6,11-dihydro-1H,5H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione – 268  
 
To a stirred Schlenk flask was added benzyl (R*)-6-(hydroxy(o-tolyl)amino)-8-methoxy-1,3-
dioxo-2-phenyl-2,3,5,6-tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-
11-carboxylate (120 mg, 0.20 mmol), platinum (IV) oxide (46 mg, 0.20 mmol) and THF (5 
mL). The resulting suspension was placed under an atmosphere of H2 and stirred at room 
temperature for 5 hours. The suspension was filtered through celite and the solvent was 
removed under reduced pressure to leave the crude product as a white solid. The crude 
product was purified by trituration from DCM to (R*)-6-(hydroxy(o-tolyl)amino)-8-methoxy-
2-phenyl-6,11-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione 
(64%, 53 mg, 0.13 mmol) as a white powder.  
Mp: 171.9 – 173.8 °C; 1H NMR (400 MHz, DMSO-d6) δH  11.44 (1H, s, NH), 8.64 (1H, s, OH), 
7.59 (1H, d, J = 8.1 Hz), 7.54 – 7.50 (4H, m), 7.46 – 7.43 (1H, m), 7.19 (1H, d, J = 8.5 Hz), 7.15 
(1H, d, J = 7.5 Hz), 6.97 – 6.91 (2H, m), 6.50 (1H, dd, J = 8.7, 2.2 Hz), 6.01 (1H, s), 4.73 (1H, d, 
J = 12.8 Hz, H13), 4.52 (1H, s, H12), 3.67 – 3.61 (1H, m, H12), 3.47 (3H, s, H28), 1.96 (3H, s, H27); 
13C NMR (101 MHz, DMSO-d6) δC 154.1 C
1, 151.8 C20, 150.5 C=O, 146.4 C=O, 131.8, 131.6, 
130.6, 130.0, 129.7, 128.9, 128.7, 127.0, 126.7, 126.5, 125.3, 122.8, 112.7, 110.7, 100.0, 
91.8, 58.3 C12, 55.4 C28, 44.3 C13, 18.0 C27; IR(neat): υmax/cm
-1 = 3442, 3394, 2939 (CH), 1699 
(CO); MS (pAPCI): 347.1 (68%, (M-(N(OH)2-Tol)+H)+), 391.1 (100%), 452.2 (4%, (M-
(H2O)+H)
+), 468.2 (2%, (M-H)+); HRMS (pAPCI): calcd C26H22N5O4 [M-H]
+: 468.1666; observed: 
468.1658. 
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1-(3,5-bis(trifluoromethyl)phenyl)-3-((1R)-(6-methoxyquinolin-4-yl)((2R,4R,5S)-5-
vinylquinuclidin-2-yl)methyl)thiourea – 291  
 
Into a Schlenk flask was added, (1S)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-
2-yl)methanamine (180 mg, 0.56 mmol) and THF (5 mL). To the stirred solution 3,5-
bis(trifluoromethyl)phenyl isothiocyanate (0.1 mL, 0.56 mmol) was added and the solution 
was stirred for 18 hours. The solvent was removed under reduced pressure to leave the 
crude product as a pale yellow oil. The product was purified using column chromatography 
(Ethyl acetate : Methanol, 300 : 5, column diameter = 3 cm, silica = 25 cm) to give 1-(3,5-
bis(trifluoromethyl)phenyl)-3-((1R)-(6-methoxyquinolin-4-yl)((2R,4R,5S)-5-vinylquinuclidin-2-
yl)methyl)thiourea (63%, 210 mg, 0.35 mmol) as a white powder.  
Rf: 0.07 (EA:MeOH 300:5); 
1H NMR (400 MHz, MeOD-d4) δH 8.65 (1H, d, J = 6.0 Hz, H
13), 8.09 
(s, 2H, H22), 8.01 (1H, br, H18), 7.91 (1H, d, J = 11.5 Hz, H15), 7.57 (1H, br, H25), 7.55 (1H, d, J = 
6.0 Hz, H12), 7.39 (1H, dd, J = 11.6, 3.3 Hz, H16), 6.34 (1H, d, J = 13.3 Hz, H10), 5.73 – 5.65 (1H, 
m, H2), 5.01 – 4.97 (2H, m, H1), 4.97 (2H, m, NH), 3.99 (3H, s, H20), 3.64 – 3.60 (1H, m), 3.50 – 
3.40 (1H, m), 3.33 – 3.27 (1H, m), 3.27 – 3.21 (1H, m), 2.82 – 2.72 (2H, m), 2.39 – 2.32 (1H, 
m), 1.72 – 1.58 (3H, m), 1.42 – 1.34 (1H, m), 0.94 – 0.85 (1H, m); 13C NMR (101 MHz, MeOH-
d4) δC 181.2 (C=S), 158.4 (C
17), 146.9 (C13), 146.0 (C11), 143.8 (C14), 141.7 (C21), 140.9 (C2), 
131.4 (q, C23), 129.9 (C15), 128.8 (C19), 124.7 (q, C24), 122.2 (C16), 122.0 (C22), 119.87 (C12), 
116.5 (C25), 113.9 (C1), 102.8 (C18), 60.2 (C9), 55.3 (C4), 55.2 (C20), 53.5 (C10), 41.6 (C5), 39.2 
(C3), 27.4 (C7), 27.1 (C8), 25.5 (C6); IR (cm-1): ν 3200 (NH), 2976 (CH sp2), 2890 (CH sp3), MS 
(pNSI): 595.2 (100%, (M+H)+), 617.2 (3%, (M+Na)+); HRMS (pNSI): calcd for C29H29F6N4OS 
[M+H]+: 595.1961; observed: 595.1949. 
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 (3aS*,10bS*)-2-methyl-10-(2,2,2-trifluoroacetyl)-4,10,10a,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 292  
 
Into a Schlenk flask was added, 3-vinyl-1H-indole (200 mg, 1.40 mmol), 1-methyl-1H-pyrrole-2,5-
dione (155 mg, 1.40 mmol) and DCM (5 mL). The solution was stirred at 70 oC for 3 hours before the 
reaction was cooled to room temperature and trifluoroacetic anhydride (1.47 mL, 7.0 mmol) was 
added. The solution was stirred at room temperature for 1 hour before the solution was poured into 
water and extracted with DCM (3 x 10 mL). The combined organic extracts were dried with MgSO4, 
filtered and the solvent was removed under reduced pressure to leave the crude product as a yellow 
oil. The crude product was purified using column chromatography (Petrol: Ethyl acetate 1: 1, column 
diameter = 2 cm, silica = 14 cm) to give (3aS*,10bS*)-2-methyl-10-(2,2,2-trifluoroacetyl)-
4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (92%, 452 mg, 1.29 
mmol) as an off white solid.  
MP: 214.3 – 216.3 oC; Rf: 0.20(Pet:EA, 3:1); 
1H NMR (300 MHz, CDCl3) δH 8.32 (d, J = 8.4 Hz, 
0.5H), 7.44 – 7.35 (1.5H, m), 7.32 – 7.20 (1H, m), 7.15 – 7.02 (1H, m), 6.17 (1H, dd, J = 6.9, 
3.5 Hz, H8), 5.02 – 4.89 (1H, m, H1), 4.30 (0.5H, app t, J = 8.1 Hz, H2), 3.80 (0.5H, app t, J = 8.1 
Hz, H2), 3.19 (1H, app t, J = 7.6 Hz, H6), 3.09 – 2.97 (1H, m, H7), 2.71 (3H, s, H4), 2.29 – 2.15 
(1H, m, H7); 13C NMR (75 MHz, CDCl3) δC δ 178.8 C=O, 178.3, 174.7, 173.9, 144.9, 140.9, 
137.1, 135.2, 130.5, 130.2, 127.7, 126.5, 126.0, 125.4, 121.3, 120.3, 119.1, 115.0 (C17, q), 
114.1, 113.5, 111.2, 77.5, 77.3, 77.1, 76.6, 61.4, 59.7, 42.0, 39.0, 38.2, 37.8, 25.1 25.1, 24.9; 
IR (cm-1): ν 3010 (CH), 2941 (CH), 1652 (CO); MS (pNSI): 297.1 (100%, (M+H))+), 615.2 (10%, 
(2M+Na)+); HRMS (pNSI): calcd for C17H17N2O3 [M+H]
+: 297.1234; observed: 297.1237.  
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tert-butyl (3aS*,10bS*)-2-methyl-1,3-dioxo-2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-
a]carbazole-10(1H)-carboxylate – 294  
 
In a boiling tube, 3-vinyl-1H-indole (100 mg, 0.70 mmol) was dissolved in DCM (3 mL). Into 
the stirred solution, N-methylmaleimide (78 mg, 0.70 mmol) was added and the sealed tube 
was heated at 70 oC for 2.5 hours. The solution was cooled to room temperature and di-tert-
butyl dicarbonate (0.64 mL, 2.8 mmol), triethylamine (0.39 mL, 2.8 mmol) and DMAP (17 
mg, 0.14 mmol) were added to the reaction. The reaction was stirred room temperature for 
48 hours before the solution was poured into water (20 mL), and extracted with DCM (2 x 
15 mL). The combined organic extracts were dried over MgSO4, filtered and the solvent was 
removed under reduced pressure to leave the crude product as an orange oil. The crude 
product was purified by column chromatography (Petrol: Diethyl ether: DCM 2: 1: 1), 
column diameter = 2 cm, silica = 19 cm) to give tert-butyl (3aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (57%, 142 mg, 0.40 
mmol) as a yellow powder. 
MP: 97.2 - 100.1 oC; Rf: 0.39 (Pet:Et2O:DCM, 2:1:1); 
1H NMR (300 MHz, CDCl3) δH 6.14 (1H, 
dd, J = 7.5, 3.7 Hz, H8), 4.74 (0.6H, app dt, J = 7.6, 3.1 Hz, H), 4.66 (0.4H, app dt, J = 7.8, 3.0 
Hz, H1), 4.33 (0.6H, app t, J = 8.2 Hz, H2), 4.04 (0.4 H, t, J = 8.4 Hz, H2), 3.22 – 3.02 (2H, m, H7 
+ H6), 2.80 (1.4H, s, H4), 2.79 (1.6H, s, H4), 2.27 – 2.14 (1H, m, H7), 1.70 (5H, s, H18), 1.64 (4H, 
s, H18); 13C NMR (75 MHz, CDCl3) δC 178.9 C=O, 174.6 C=O, 137.8, 130.0, 125.9, 122.3, 120.4, 
120.2, 115.9, 115.7, 111.8, 82.1 C17, 59.5 C1, 41.0 C2, 37.8 C6, 28.5 C18, 24.9 C4, 24.7 C7; IR 
(cm-1): ν 2975 (CH), 2930 (CH), 1695 (CO); MS (pNSI): 255.1 (100%, (M-(Boc)+H))+), 299.1 
(47%, (M-(C(Me3))+H)
+), 355.2 (20%, (M+H)+), 372.2 (57%, (M+(NH4)
+)), 726.4 (5%, 
(2M+(NH4)
+)); HRMS (pNSI): calcd for C20H26N3O4 [M+NH4]
+: 372.1918; observed: 372.1919. 
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tert-butyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 298  
 
To a stirred Schlenk flask was added tert-butyl (3aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (60 mg, 0.17 mmol), 
nitrosobenzene (18 mg, 0.17 mmol) and DCM (4 mL). The solution was stirred at room 
temperature for 4 hours. The solvent was removed under reduced pressure to leave the 
crude product as a pale yellow solid. The crude product was purified by column 
chromatography (Petrol: Diethyl ether: DCM 2: 1: 1,  column diameter = 1 cm, silica = 15 cm) 
to give tert-butyl (3aS*,5S*,10bS*)-5-(hydroxy(phenyl)amino)-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (47%, 37 mg, 0.08 
mmol) as a yellow powder. 
MP: 152.3 - 155.0 oC; Rf: 0.61 (Pet:Et2O:DCM, 2:1:1); 
1H NMR (400 MHz, CDCl3) δH 8.12 (d, J = 
8.0 Hz), 7.73 (1H, d, J = 7.1 Hz), 7.33 – 7.27 (3H, m), 7.22 (2H, d, J = 6.9 Hz), 7.18 – 7.14 (1H, 
m), 7.01 (1H, app t, J = 6.4 Hz), 5.02 (1H, d, J = 7.1 Hz, H2), 4.96 (1H, br s, OH), 4.80 (1H, app 
t, J = 4.7 Hz H8), 3.61 – 3.48 (1H, m, H6), 2.87 (3H, s, H4), 2.38 – 2.31 (1H, m, H7), 2.09 – 2.03 
(1H, m, H7), 1.69 (9H, s, H22); 13C NMR (101 MHz, CDCl3) δC 178.3, 174.5, 150.8, 150.1, 137.1, 
130.0, 129.0, 127.2, 124.7, 122.9, 122.2, 119.7, 117.6, 116.9, 115.2, 84.7 C21, 57.7 C8, 40.0 
H2, 39.2 H6, 27.8 C4, 24.9 C22, 22.3 C7; IR (cm-1): ν 3384 (OH), 2981 (CH), 1699 (CO); MS 
(pNSI): 253.1 (100%, (M-((N(OH)Ph)(Boc))+H)+), 353.1 (60%, (M-(N(OH)Ph))+), 360.1 (20%, 
(M-(Boc)+H)+), 460.2 (60%, (M-H)+), 462.2 (5%, (M+H)+), 923.4 (4%, 2M+H)+); HRMS (pNSI): 
calcd for C26H28N3O5 [M+H]
+: 462.2023; observed: 462.2020.  
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tert-butyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 299  
 
To a stirred Schlenk flask was added tert-butyl (3aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (100 mg, 0.28 
mmol), 2-methyl-1-nitrosobenzene (34 mg, 0.17 mmol) and DCM (4 mL). The solution was 
stirred at room temperature for 3 hours. The solvent was removed under reduced pressure 
to leave the crude product as a yellow solid. The crude product was purified by column 
chromatography (Petrol: Diethyl ether: DCM 2: 1: 1,  column diameter = 1 cm, silica = 16 cm) 
to give tert-butyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (37%, 49 mg, 0.10 
mmol) as an off white powder. 
MP: 157.9 - 159.6 oC; Rf: 0.50 (Pet:Et2O:DCM, 2:1:1); 
1H NMR (400 MHz, CDCl3) δH 8.11 (1H, 
d, J = 8.6 Hz), 7.66 (1H, d, J = 7.9 Hz), 7.57 (1H, d, J = 8.1 Hz), 7.30 – 7.24 (1H, m), 7.21 (1H, 
app t, J = 7.7 Hz), 7.16 – 7.09 (2H, m), 7.05 (1H, app t, J = 7.4 Hz), 5.08 (1H, d, J = 8.1 Hz, H2), 
4.97 (1H, br s, OH), 4.41 – 4.34 (1H, app t, J =5.7 Hz, H8), 3.67 (1H, app q, J = 7.4 Hz, H6), 2.91 
(3H, s, H4), 2.31 (3H, s, H11), 2.59 (1H, app dt, J = 12.9, 6.2 Hz, H7), 1.98 (1H, ddd, J = 12.9, 7.6, 
4.6 Hz, H7), 1.73 (9H, s, H25); 13C NMR (101 MHz, CDCl3) δC 178.6, 174.5, 150.3, 149.2, 137.0, 
131.1, 130.0, 129.8, 127.6, 126.5, 125.2, 124.7, 122.9, 121.5, 120.0, 117.6, 115.3, 84.7 C24, 
57.4 C8, 40.3 C2, 39.1 C6, 28.2 C25, 25.2 C4, 23.9 C7, 18.6 C11; IR (cm-1): ν 3474 (OH), 2981 (CH), 
2929 (CH), 1696 (CO); MS (pNSI): 253.1 (100%, (M-((N(OH)Ph)(Boc))+H)+), 353.1 (72%, (M-
(N(OH)2-Tol))+), 374.2 (38%, (M-(Boc)+H)+), 458.2 (32%, (M-(H2O)+H)
+), 474.2 (62%, (M-H)+), 
475.2 (18%, (M+H)+), 498.2 (30%, (M+Na)+),  973.4 (15%, 2M+Na)+); HRMS (pNSI): calcd for 
C27H30N3O5 [M+H]
+: 476.2180; observed: 476.2173.  
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tert-butyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-1,3-
dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate – 300  
 
To a stirred Schlenk flask was added tert-butyl (3aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (57 mg, 0.16 mmol) 
and DCM (3 mL). The solution was cooled to 0 oC before 4-phenyl-3H-1,2,4-triazole-3,5(4H)-
dione (35 mg, 0.20 mmol) was added. The solution was stirred at 0 oC for 4 hour before the 
solvent was removed under reduced pressure to leave the crude product as an orange oil. 
The crude product was purified by column chromatography (Petrol: Diethyl ether: DCM 2: 1: 
1,  column diameter = 1 cm, silica = 14 cm) to tert-butyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-
phenyl-1,2,4-triazolidin-1-yl)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-
a]carbazole-10(1H)-carboxylate (46%, 39 mg, 0.07 mmol) as a yellow powder. 
MP: 142.5 – 144.7 oC; Rf: 0.06 (Pet:Et2O:DCM, 2:1:1); 
1H NMR (400 MHz, CDCl3) δH 8.08 (1H, 
d, J = 8.4 Hz), 7.52 (1H, d, J = 7.7 Hz), 7.43 (4H, app dt, J = 13.0, 7.3 Hz), 7.38 – 7.28 (2H, m), 
7.21 (1H, app t, J = 7.5 Hz), 5.55 (1H, app t, J = 5.3 Hz, H8), 5.07 (1H, d, J = 8.0 Hz, H2), 3.61 – 
3.55 (1H, m, H6), 2.92 (3H, s, H4), 2.45 (1H, dt, J = 13.8, 5.7 Hz, H7), 2.24 (1H, ddd, J = 14.1, 
8.9, 4.3 Hz, H7), 1.68 (9H, s, H24); 13C NMR (101 MHz, CD2Cl2) δC 177.6 C=O, 173.6 C=O, 153.7, 
152.5, 150.0, 131.0, 130.8, 129.3, 128.4, 126.1, 126.0, 125.5, 125.4, 123.5, 118.8, 115.7, 
113.2, 85.3 C23, 47.9 C8, 39.9 C2, 38.4 C6, 28.2 C24, 27.4 C4, 25.3 C7; IR (cm-1): ν 3251 (NH), 
3075 (CH), 2942 (CH), 1691 (CO); MS (pNSI): 253.1 (100%, (M-((PTAD)(Boc))+H)+), 474.1 
(29%, (M-(C(Me)3+H)
+), 530.2 (30%, (M+H)+), 547.2 (100%, (M+NH4)
+), 1076.4 (14%, 
(2M+(NH4)
+); HRMS (pNSI): calcd for C28H28N5O6 [M+H]
+: 530.2034; observed: 530.2031. 
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(3aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione – 301 
 
In a boiling tube, 3-vinyl-1H-indole (0.20 g, 1.4 mmol) was dissolved in DCM (4 mL). Into the 
stirred solution, N-methylmaleimide (0.16 g, 1.4 mmol) was added and the sealed tube was 
heated at 70 oC for 2.5 hours. The solution was cooled to room temperature and acetic 
anhydride (0.66 mL, 7.0 mmol) was added to the reaction. The reaction was stirred at room 
temperature for 48 hours before the solution was poured into a solution of sodium 
bicarbonate (30 mL) and extracted with DCM (2 x 10 mL). The combined organic layers were 
dried over MgSO4, filtered and the solvent removed under reduced pressure to leave the 
crude product as a pale orange yellow solid. The crude product was purified by column 
chromatography (Petrol: Ethyl Acetate 3: 1 (300 mL) Petrol : Ethyl Acetate 1 : 1 (200 mL), 
column diameter = 2 cm, silica = 18 cm) to give (3aS*,10bS*)-10-acetyl-2-methyl-
4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (56%, 0.23 g, 0.77 
mmol) as a white powder. 
MP: 186.6 - 189.0 oC; Rf: 0.10 (Pet:EA, 1:1); 
1H NMR (400 MHz, CDCl3) δH 7.40 (1H, d, J = 7.6 
Hz), 7.27 – 7.22 (2H, m), 7.02 – 6.98 (1H, m), 6.13 (1H, app dt, J = 7.3, 3.6 Hz, H8), 4.86 (1H, 
dd, J = 6.7, 3.3 Hz, H1), 4.37 (1H, app t, J = 7.9 Hz,  H2), 3.17 (1H, t, J = 7.9 Hz, H6), 3.03 (1H, 
app dd, J = 14.3, 7.4 Hz, H7), 2.73 (3H, s, H4), 2.57 (3H, s, H17), 2.21 (1H, app ddq, J = 14.3, 
6.8, 3.4 Hz, H7); 13C NMR (101 MHz, CDCl3) δC 179.3 C=O, 175.4 C=O, 169.0 C=O, 144.0, 
136.9, 130.0, 127.4, 123.2, 121.5, 114.3, 112.7, 112.7, 59.8 C1, 40.1 C2, 38.0 C6, 25.8C4, 25.2 
C7, 25.0 C17; IR (cm-1): ν 3051 (CH), 2930 (CH), 1696 (CO); MS (pNSI): 297.1 (100%, (M+H))+), 
615.2 (10%, (2M+Na)+); HRMS (pNSI): calcd for C17H17N2O3 [M+H]
+: 297.1234; observed: 
297.1237.  
                                                                                                                                        Chapter 6 - Experimental 
196 | P a g e  
 
(3aS*,5S*,10bS*)-10-acetyl-5-(hydroxy(phenyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 303  
 
To a stirred Schlenk flask was added (3aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60 mg, 0.20 mmol), nitrosobenzene 
(22 mg, 0.20 mmol) and DCM (3 mL). The solution was stirred at room temperature for 18 
hours. The solvent was removed under reduced pressure to leave the crude product as a 
pale red solid. The crude product was purified by column chromatography (Petrol: Diethyl 
ether 2: 1,  column diameter = 1 cm, silica = 16 cm) to give (3aS*,5S*,10bS*)-10-acetyl-5-
(hydroxy(phenyl)amino)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione (64%, 52 mg, 0.13 mmol) as an off white powder. 
MP: 88.7 - 90.3 oC; Rf: 0.06 (Pet:Et2O, 2:1); 
1H NMR (400 MHz, CDCl3) δH 7.81 – 7.64 (1H, m), 
7.37 – 7.25 (2H, m), 7.25 – 7.12 (2H, m), 7.04 – 7.00 (1H, m), 5.61 (1H, br s, OH), 5.03 – 4.99 
(1H, m), 4.80 – 4.75 (1H, m), 3.54 – 3.42 (1H, m), 2.80 (6H, s, H4 + H21), 2.39 – 2.30 (1H, s), 
2.01 – 1.92 (1H, m); 13C NMR (101 MHz, CD2Cl2) δC 178.4 (C=O), 174.7 (C=O), 171.1 (C=O), 
151.0, 136.5, 130.6, 129.0, 128.0, 124.8, 123.0, 122.3, 120.5, 118.7, 117.1, 114.1, 57.8 C8, 
39.9 C2, 39.2 C6, 27.3 C21, 24.9 C4, 22.6 C7; IR (cm-1): ν 3359 (OH), 2956 (CH), 2859 (CH), 1695 
(CO); MS (pNSI): 295.1 (34%, (M-(N(OH)Ph))+), 426.1 (100%, (M+Na)+), 807.3 (16%, (2M+H)+), 
829.3 (36%, (2M+Na)+); HRMS (pNSI): calcd for C23H21N3O4Na [M+Na]
+: 426.1424; observed: 
426.1424.  
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(3aS*,5S*,10bS*)-10-acetyl-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 304  
 
To a stirred Schlenk flask was added (3aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60 mg, 0.20 mmol), 2-mehtyl-1-
nitrosobenzene (25 mg, 0.20 mmol) and DCM (3 mL). The solution was stirred at room 
temperature for 18 hours. The solvent was removed under reduced pressure to leave the 
crude product as a pale yellow solid. The crude product was purified by column 
chromatography (Petrol: Ethyl Acetate 3: 1,  column diameter = 1 cm, silica = 14 cm) to give 
(3aS*,5S*,10bS*)-10-acetyl-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (75%, 63 mg, 0.15 mmol) as a pale 
yellow powder. 
MP: 104.7 - 106.5 oC; Rf: 0.50 (Pet:EA, 1:1); 
1H NMR (400 MHz, CDCl3) δH  7.68 (1H, d, J = 8.4 
Hz), 7.57 (1H, d, J = 8.1 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.27 (1H, d, J = 7.7 Hz), 7.20 (1H, app td, J 
= 8.1, 7.5, 2.1 Hz), 7.11 (1H, app t, J = 7.6 Hz), 7.08 – 7.01 (2H, m), 5.28 (1H, br s, OH), 5.18 
(1H, d, J = 8.1 Hz, H2), 4.38 (1H, dd, J = 6.0, 4.5 Hz, H8), 3.70 (1H, app td, J = 8.1, 5.6 Hz, H2), 
2.65 (1H, app dt, J = 13.5, 5.9 Hz, H7), 2.25 (3H, s, H10), 1.88 (1H, ddd, J = 13.5, 8.4, 4.4 Hz, 
H7); 13C NMR (101 MHz, CD2Cl2) δC 178.7 C=O, 174.8 C=O, 171.3 C=O, 149.5, 136.0, 130.9, 
130.9, 130.1, 128.2, 126.6, 125.3, 124.6, 122.9, 121.7, 120.6, 118.1, 113.6, 57.5 C8, 40.2 C2, 
38.9 C6, 29.8 C7, 27.4 C23, 25.1 C10; IR (cm-1): ν 3379 (OH), 3008 (CH), 2922 (CH), 1691 (CO); 
MS (pNSI): 295.1 (21%, (M-(N(OH)o-Tol))+), 440.2 (100%, (M+Na)+), 857.3 (16%, (2M+Na)+); 
HRMS (pNSI): calcd for C24H23N3O4Na [M+Na]
+: 440.1581; observed: 440.1581. 
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(3aS*,5S*,10bS*)-10-acetyl-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 305  
 
To a stirred Schlenk flask was added (3aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60 mg, 0.20 mmol) and DCM (3 mL). 
The solution was cooled to 0 oC before 4-phenyl-3H-1,2,4-triazole-3,5(4H)-dione (35 mg, 
0.20 mmol) was added. The solution was stirred at 0 oC for 1 hour before the solvent was 
removed under reduced pressure to leave the crude product as an orange oil. The crude 
product was purified by column chromatography (Petrol: Ethyl Acetate 1: 1,  column 
diameter = 1 cm, silica = 15 cm) to give (3aS*,5S*,10bS*)-10-acetyl-5-(3,5-dioxo-4-phenyl-
1,2,4-triazolidin-1-yl)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-
dione (57%, 54 mg, 0.11 mmol) as an orange powder. 
MP: 238.4 - 240.1 oC; Rf: 0.07 (Pet:EA, 1:1); 
1H NMR (400 MHz, CDCl3) δH 8.80 (1H, br s, NH), 
7.62 (1H, d, J = 8.4 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.46 – 7.41 (2H, m), 7.41 – 7.36 (2H, m), 7.33 
– 7.28 (2H, m), 7.29 – 7.24 (1H, m), 5.57 (1H, app t, J = 4.8 Hz, H8), 5.07 (1H, d, J = 7.9 Hz, H2), 
3.62 – 3.49 (1H, m, H2), 2.88 (3H, s, H4), 2.69 (3H, s, H23), 2.53 – 2.43 (1H, m, H7), 2.09 (1H, 
ddd, J = 14.7, 10.4, 5.4 Hz, H7); 13C NMR (101 MHz, CD2Cl2) δC 177.6, 173.9, 154.5, 153.6, 
152.1, 136.2, 131.6, 131.0, 129.3, 128.5, 126.7, 125.7, 125.6, 125.4, 123.5, 119.4, 113.9, 
47.2, 39.9, 38.3, 28.0, 27.1, 25.2; IR (cm-1): ν 3255 (NH), 3080 (CH), 2932 (CH), 1693 (CO); MS 
(pNSI): 295.1 (44%, (M-(PTAD)+), 472.2 (100%, (M+H)+), 489.2 (81%, (M+(NH4))
+), 960.3 
(35%, (2M+(NH4)
+)); HRMS (pNSI): calcd for C25H22N5O5 [M+H]
+: 472.1615; observed: 
472.1606. 
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(1S)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanamine – 306  
 
Into a Schlenk flask, quinine (0.50 g, 1.54 mmol), triphenylphoshine (0.49 g, 1.84 mmol) and 
THF (30 mL) were added. The solution was cooled to 0 oC and diisopropyl azodicarboxylate 
(0.36 mL, 1.84 mmol) was added. In a separate flask, a solution of diphenyl phosphoryl azide 
(0.39 mL, 1.84 mmol) in THF (10 mL) was prepared. The solution was added to the Schlenk 
flask dropwise and the resulting solution was warmed to room temperature and stirred for 
18 hours. The reaction was heated to 55 oC for 2 hours before triphenylphosphine (0.49 g, 
1.84 mmol) was added. Heating was maintained until gas evolution had ceased (2 hours). 
The reaction was cooled to room temperature and water (1 mL) was added and the solution 
stirred for a further 3 hours. The solvent was removed under reduced pressure and the 
residue was dissolved in DCM:HCl (20 mL). The aqueous phase was washed with DCM and 
then made alkaline with NaOH (10 mL) and washed with DCM (20 mL). The organic layer 
was dried with NaSO4, filtered, and the solvent was removed under reduced pressure to 
leave the crude product as a white powder. The crude product was purified using column 
chromatography (Methanol: Ethyl acetate: Ammonium hydroxide, 50: 50: 1, column 
diameter = 3 cm, silica = 20 cm) to give (1S)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-
vinylquinuclidin-2-yl)methanamine (44%, 220 mg, 0.668 mmol) as a pale orange oil.  
Rf: 0.08 (MeOH:EA, 1:1); 
1H NMR (400 MHz, MeOD-d4) δH 8.69 (1H, d, J = 4.7 Hz, H
7), 7.97 
(1H, d, J = 9.2 Hz, H9), 7.68 (1H, br, H3), 7.61 (1H, d, J = 4.7 Hz, H6), 7.44 (1H, dd, J = 9.2, 2.7 
Hz, H10), 5.92 - 5.90 (1H, m, H19), 5.06 - 4.96 (2H, m, H20), 4.92 (2H, br, NH2), 4.74 (1H, d, J = 
10.1 Hz, H11), 4.00 (3H, s, H1), 3.39 - 3.14 (3H, m), 2.87 - 2.76 (2H, m), 2.38 - 2.24 (1H, m), 
1.61 - 1.56 (3H, m), 1.48 - 1.40 (1H, m), 0.75 - 0.68 (1H, m); 13C NMR (101 MHz, MeOD-d4) δC 
158.4 (C2), 147.9 (C5), 147.1 (C7), 143.8 (C8), 141.6 (C19), 130.2 (C9), 129.0 (C4), 122.1 (C10), 
119.8 (C6), 113.6 (C20), 101.5 (C3), 62.0 (C12), 55.8 (C17), 55.0 (C1), 51.1 (C11), 40.4 (C16), 39.7 
(C18), 27.7 (C15), 27.6 (C13), 25.7 (C14);  IR (cm-1): ν 3620 (NH), 2937 (CH), 2866 (CH), 1228 
(CO). 
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(3aS*,10bS*)-2methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione - 148 
 
Table 1.  Crystal data and structure refinement for mjh80. 
 
Identification code  mjh80 
Chemical formula (moiety) C22H20N2O4S 
Chemical formula (total) C22H20N2O4S 
Formula weight  408.46 
Temperature  150(2) K 
Radiation, wavelength  MoK , 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 10.5141(8) Å  = 90° 
 b = 17.9454(11) Å  = 113.865(9)° 
 c = 11.0976(8) Å  = 90° 
Cell volume 1914.9(2) Å3 
Z 4 
Calculated density  1.417 g/cm3 
Absorption coefficient  0.202 mm1 
F(000) 856 
Crystal colour and size colourless, 0.30  0.30  0.30 mm3 
Reflections for cell refinement 3401 (  range 3.0 to 28.4°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 28.5° 
Index ranges h 13 to 10, k 23 to 21, l 14 to 13 
Completeness to  = 25.0° 99.8 %  
Reflections collected 10008 
Independent reflections 4083 (Rint = 0.0256) 
Reflections with F2>2  3395 
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Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9419 and 0.9419 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0407, 1.1952 
Data / restraints / parameters 4083 / 0 / 265 
Final R indices [F2>2 ] R1 = 0.0408, wR2 = 0.0939 
R indices (all data) R1 = 0.0522, wR2 = 0.1012 
Goodness-of-fit on F2 1.040 
Extinction coefficient 0.0023(7) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.35 and 0.43 e Å3 
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(3aS*,10aS*,10bS*)-2-phenyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione – 149 
 
Table 1.  Crystal data and structure refinement for mjh120022. 
 
Identification code  mjh120022 
Chemical formula (moiety) C27H22N2O4S 
Chemical formula (total) C27H22N2O4S 
Formula weight  470.53 
Temperature  150(2) K 
Radiation, wavelength  MoK , 0.71073 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 10.5762(6) Å  = 90° 
 b = 20.2985(8) Å  = 116.781(7)° 
 c = 11.4519(6) Å  = 90° 
Cell volume 2194.79(19) Å3 
Z 4 
Calculated density  1.424 g/cm3 
Absorption coefficient  0.187 mm1 
F(000) 984 
Crystal colour and size colourless, 0.30  0.30  0.20 mm3 
Reflections for cell refinement 4397 (  range 2.9 to 28.4°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 28.5° 
Index ranges h 10 to 14, k 21 to 26, l 15 to 15 
Completeness to  = 25.0° 99.8 %  
Reflections collected 13075 
Independent reflections 4661 (Rint = 0.0310) 
Reflections with F2>2  3757 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9461 and 0.9636 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
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Weighting parameters a, b 0.0413, 0.9706 
Data / restraints / parameters 4661 / 0 / 309 
Final R indices [F2>2 ] R1 = 0.0410, wR2 = 0.0901 
R indices (all data) R1 = 0.0566, wR2 = 0.0993 
Goodness-of-fit on F2 1.040 
Extinction coefficient 0.0022(6) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.32 and 0.48 e Å3 
  
                                                                                                                                                                  Appendix I 
208 | P a g e  
 
2-phenyl-11-tosyl-11,11a-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-
1,3(2H)-dione - 151 
 
Table 1.  Crystal data and structure refinement for mjh105. 
 
Identification code  mjh105 
Chemical formula (moiety) C25H20N4O4S·0.5CH2Cl2 
Chemical formula (total) C25.50H21ClN4O4S 
Formula weight  514.97 
Temperature  150(2) K 
Radiation, wavelength  CuK , 1.54178 Å 
Crystal system, space group  monoclinic, P21/c 
Unit cell parameters a = 6.2586(2) Å  = 90° 
 b = 43.8481(9) Å  = 93.143(2)° 
 c = 17.0987(3) Å  = 90° 
Cell volume 4685.3(2) Å3 
Z 8 
Calculated density  1.460 g/cm3 
Absorption coefficient  2.634 mm1 
F(000) 2136 
Crystal colour and size colourless, 0.30  0.30  0.10 mm3 
Reflections for cell refinement 5338 (  range 2.0 to 62.3°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.0 to 62.3° 
Index ranges h 3 to 6, k 41 to 49, l 19 to 19 
Completeness to  = 62.3° 96.9 %  
Reflections collected 13837 
Independent reflections 7206 (Rint = 0.0228) 
Reflections with F2>2  5704 
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Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5055 and 0.7787 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0522, 9.6468 
Data / restraints / parameters 7206 / 0 / 641 
Final R indices [F2>2 ] R1 = 0.0566, wR2 = 0.1451 
R indices (all data) R1 = 0.0705, wR2 = 0.1532 
Goodness-of-fit on F2 1.086 
Extinction coefficient 0.00006(3) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.40 and 0.41 e Å3 
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Table 1.  Crystal data and structure refinement for mjh12. 
 
Identification code  mjh120038 
Chemical formula (moiety) C22H19BrN2O4S·0.5CH2Cl2 
Chemical formula (total) C22.50H20BrClN2O4S 
Formula weight  529.83 
Temperature  150(2) K 
Radiation, wavelength  CuK , 1.54178 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 6.5785(2) Å  = 90° 
 b = 25.1833(8) Å  = 93.607(2)° 
 c = 13.7502(4) Å  = 90° 
Cell volume 2273.46(12) Å3 
Z 4 
Calculated density  1.548 g/cm3 
Absorption coefficient  4.681 mm1 
F(000) 1076 
Crystal colour and size colourless, 0.30  0.30  0.04 mm3 
Reflections for cell refinement 5759 (  range 1.8 to 67.2°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.5 to 66.7° 
Index ranges h 7 to 7, k 26 to 29, l 16 to 10 
Completeness to  = 33.5° 100.0 %  
Reflections collected 13891 
Independent reflections 3990 (Rint = 0.0325) 
Reflections with F2>2  3461 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.3341 and 0.8349 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0758, 3.2435 
Data / restraints / parameters 3990 / 2 / 298 
                                                                                                                                                                  Appendix I 
211 | P a g e  
 
Final R indices [F2>2 ] R1 = 0.0447, wR2 = 0.1252 
R indices (all data) R1 = 0.0518, wR2 = 0.1322 
Goodness-of-fit on F2 1.056 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.10 and 0.50 e Å3 
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6-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-phenyl-11-tosyl-6,11-dihydro-1H,5H-
[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione – 191  
 
Table 1 Crystal data and structure refinement for mjh140002.  
Identification code  mjh140002  
Empirical formula  C33H25N7O6S  
Formula weight  647.66  
Temperature/K  150.00(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  13.1236(3)  
b/Å  20.8432(5)  
c/Å  12.0391(2)  
α/°  90  
β/°  100.991(2)  
γ/°  90  
Volume/Å3  3232.74(13)  
Z  4  
ρcalcmg/mm
3  1.331  
m/mm-1  1.360  
F(000)  1344.0  
Crystal size/mm3  0.25 × 0.1 × 0.06  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection  6.862 to 132.494°  
Index ranges  -14 ≤ h ≤ 15, -24 ≤ k ≤ 24, -14 ≤ l ≤ 10  
Reflections collected  23327  
Independent reflections  5646 [Rint = 0.0383, Rsigma = 0.0297]  
Data/restraints/parameters  5646/0/428  
Goodness-of-fit on F2  1.036  
Final R indexes [I>=2σ (I)]  R1 = 0.0357, wR2 = 0.0863  
Final R indexes [all data]  R1 = 0.0464, wR2 = 0.0927  
Largest diff. peak/hole / e Å-3  0.35/-0.36 
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(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 200  
 
Table 1.  Crystal data and structure refinement for mjh12. 
 
Identification code  mjh120026 
Chemical formula (moiety) C28H23N3O5S·CH2Cl2 
Chemical formula (total) C29H25Cl2N3O5S 
Formula weight  598.48 
Temperature  150(2) K 
Radiation, wavelength  CuK , 1.54178 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 10.0614(5) Å  = 104.231(4)° 
 b = 10.2208(5) Å  = 95.071(4)° 
 c = 15.2649(7) Å  = 109.240(4)° 
Cell volume 1411.79(12) Å3 
Z 2 
Calculated density  1.408 g/cm3 
Absorption coefficient  3.133 mm1 
F(000) 620 
Reflections for cell refinement 7995 (  range 3.0 to 66.9°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 67.0° 
Index ranges h 11 to 11, k 11 to 12, l 17 to 18 
Completeness to  = 67.0° 98.6 %  
Reflections collected 13046 
Independent reflections 4954 (Rint = 0.0293) 
Reflections with F2>2  4280 
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Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.86739 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0620, 1.1284 
Data / restraints / parameters 4954 / 0 / 336 
Final R indices [F2>2 ] R1 = 0.0485, wR2 = 0.1283 
R indices (all data) R1 = 0.0546, wR2 = 0.1315 
Goodness-of-fit on F2 1.093 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.67 and 0.37 e Å3 
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(3aS*,5S*,10bS*)-5-((R)-hydroxy(perfluorophenyl)methyl)-2-methyl-10-tosyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione – 215  
 
Table 1.  Crystal data and structure refinement for mjh12. 
 
Identification code  mjh120042 
Chemical formula (moiety) C24H20F5N3O5S 
Chemical formula (total) C24H20F5N3O5S 
Formula weight  557.49 
Temperature  150(2) K 
Radiation, wavelength  MoK , 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 7.9070(4) Å  = 90° 
 b = 14.2862(7) Å  = 101.016(5)° 
 c = 20.6839(10) Å  = 90° 
Cell volume 2293.4(2) Å3 
Z 4 
Calculated density  1.615 g/cm3 
Absorption coefficient  0.227 mm1 
F(000) 1144 
Reflections for cell refinement 5543 (  range 2.8 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.8 to 28.6° 
Index ranges h 10 to 10, k 18 to 18, l 26 to 24 
Completeness to  = 25.0° 99.2 %  
Reflections collected 23890 
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Independent reflections 5125 (Rint = 0.0596) 
Reflections with F2>2  3582 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.98002 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0401, 1.5195 
Data / restraints / parameters 5125 / 0 / 351 
Final R indices [F2>2 ] R1 = 0.0492, wR2 = 0.0953 
R indices (all data) R1 = 0.0864, wR2 = 0.1108 
Goodness-of-fit on F2 1.027 
Extinction coefficient 0.0001(5) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.34 and 0.37 e Å3 
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(3aS,10bS)-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione – 256  
 
Table 1 Crystal data and structure refinement for MJH130014  
 
Identification code  MJH130014  
Empirical formula  C22H21N3O3  
Formula weight  375.42  
Temperature/K  150.01(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.4756(2)  
b/Å  9.6962(3)  
c/Å  12.5017(3)  
α/°  68.321(3)  
β/°  71.529(3)  
γ/°  81.860(2)  
Volume/Å3  905.20(5)  
Z  2  
ρcalcmg/mm
3  1.377  
m/mm-1  0.756  
F(000)  396.0  
Crystal size/mm3  0.5681 × 0.5364 × 0.2474  
2Θ range for data collection  7.94 to 132.56°  
Index ranges  -10 ≤ h ≤ 10, -11 ≤ k ≤ 11, -14 ≤ l ≤ 14  
Reflections collected  30625  
Independent reflections  3153[R(int) = 0.0292]  
Data/restraints/parameters  3153/0/326  
Goodness-of-fit on F2  1.075  
Final R indexes [I>=2σ (I)]  R1 = 0.0365, wR2 = 0.0921  
Final R indexes [all data]  R1 = 0.0373, wR2 = 0.0928  
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Largest diff. peak/hole / e Å-3  0.19/-0.28  
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 Vitamin A defi ciency is a major public health issue in 
the developing world due to inadequate intake of both 
preformed vitamin A and provitamin A carotenoids in the 
diet ( 1 ). However, detection of subclinical defi ciency is 
problematic because   85% of vitamin A is stored in the 
liver while the level of vitamin A circulating in the blood is 
under strict homeostatic control and not indicative of he-
patic reserves ( 2 ). Increasing the intake of provitamin A 
carotenoids, primarily through   -carotene, is seen as a safe 
way of restoring the vitamin A reserves of an individual 
because high doses of preformed vitamin A have adverse 
health effects ( 3 ). Although the current vitamin A equiva-
lency ratio for   -carotene is estimated at 12:1 (by weight) 
( 4 ), large inter-individual variations in both absorption 
and conversion have been observed ( 5–8 ). 
 In the intestinal mucosa, a proportion of absorbed 
  -carotene undergoes centric cleavage by the   -carotene 
15,15 ′ -monooxygenase 1 (BCMO1) enzyme to produce 
two molecules of retinal which are further reduced to 
retinol (vitamin A) ( 9 ). For export into the circulation, 
retinol is esterifi ed to a long chain fatty acid, typically 
palmitate, and incorporated, along with intact   -carotene, 
into chylomicrons ( 10 ). Subsequently, retinyl esters are ei-
ther stored in hepatic stellate cells or hydrolyzed back to 
retinol by the liver for repartition to other tissue compart-
ments bound to retinol binding protein (RBP). 
 Currently, stable isotope dilution offers the most accu-
rate determination of   -carotene bioeffi cacy and vitamin 
A status irrespective of high endogenous circulating levels 
of these micronutrients ( 1, 2 ). However, the minimum 
dose to be administered has been dictated by the detection 
limit of the analytical method ( 2 ). Furthermore, isolation 
 Abstract  Isotope dilution is currently the most accurate 
technique in humans to determine vitamin A status and bio-
availability/bioconversion of provitamin A carotenoids such 
as   -carotene. However, limits of MS detection, coupled 
with extensive isolation procedures, have hindered investi-
gations of physiologically-relevant doses of stable isotopes 
in large intervention trials. Here, a sensitive liquid chroma-
tography-tandem mass spectrometry (LC/MS/MS) analyti-
cal method was developed to study the plasma response 
from coadministered oral doses of 2 mg [ 13 C 10 ]  -carotene 
and 1 mg [ 13 C 10 ]retinyl acetate in human subjects over a 2 
week period. A reverse phase C 18 column and binary mobile 
phase solvent system separated   -carotene, retinol, retinyl 
acetate, retinyl linoleate, retinyl palmitate/retinyl oleate, and 
retinyl stearate within a 7 min run time. Selected reaction mon-
itoring of analytes was performed under atmospheric pres-
sure chemical ionization in positive mode at  m/z 537 → 321 
and  m/z 269 → 93 for respective [ 12 C]  -carotene and [ 12 C] 
retinoids;  m/z 547 → 330 and  m/z 274 → 98 for [ 13 C 10 ]  -carotene 
and [ 13 C 5 ] cleavage products; and  m/z 279 → 100 for metabo-
lites of [ 13 C 10 ]retinyl acetate. A single one-phase solvent ex-
traction, with no saponifi cation or purifi cation steps, left 
retinyl esters intact for determination of intestinally-derived 
retinol in chylomicrons versus retinol from the liver bound 
to retinol binding protein.  Coadministration of [ 13 C 10 ]
retinyl acetate with [ 13 C 10 ]  -carotene not only acts as a refer-
ence dose for inter-individual variations in absorption and 
chylomicron clearance rates, but also allows for simulta-
neous determination of an individual’s vitamin A status. —
Oxley, A., P. Berry, G. A. Taylor, J. Cowell, M. J. Hall, J. 
Hesketh, G. Lietz, and A. V. Boddy.  An LC/MS/MS method 
for stable isotope dilution studies of   -carotene bioavailabil-
ity, bioconversion, and vitamin A status in humans.  J. Lipid 
Res. 2014. 55:  319–328. 
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 Synthesis of retinyl esters 
 Retinyl esters were synthesized via an enzyme-catalyzed trans-
esterifi cation ( 19 ) as follows. Into a dry Schlenk fl ask, retinyl ac-
etate (33 mg, 0.10 mmol), Novozyme 435 (120 mg), and Aberlyst 
A-21 (50 mg) were suspended in dry toluene (5 ml). The reaction 
mixture was stirred under an atmosphere of N 2 , and fi ve equiva-
lents (0.50 mmol) of the appropriate acid (palmitic, stearic, lino-
leic, or oleic) were added. After 20 h at room temperature, the 
reaction mixture was fi ltered and the solvent was removed under 
reduced pressure to give a mixture (approximately 1:4) of the 
desired retinyl ester and unreacted acid. The resulting mixtures 
were used without further purifi cation as LC/MS/MS standards 
for the corresponding retinyl esters. 
 Subjects and blood collection 
 Healthy male and female volunteers with an age range of 18–45 
years were recruited into the “BetaSNP” dietary intervention study 
where written informed consent was obtained. Exclusion criteria 
were: pregnancy, smoking, high blood pressure, diabetes, BMI >30, 
liver/kidney/gastrointestinal disease, lipid metabolic disorders, 
and consumption of multivitamins (containing vitamins A, C, E) or 
  -carotene supplements 3 months prior to the study start. The study 
was conducted according to the guidelines set forth in the Declara-
tion of Helsinki, and all procedures involving human subjects were 
approved by the National Research Ethics Service (NRES), North 
East - Sunderland Committee (REC 09/H0904/20) before registra-
tion with the UK Clinical Research Network (UKCRN: 7413). The 
[ 13 C 10 ]  -carotene and [ 
13 C 10 ]retinyl acetate were prepared for oral 
administration in sunfl ower oil, at respective concentrations of 2 mg 
ml –1 and 1 mg ml –1 , by sonication in amber bottles at room tempera-
ture for 30 min. Oil solutions were then stored in sterile 1 ml tip-
cap amber oral syringes (Becton Dickinson, Oxford, UK) and 
used within 1 week of preparation. Fasted subjects were cannulated 
via the antecubital vein and blood was drawn into 10 ml EDTA Vacu-
tainer tubes (Becton Dickinson). Subjects then received the dual 
isotopic oral dose of 2 mg [ 13 C 10 ]  -carotene and 1 mg [ 
13 C 10 ]retinyl 
of carotenoids/retinoids from the plasma matrix for MS 
analysis often involves extensive and time-consuming 
extraction/purifi cation procedures that have included: 
saponifi cation, solid-phase extraction, preparative HPLC, 
and, in the case of GC-MS analysis, further conversion to 
 tert -butyl-dimethylsilyl derivatives ( 11–18 ). The aim was to 
develop an analytical method that involved a simplifi ed 
extraction procedure, sensitive MS/MS for detection of 
physiological doses of stable isotopes, and short LC run-
times so as to be suitable for high-throughput of samples 
from human intervention studies. 
 MATERIALS AND METHODS 
 Chemicals 
 The following carotenoid and retinoid (>95% all- trans ) stan-
dards were purchased from Sigma (St. Louis, MO):   -carotene, 
lycopene, retinol, retinyl acetate, and retinyl palmitate. The [12-, 
12 ′ -, 13-, 13 ′ -, 14-, 14 ′ -, 15-, 15 ′ -, 20-, 20 ′ - 13 C 10 ]  -carotene and [8-, 9-, 
10-, 11-, 12-, 13-, 14-, 15-, 19-, 20- 13 C 10 ]retinyl acetate ( Fig. 1 ) to 
be administered to human subjects were custom synthesized by 
Buchem BV (Apeldoorn, The Netherlands) and certifi ed fi t for 
human consumption. Similarly, the [8-, 8 ′ -, 9-, 9 ′ -, 10-, 10 ′ -, 11-, 11 ′ -, 
12-, 12 ′ -, 13-, 13 ′ -, 14-, 14 ′ -, 15-, 15 ′ -, 19-, 19 ′ -, 20-, 20 ′ - 13 C 20 ]  -
carotene, [12-, 13-, 14-, 15-, 20- 13 C 5 ]retinol, and [10-, 19-, 19-, 
19-d4]retinyl palmitate stable isotopes ( Fig. 1 ) were also purchased 
from Buchem BV. Methanol, propan-2-ol, chloroform, ethanol, 
ethyl acetate, toluene, and acetic acid were all of HPLC grade and 
purchased from Fisher Scientifi c (Loughborough, UK). Butylated 
hydroxytoluene (BHT), Novozyme 435, and ammonium acetate 
were obtained from Sigma-Aldrich (St. Louis, MO). Aberlyst A-21, 
linoleic acid, oleic acid, and stearic acid for synthesis of retinyl es-
ters were obtained from Alfa Aesar (Heysham, Lancashire, UK). 
 Fig.  1.   -carotene and retinyl acetate metabolism. Position of [ 13 C] labels are shown for [ 13 C 10 ]  -carotene and [ 
13 C 10 ]retinyl acetate, and derived 
metabolites. Inserts show the [ 13 C 20 ]  -carotene and d4-retinyl palmitate used for method validation. Asterisks (*) denote position of [ 
13 C] labels. 
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returned to 80% B for 3 min to re-equilibrate. Flow rate was 
1.0 ml min   1 with an injection volume of 10   l. 
 An API4000 triple quadrupole LC/MS/MS (Applied Biosystems, 
Carlsbad, CA) was used for analysis with atmospheric pressure 
chemical ionization (APCI) performed in positive ion mode using 
nitrogen gas with the following optimum settings: collision gas, 7; 
curtain gas, 10; ion source gas 1, 60; ion source gas 2, 15. Tempera-
ture of the heated nebulizer was 400°C with an ionspray voltage of 
5,500. Optimization of MS/MS parameters for all analytes was per-
formed by selecting precursor ions of [M+H] + for   -carotene, 
[M+H-18] + for retinol, [M+H-256] + for retinyl palmitate, and 
[M+H-60] + for retinyl acetate to obtain product ion spectra. Quanti-
tation of analytes was performed in selected reaction monitoring 
(SRM) mode; mass transitions and optimized MS/MS parameters 
are given in  Table 1 . Analyst® software v1.4.1 (AB SCIEX, Framing-
ham, MA) was used for SRM, peak integration, and analyte quantita-
tion. Peak areas were adjusted according to internal standard 
recovery ([ 13 C 10 ]retinyl acetate for retinoids and [ 
13 C 20 ]  -carotene 
for carotenes) and quantifi ed against external calibration curves of 
[ 12 C]  -carotene, [ 12 C]retinol, and [ 12 C]retinyl palmitate ( Table 2 ). 
 LC/MS/MS validation 
 The [ 12 C] species of   -carotene, retinol, and retinyl palmitate 
were used to assess linear dynamic ranges, limits of detection, limits 
of quantitation, intra-/inter-day assay precision, and to construct ex-
ternal calibration curves. Stock solutions of   -carotene and retinyl 
palmitate were prepared in chloroform containing 0.1% BHT at 
respective concentrations of 0.2 mg ml   1 and 1.0 mg ml   1 . Retinol 
was dissolved in ethanol containing 0.1% BHT at 1.0 mg ml   1 . Stock 
solutions were diluted in ethanol for spectrophotometric deter-
mination of absolute concentration at   max 450 nm for   -carotene 
and   max 325 nm for retinol and retinyl palmitate. Concentrations 
were calculated from published extinction coeffi cients (E 1% 1cm ) for 
these compounds in ethanol ( 20, 21 ). A standard mix of analytes 
was prepared in ethanol to study linear dynamic range via serial dilu-
tion (11   M–5 nM), and for determination of intra- and inter-day 
assay precision (1   M) through multiple injections. 
 RESULTS 
 APCI in positive mode offered greater linear dynamic 
range for both   -carotene and retinoids compared with 
electrospray ionization (ESI). APCI of retinoids resulted 
in the elimination of terminal functional groups to produce 
acetate along with a standardized breakfast meal consisting of a muf-
fi n and yogurt smoothie. The meal was designed to refl ect the same 
nutrient content as described by Borel et al. ( 5 ) containing 46.3 g of 
fat (55.5% of total energy intake). Blood was subsequently collected 
at 2, 4, 6, 8, 10, and 12 h postdose via cannulation, and at 24, 48, 168, 
and 336 h by simple venipuncture. Each blood sample was immedi-
ately centrifuged at 4°C upon collection and the plasma stored at 
  80°C until analysis. 
 Plasma extraction and analyte recovery 
 An ethanol/ethyl acetate (1:1) solvent extraction was applied 
to plasma samples to ensure adequate recovery of all analytes 
without coextraction of lipids known to interfere with LC/MS 
analyses. All extraction procedures were performed under yel-
low lighting. To 1 ml of plasma, 10   l (50 pmol) each of the 
[ 13 C 10 ]retinyl acetate and [ 
13 C 20 ]  -carotene internal standards 
were added before denaturing with 5 ml of ethanol and 5 ml of 
ethyl acetate. The sample was then shaken on an orbital shaker 
for 10 min and centrifuged at 10,000 rpm for 30 min at 4°C. 
The supernatant was transferred to a clean glass tube and the 
solvent evaporated to dryness under a stream of nitrogen. The 
residue was resuspended in 100   l of ethyl acetate, by vortexing 
briefl y, and transferred to amber glass vials ready for LC/MS/MS 
injection. 
 Due to endogenous levels of [ 12 C]  -carotene, retinol, and reti-
nyl palmitate always being present in “control” plasma, recovery 
of target analytes from the plasma matrix was assessed using the 
following stable isotopes: [ 13 C 10 ]  -carotene, [ 
13 C 5 ]retinol, and 
d4-retinyl palmitate. Blank plasma was generously provided by 
the Blood Transfusion Service, Newcastle upon Tyne Hospitals 
(UK). For extraction effi ciency experiments, 10   l of [ 13 C 10 ]  -
carotene, [ 13 C 5 ]retinol, and d4-retinyl palmitate in ethanol were 
spiked into 1 ml of control plasma at a fi nal concentration of 
5   M. Plasma was then extracted as described above. 
 LC/MS/MS analysis 
 Chromatographic separation of   -carotene and retinoids was 
achieved using a Perkin Elmer Series 200 LC (Beckonsfi eld, UK) 
equipped with a Gemini C 18 column (3   m; 50 mm × 2 mm i.d. ) 
and SecurityGuard C 18 column (4 × 3 mm) both from Phenome-
nex (Cheshire, UK) maintained at 30°C. Reverse phase elution of 
analytes was performed with mobile phases of 0.1M aqueous am-
monium acetate pH 5 (A) and 50:50 (w/w) methanol/isopropanol 
(B). The mobile phase system consisted of a 1 min linear gradient 
from 80% to 99% B, held at 99% B for 3 min, then immediately 
 TABLE 1. LC retention times, SRM mass ion transitions (Q1/Q3), and MS parameters of analytes 
Analyte
Retention 
Time (min)
SRM Transitions 
( m/z )
Declustering 
Potential (V)
Entrance 
Potential (V)
Collision 
Energy (eV)
Collision Exit 
Potential (V)
[ 12 C]retinol 0.63 269 → 93 51 10 27 6
[ 13 C 5 ]retinol 0.62 274 → 98 51 10 27 6
[ 13 C 10 ]retinol 0.62 279 → 100 41 10 27 6
[ 13 C 10 ]retinyl acetate 0.91 279 → 100 41 10 27 6
[ 12 C]retinyl linoleate 2.20 269 → 93 51 10 27 6
[ 13 C 5 ]retinyl linoleate 2.20 274 → 98 51 10 27 6
[ 13 C 10 ]retinyl linoleate 2.20 279 → 100 41 10 27 6
[ 12 C]retinyl palmitate/oleate 2.36 269 → 93 51 10 27 6
[ 13 C 5 ]retinyl palmitate/oleate 2.36 274 → 98 51 10 27 6
[ 13 C 10 ]retinyl palmitate/oleate 2.35 279 → 100 41 10 27 6
d4-Retinyl palmitate 2.34 273 → 94 41 10 31 2
[ 12 C]retinyl stearate 2.63 269 → 93 51 10 27 6
[ 13 C 5 ]retinyl stearate 2.63 274 → 98 51 10 27 6
[ 13 C 10 ]retinyl stearate 2.63 279 → 100 41 10 27 6
[ 12 C]  -carotene 2.96 537 → 321 46 10 33 32
[ 13 C 10 ]  -carotene 3.00 547 → 330 86 10 33 18
[ 13 C 20 ]  -carotene 2.99 557 → 335 66 10 29 24
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clearly distinct from retinyl acetate (171.2 ppm) and palmitic 
acid (180.4 ppm). Similar  13 C NMR signals were observed for 
retinyl stearate (174.0 ppm), retinyl oleate (174.0 ppm), and 
retinyl linoleate (173.9 ppm), confi rming the production 
of each of the retinyl esters. Synthetic retinyl palmitate was 
compared against commercially-available retinyl palmitate by 
LC/MS/MS providing the same retention time and mass 
spectra, further confi rming the formation of the desired reti-
nyl esters. Consequently, LC/MS/MS peaks at 2.20 and 2.63 
min were confi rmed as retinyl linoleate and retinyl stearate 
while retinyl oleate coeluted with retinyl palmitate at 2.36 
min. Total LC run-time was 7 min, which included a column 
re-equilibration period of 3 min. 
 From extraction effi ciency experiments (n = 6), the re-
coveries of [ 13 C 5 ]retinol, d4-retinyl palmitate, and [ 
13 C 20 ]  -
carotene were 39% (±1.9% SD), 36% (±2.3% SD), and 30% 
(±1.6% SD) respectively. Although recovery of analytes was 
relatively low, the mild extraction procedure employed ne-
gated the detrimental effects associated with co-extracted 
lipids during MS analysis. Furthermore, total analyte concen-
trations were calculated using the internal standards [ 13 C 10 ]
retinyl acetate and [ 13 C 20 ]  -carotene, thus correcting for the 
low recovery. On-column validation of linear dynamic range, 
limit of detection, and intra- and inter-day precision for [ 12 C] 
analytes are given in  Table 2 . Limits of detection ranged from 
10 fmol for retinol to 50 fmol for   -carotene. Linear dynamic 
ranges were over two to three orders of magnitude with  r 2 
values of >0.999 (supplementary Fig. II). Intra- and inter-day 
precision ranged from 3.7 to 3.8% relative standard deviation 
(RSD) and from 6.5 to 7.8% RSD , respectively. 
 Administered 2 mg [ 13 C 10 ]  -carotene could be de-
tected in plasma from 2 h to 2 weeks postdose ( Fig. 5 ). 
The [ 13 C 10 ]  -carotene plasma response exhibited an ini-
tial increase to 10 nmol/l at 6 h, followed by a brief pla-
teau to 8 h, then a steady rise to a maximum of 25 nmol/l 
at 24 h. The [ 13 C 10 ]  -carotene cleavage product, [ 
13 C 5 ]
retinyl palmitate, rapidly attained a maximum concen-
tration of 50 nmol/l at 4 h postdose, while [ 13 C 5 ]retinol 
started to appear at 3–4 h in plasma and peaked at 10 h. 
Metabolites of the 1 mg [ 13 C 10 ]retinyl acetate dose reached 
plasma concentrations 4- to 6-fold higher than [ 13 C 10 ]  -
carotene and derived cleavage products. Plasma kinetics 
of [ 13 C 10 ]retinol and [ 
13 C 10 ]retinyl palmitate mirrored 
those observed for [ 13 C 5 ]retinol and [ 
13 C 5 ]retinyl palmi-
tate. Retinol secreted from the intestine was predomi-
nantly esterifi ed to palmitate and oleate. However, retinyl 
identical Q1 precursor ions of [M+H–H 2 O] 
+ for retinol, 
[M+H–CH 3 CO 2 H] 
+ for retinyl acetate, and [M+H–CH 3 
(CH 2 ) 14 CO 2 H] 
+ for retinyl palmitate. Consequently, it was 
necessary to adequately separate retinoids by LC before 
selected reaction monitoring (SRM ) at  m/z 269 → 93,  m/z 
274 → 98, and  m/z 279 → 100 for respective [ 12 C], [ 13 C 5 ], 
and [ 13 C 10 ] isotopologues ( Table 1 ). The abundant Q3 
product ion for retinoids was due to cleavage at the C 9 -C 10 
double bond where the selected polyene chain fragment 
contained all [ 13 C] labels from  m/z 274 and seven of the 
[ 13 C] labels from  m/z 279 ( Fig. 2 ). 
 APCI of   -carotene resulted in protonation of the mole-
cule [M+H] + with an abundant Q3 product ion at  m/z 177 
irrespective of isotopic composition ( m/z 537 → 177 [ 12 C] 
and  m/z 547 → 177 [ 13 C];  Fig. 3 ). The geometric isomer of 
  -carotene, lycopene, also produced a fragment Q3 ion at 
 m/z 537 → 177 and possessed an identical LC retention time 
to   -carotene. Furthermore, an unidentifi ed compound was 
observed in “blank” plasma at  m/z 547 → 177 which could not 
be separated from   -carotene by LC. Therefore, an alterna-
tive less abundant fragment of higher  m/z was selected for 
[ 13 C]  -carotene at  m/z 330 ( Fig. 3 ). This product ion was 
the result of cleavage at C 12 -C 13 and contained the majority 
of the [ 13 C] labeling from  m/z 547 and also from  m/z 557 as 
internal standard. The corresponding fragment for [ 12 C]  -
carotene at  m/z 321 was not present for lycopene. Both 
 trans - and  cis -  -carotene isomers produced the same Q3 prod-
uct ions (supplementary Fig. I). Optimized MS/MS parame-
ters and SRM transitions for all analytes are given in  Table 1 . 
 Retinol and retinyl acetate were separated to baseline on a 
C 18 reversed-phase column with a 1 min linear gradient of 
80–99% methanol/isopropanol (50:50, w/w); their respec-
tive retention times were 0.63 and 0.91 min ( Fig. 4 ). Retinyl 
palmitate and   -carotene eluted at 2.36 min and 2.96 min 
respectively under isocratic conditions of 99% methanol/iso-
propanol. From extracted control plasma, two additional 
peaks were observed at  m/z 269 → 93 that fl anked the retinyl 
palmitate peak. As these peaks were suspected to be alterna-
tive fatty acid esters of retinol, it was necessary to synthesize 
noncommercially available retinyl esters. The presence of the 
postulated retinyl esters was confi rmed through the use of 
natural abundance  13 C NMR measured in CDCl 3 using a 
Jeol ECS-400 MHz.  13 C NMR analysis of the reaction be-
tween palmitic acid and retinyl acetate revealed a signal at 
174.0 ppm which correlates to the carbonyl carbon of retinyl 
palmitate (in comparison to commercial standards) and was 
 TABLE 2. Limits of detection, limits of quantitation, linear dynamic ranges, calibration curves, correlation coeffi cients, and intra-/inter-day 
variations of [ 12 C] standards used for quantitation of analytes 
Analyte
LOD a 
(pmol)
LOQ b 
(pmol)
Linear Range 
(pmol)
Slope c 
(a × 10 5 )
Intercept c 
(b × 10 4 )
Correlation 
Coeffi cient 
( r 2 )
Intra-day d 
(%RSD)
Inter-day e 
(%RSD)
[ 12 C]retinol 0.01 0.03 0.03–110 7.937 4.219 0.999 3.8 6.5
[ 12 C]retinyl palmitate 0.03 0.10 0.10–100 4.388 1.689 0.999 3.7 7.1
[ 12 C]  -carotene 0.05 0.17 0.17–90 1.701 0.455 1.000 3.7 7.8
 a Limit of detection (S/N = 3; n = 5)
 b Limit of quantitation (S/N = 10; n = 5)
 c Calibration curves (y = ax + b ).
 d Intra-day, n = 50.
 e Inter-day, n = 8.
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 Fig.  2. Flow-injection APCI-MS/MS product ion mass spectra of  m/z 269 [ 12 C]retinol (A),  m/z 274 [ 13 C 5 ]retinol (B), and  m/z 279 [ 
13 C 10 ]
retinol (C) in positive mode. Asterisks (*) denote position of [ 13 C] labels. 
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of accelerator MS ( 22, 23 ), this method involves the adminis-
tration of radiolabeled material, albeit at micro-doses, and 
requires laborious sample fractionation to distinguish me-
tabolites, followed by very expensive analysis using highly spe-
cialized equipment that is not widely available. Even if other 
MS methods such as gas chromatography/combustion/iso-
tope-ratio MS and electron capture negative chemical ioniza-
tion MS allow effective use of physiological doses of retinol 
( 24, 25 ) and   -carotene ( 26 ) tracers, these methods have 
the disadvantage of requiring extensive sample preparation, 
linoleate levels were higher than retinyl stearate for [ 13 C 5 ] 
cleavage products while retinyl stearate was higher than 
retinyl linoleate for [ 13 C 10 ]retinol. 
 DISCUSSION 
 In human intervention studies, the size of stable isotope 
dose given is largely determined by the limit of detection of 
the analytical method ( 1, 2 ). Although carotene absorption 
and metabolism may be tracked by the very sensitive method 
 Fig.  3. Flow-injection APCI-MS/MS product ion mass spectra of  m/z 537 [ 12 C]  -carotene (A) and  m/z 547 [ 13 C 10 ]  -carotene (B) in posi-
tive mode. Asterisks (*) denote position of [ 13 C] labels. 
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allows for the fi rst time the analysis of both [ 13 C] retinoid and 
  -carotene tracers simultaneously using chemical ionization 
(APCI) in positive mode. Furthermore, the new method is 
more sensitive than comparable LC/MS methods, with detec-
tion limits of 10 fmol for retinol and 50 fmol for   -carotene 
compared with 233 ( 27 ) and 672 fmol ( 29 ) for retinol and 
250 ( 17 ), 559 ( 28 ), and 57 fmol ( 27 ) for   -carotene in previ-
ous methods. 
 The single solvent extraction procedure developed here 
for both carotenoids and retinoids negated the effect of 
including HPLC purifi cation and derivatization, before injec-
tion into the MS. In contrast, the application of liquid chro-
matography mass spectrometry (LC/MS) to the analysis of 
retinoid and carotenoid tracers offers the advantages of high 
sensitivity and selectivity without the need for hydrolysis and 
derivatization ( 17, 27–30 ). However, isolation of carotenoids 
and retinoids from the plasma matrix is frequently carried 
out individually leading to separate injections, use of dif-
ferent LC systems, MS ionization methods (APCI/ESI) and 
modes (positive/negative) ( 11–18 ). The current method 
 Fig.  4. APCI (positive mode) LC/MS/MS chromatograms from a human subject plasma sample 6 h postdose showing [ 12 C], [ 13 C 10 ], and 
[ 13 C 5 ] isotopologues of   -carotene (  C), retinol (ROH), retinyl linoleate (RL), retinyl palmitate/oleate (RPO), and retinyl stearate (RS). 
[ 13 C 10 ]retinyl acetate (RA) and [ 
13 C 20 ]  -carotene were used as internal standards. SRM transitions are given for each chromatogram. 
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of plasma retinyl esters is progressively and irreversibly 
transferred to the denser LDL fraction resulting in 32% of 
the plasma retinyl esters localized to the LDL fraction 12 h 
after fat load ( 34 ). This transfer of retinyl esters is even 
more substantial in subjects with familial hypercholes-
terolemia ( 35 ). Furthermore, inter-individual variation in 
chylomicron clearance kinetics, such as delayed chylomi-
cron remnant clearance in subjects with endogenous hyper-
triglyceridemia ( 36 ) or variation in chylomicron recovery 
during TRL preparation and analysis, reduces the accuracy 
of this approach to directly measure the mass of retinyl 
interfering plasma lipids ( 31 ), without saponifi cation, leaving 
retinyl esters intact. Consequently, it was not necessary to 
prepare triglyceride-rich lipoprotein (TRL) fractions to dis-
criminate newly-absorbed intestinally-derived retinyl esters 
from retinol secreted by the liver bound to RBP. However, 
it is recognized that small amounts (  3%) of unesterifi ed 
retinol, derived from administered retinyl acetate and 
  -carotene, may be present in lymph chylomicrons ( 32, 33 ). 
Although TRL fractions, obtained by ultracentrifugation at 
a solution density of <1.006 g ml   1 , contain >83% of retinyl 
esters in the fi rst 6 h postprandial period, a large percentage 
 Fig.  5. Quantitative LC/MS/MS analysis of mean plasma responses from 45 human subjects (± SEM) over the whole 14 day study period 
(A, C) and during the fi rst 48 h (B, D). Administered [ 13 C 10 ]  -carotene (  C) and resulting [ 
13 C 5 ] cleavage products (ROH, retinol; RE, 
total retinyl esters; RL, retinyl linoleate; RPO, retinyl palmitate/retinyl oleate; RS, retinyl stearate) are shown in (A) and (B). [ 13 C 10 ] me-
tabolites of administered [ 13 C 10 ]retinyl acetate are shown in (C) and (D). 
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esters or   -carotene absorbed ( 37 ). Thus, the current 
method can detect intestinally-derived retinyl esters with 
more accuracy compared with methods employing TRL 
separations ( 27, 37, 38 ). 
 The current method also allows   -carotene bioeffi cacy 
and vitamin A dilution to be studied concurrently due to 
differential extrinsic [ 13 C] labeling of administered com-
pounds. [ 13 C] isotopes were selected because deuterated 
compounds are subject to hydrogen-deuterium exchange 
and possess different physicochemical characteristics re-
sulting in altered LC retention times and solvent extraction 
effi ciencies ( 2, 11, 28 ). Position of [ 13 C 10 ] labels around 
the centric 15,15 ′ double bond on the   -carotene mole-
cule allowed BCMO1 [ 13 C 5 ] cleavage products to be distin-
guished from [ 13 C 10 ] metabolites of [ 
13 C 10 ]retinyl acetate. 
Although both [ 13 C 10 ] and [ 
13 C 5 ] metabolites displayed 
similar plasma kinetic profi les, concentrations of [ 13 C 5 ]
retinol and retinyl esters were 3- to 4-fold lower even 
though twice the dose of [ 13 C 10 ]  -carotene was adminis-
tered. It is known that intestinal absorption of synthetic 
  -carotene is limited although bioavailability is distinctly 
enhanced when dissolved in oil ( 39 ). Regarding retinyl es-
ters, both [ 13 C 10 ] and [ 
13 C 5 ]retinol were preferentially es-
terifi ed to palmitate and oleate. However, subsequent 
specifi cities of [ 13 C 5 ]retinol for linoleate and [ 
13 C 10 ]retinol 
for stearate were observed, which suggests differences in 
subcellular compartmentalization between preformed 
retinol and retinol from provitamin A sources in the en-
terocyte before incorporation in chylomicrons. 
 Retinyl acetate was coadministered with   -carotene as 
a reference dose to correct for inter- and intra-individual 
variations in intestinal absorption and chylomicron clear-
ance rates ( 37 ). The [ 13 C 10 ]retinyl acetate dose can also be 
used to determine total body vitamin A reserves after a suf-
fi cient period (circa 3 days) of isotope dilution with en-
dogenous pools ( 1 ). In some previous studies, the reference 
dose was not administered concomitantly with   -carotene 
to avoid competition during intestinal absorption ( 12, 14 ). 
Single doses of   -carotene have ranged from 5 to 126 mg 
due to analytical detection limits dictating the minimum 
dose that can be administered to human subjects. How-
ever,   -carotene bioefficacy is dose-dependent when 
>4 mg is ingested ( 40 ), while doses >6 mg perturb the 
steady-state equilibrium in the blood ( 41 ). The 2 mg utilized 
in the current study represents a true physiological dose 
according to the estimated daily intake of   -carotene in 
UK and US populations ( 39 ). Although lower doses have 
been administered daily over a prolonged period to reach 
a plateau of isotopic enrichment in the blood ( 15, 16 ), 
multiple dosing cannot establish uptake kinetics. 
 In summary, this new sensitive analytical method allows 
for the simultaneous study of   -carotene bioeffi cacy and 
vitamin A status in human subjects at physiological doses 
for at least 2 weeks. The simple extraction procedure and 
single 7 min LC/MS run-time for all analytes makes the 
method applicable to the high throughput of samples gen-
erated in large human intervention studies.  
 The authors are grateful for the comments of Dr. Achim 
Treumann (Proteomics and Biological Mass Spectrometry 
Facil ity, New castle University) during manuscript preparation. 
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